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I. Abstract 
The immune system has the potential to selectively target and eliminate 
tumours cells. However, the induction of an immunosuppressive environment 
by factors released by tumours cells, or by the tumour stroma, in combination 
with difficulties in differentiating between healthy and malignant cells, 
contributes to inefficient or disabled anti-tumour immune responses. A variety 
of different immunotherapeutic approaches are being developed to tip the 
balance in favour of anti-tumour immunity. Many of these approaches are 
designed to stimulate improved activity of T cells with specificity for tumour-
associated antigens. 
 
This thesis explores how T cell-mediated responses are initiated and 
maintained in immunotherapy, with an emphasis on the role of antigen 
presentation by resident dendritic cells (DCs). An animal model was used in 
which a DC subset in the spleen that expresses the cell marker langerin could 
be selectively ablated during the course of therapy. As these DCs have been 
shown to be uniquely capable of acquiring circulating antigens and cellular 
debris, and have a heightened capacity for cross-priming CD8+ T cells, it was 
hypothesised that the function of these cells could play a significant role in 
determining the outcome of immunotherapies.  
 
A model of adoptive T cell therapy was examined in mice challenged with an 
intravenously administered lymphoma that formed tumour foci in a variety of 
locations in the body. Treating established tumours by adoptively transferring 
in vitro activated effector CD8+ T cells significantly increased their symptom-
free survival. The protection received by this therapy was dependent on a 
stimulus being provided by endogenous langerin+ CD8α+ DCs to the 
transferred T cells. In the absence of langerin+ CD8α+ DCs, the proportion 
and number of transferred anti-tumour CD8+ T cells was lower in the blood 
and spleen. However, no obvious differences in phenotype and function could 
be defined. Langerin+ CD8α+ DCs therefore contribute to the maintenance of 
an effective CD8+ T cell-based immunotherapy and the role of endogenous 
 iv 
DCs should be taken into consideration during the design of 
immunotherapies. 
 
To investigate the role of langerin+ CD8α+ DCs in initiating effector T cell 
responses, a novel whole-cell vaccine was developed for the treatment of 
acute myeloid leukaemia (AML). This vaccine exploited the stimulatory 
functions of invariant natural killer T cells, and was therefore administered 
intravenously to access the large invariant natural killer T cell compartment of 
the spleen. The vaccine completely protected mice from developing 
leukaemia when challenged with AML cells after vaccination, with CD4+ and 
CD8+ T cells mediating protection. The immune response generated by the 
vaccine was shown to be completely dependent on langerin+ CD8α+ DCs. In 
hosts with established tumours; however, the vaccine was ineffective. This 
may have been partially due to a reduced function of langerin+ CD8α+ DCs as 
their activation phenotype was significantly reduced in the presence of 
established AML; however, non-specific T cells could still be stimulated via 
these DCs. Reduced vaccine efficacy was associated with increased number 
and/or function of suppressor cells, including regulatory T cells and myeloid 
derived suppressor cells within the host. In addition, in leukemic hosts, the 
proportion of T cells in the spleen was reduced, and the function of AML-
specific CD4+ T cells, but not CD8+ T cells, was impaired. Driving AML-
bearing hosts into remission with chemotherapy prior to vaccination enabled 
the vaccine to protect the host from subsequent AML challenge. Langerin+ 
CD8α+ DCs are therefore responsible for initiating the vaccine-induced 
immune response in this model and their suppression may have contributed 
to the inefficacy of the vaccine in the presence of established tumours. 
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24G2    anti-CD16/32 FcR blocking antibody 
2-ME    2-mercaptoethanol 
A20    mouse B cell lymphoma cell line 
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J558    mouse plasmacytoma cell line 
KLRG-1   killer cell lectin-like receptor subfamily G member 1 
KO    knockout 
L    ligand 
Lang-EGFPDTR  langerin-diphtheria toxin receptor mice 
LCMV    Lymphocytic choriomeningitis virus  
LDFB    live dead fixable blue 
LPS    lipopolysaccharide 
Ly6c    lymphocyte antigen 6 complex, locus C 
MCP-1   macrophage chemotactic protein - 1 
MFI    mean fluorescence intensity 
MHC    major histocompatibility complex 
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NK    natural killer 
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PAMP    pathogen associated molecular pattern 
PBS    phosphate buffered saline 
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PRR    pattern recognition receptor 
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RBC    red blood cell 
RNA    ribonucleic acid 
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TCM    T central memory 
TCR    T cell receptor 
TEM    T effector memory 
TGF    transforming growth factor 
Th    T helper 
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TNF    Tumour necrosis factor 
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1.1 General overview 
A tumour arises when a normal cell looses control of its cell cycle, resulting in 
uncontrolled proliferation. The causative factors are diverse but have been 
associated with age, weight and contact with carcinogens, such as tobacco 
smoke. In 2009, cancer was the leading cause of death in New Zealand, 
accounting for 28.9 % of all deaths (1). It has been estimated that there will be 
a 45 % increase in deaths attributed to cancer by 2030 worldwide, which 
indicates an extra 4.3 million new cases of cancer per year (2). Current 
standard treatments for cancer include surgery, chemotherapy and radiation 
therapy, however the benefits of these treatments vary significantly depending 
on the type of cancer and how early it is detected. Surgery can only be 
performed if the tumour is accessible, and is only beneficial if the tumour has 
not metastasized to other areas of the body. Chemotherapy and radiotherapy 
are generally treatments that target proliferating cells, and therefore are not 
tumour specific. As a result these therapies can cause significant damage to 
healthy cells, with adverse side effects ranging from nausea to severe 
morbidity. 
 
The immune system is highly effective at protecting the body from invading 
pathogens, but it is now recognised that it can prevent the development of 
tumours within a host. This was made evident by experiments demonstrating 
that immunodeficient mice develop spontaneous tumours much faster than 
immunosufficient mice, indicating that the immune system prevents 
spontaneous and carcinogen-induced tumour development (3). However, the 
immune system has evolved to avoid attacking healthy tissue, as the risks to 
the host associated with autoimmunity can be significant. This poses a 
problem for generating an immune response against tumours because tumour 
cells derive initially from healthy host cells, and therefore express a largely 
“normal” repertoire of proteins (or “self-antigens). Immune cells that have the 
potential to attack tumour cells have largely been removed from the immune 
system to permit tolerance of self-antigens and prevent autoimmunity. Anti-
tumour immunity is therefore reliant on stimulating responses from immune 
cells that have avoided this depletion process, and are therefore likely to have 
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only low affinity for self-antigens, or must be targeted to neo-antigens that are 
unique to the tumour tissue. In addition, immune suppression specifically 
generated by tumours is capable of preventing the activation and function of 
an anti-tumour immune response. These themes will be discussed in more 
detail later in the chapter. 
 
To understand anti-tumour immunity in more detail for this thesis, it is 
necessary to give a brief overview of the broad features of the immune 
system, which is currently best understood in the context of defence against 
pathogens. The immune system can broadly be differentiated into two main 
components, the innate and adaptive immune response. Both arms have 
distinct functions that cooperate together to protect the host. The first-line of 
immune defence consists of the innate immune system, which responds to 
infectious agents in a generic way and therefore rapidly provides a non-
specific, blanket defence in response to exposure to pathogens (4). In 
contrast, the adaptive immune response takes time to develop, but is highly 
selective due the process of stimulating only immune cells that have 
pathogen-specific antigen-receptors. Following activation, these cells undergo 
clonal expansion and differentiate into effector cells. Importantly, it is now 
clear that there is cross-talk between the innate and adaptive arms of the 
immune system, with the early events triggered by innate cells laying the 
groundwork for an effective adaptive immune response. 
 
The innate immune system consists of a variety of different cells, each of 
which have distinct functions in eliminating pathogens. These cells include 
macrophages, neutrophils, DCs, mast cells, eosinophils and natural killer cells 
(NK cells), each briefly discussed below.  
 
Macrophages, neutrophils and DCs are three main phagocytic innate immune 
cells. These cells can ingest pathogens and kill them by producing powerful 
degradative molecules called lysosymes. Macrophages can be found in 
almost every tissue within the body, the majority of which originate from 
myeloid precursors in the bone marrow that differentiate into monocytes. 
Once developed, monocytes circulate in the blood and bone marrow and 
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migrate into tissues during infection where they can differentiate into 
macrophages (5). In addition, macrophages can differentiate directly from 
myeloid precursors in the bone marrow before migrating into tissues. In the 
context of infection, macrophages can be induced to secrete molecules into 
the environment that induce inflammation and recruit other cells of the 
immune system to aid in host-defence (6). Although capable of presenting 
acquired antigens to antigen-specific cells of the adaptive immune system, 
their role in coordinating the immune system depends on their activation state. 
The phenotype of macrophages can range from inflammatory to suppressive, 
depending on the stimuli they receive (7). A key mechanism of the adaptive 
immune response is to induce the differentiation of macrophages toward the 
inflammatory phenotype, thereby aiding the elimination of pathogens. 
However, in most tumour environments the presence of macrophages is 
associated with a poor prognosis due to an anti-inflammatory phenotype (7). 
 
Neutrophils traffic in the blood and only migrate into tissues in response to 
inflammation. They can kill microorganisms by phagocytosis and by the 
release of reactive oxygen species (ROS) into the phagosome. In addition, 
neutrophils are able to expel their intracellular components, including their 
DNA, bound with granules. This structure is able to capture and limit the 
activity of microorganisms (8). The involvement of neutrophils in the adaptive 
immune response is limited and not well understood. In the marginal zone of 
the spleen, neutrophils activate B cells by producing the B cell stimulating 
cytokine called a proliferation-inducing ligand (APRIL), leading to the 
production of antibodies by B cells, independently of T cells (9).  
 
DCs are the main focus of this thesis. Like macrophages, they are found in 
most tissues in the body and can phagocytose cellular material, circulating 
antigens and whole pathogens. However, unlike macrophages their main role 
is to coordinate adaptive immune responses. In the steady state (i.e. in the 
absence of infection), the stimulation provided by DCs to cells of the adaptive 
immune system can be inhibitory to prevent immune responses against self-
tissue. In the presence of signals of infection or evidence of tissue destruction, 
DCs serve as the most potent stimulators of adaptive immune responses (4). 
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Phagocytosed antigens are processed and presented in a manner that 
promotes activation of antigen-specific lymphocytes. These functions will be 
described later in the thesis, with emphasis on stimulating T cells. 
 
Eosinophils and basophils are cells of the innate immune system that attack 
pathogens, such as parasites, that are too large to be engulfed by 
macrophages. When these cells are activated they release toxic molecules 
that damage pathogens. These cells are not of relevance in this thesis and 
will not be discussed in any detail. 
 
NK cells are lymphocytes of the innate immune system that are capable of 
producing and releasing cytotoxic molecules that can cause cell death. 
Broadly speaking, although fully “armed” with cytotoxic mediators, they remain 
inactive through interaction with inhibitory molecules expressed by healthy 
cells. The loss of these molecules, combined with interaction with ‘stress-
induced’ stimulatory molecules on infected or perturbed cells, promotes NK 
activity. NK cells also produce large quantities of cytokines following 
stimulation, which aid in exacerbating the immune response (10). 
 
The adaptive immune system consists of T and B lymphocytes, each bearing 
randomly generated antigen-receptors. As noted, adaptive immune responses 
are slower due to the process of clonal selection of antigen-specific cells. 
While B cells produce antibodies that play a crucial role in adaptive immunity, 
including in cancer, this thesis will focus primarily on T cells, which have been 
shown to have therapeutic activity in many models of cancer, and show 
promise as effector cells in the clinic. 
 
As a population, T cells are usually divided into two broad categories on the 
basis of expression of CD4 or CD8. Although not described here, it is 
important to note that other populations of T cells do exist, such as the innate-
like T cells that will be discussed later in the chapter. Broadly speaking, T 
cells expressing CD4 differentiate into cytokine-secreting T “helper” cells upon 
activation and function largely by activating or enhancing the functions of 
other immune cells, including DCs, macrophages and CD8+ T cells. In 
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contrast, T cells expressing CD8 differentiate into cytotoxic T cells (cytotoxic T 
lymphocytes; CTL) that are capable of producing cytotoxic molecules and 
cytokines that can kill target cells. It should be noted that the functions of 
these two cell types is not exclusive, as CD4+ T cells have been demonstrated 
to develop cytotoxic functions in some settings (11). Both classes of T cell 
derive from bone marrow precursors, and mature in the thymus. T cells that 
recognise self-antigens with high affinity are deleted from the repertoire, and 
the remaining cells then distribute into the lymphoid organs (12). The process 
of activating T cells is complex, and is heavily reliant on cues received by 
antigen presenting cells (APCs), primarily DCs, that provide signals indicating 
danger to the host. Tissue-resident DCs must acquire antigens and bring 
them to lymphoid tissues to stimulate T cells specific for those antigens. 
Alternatively, DCs that reside in lymphoid tissues acquire antigens that drain 
into the tissue, either from the blood during circulation, or via the lymphatic 
system. Either way, processed antigens must be presented by mature DCs to 
induce T cell activation. Once activated, CD8+ T cells are able to migrate to 
sites of inflammation and kill antigen-expressing or infected cells by releasing 
cytotoxic molecules (13). They are also capable of targeted release of 
cytokines, which can improve or exacerbate the immune response. On the 
other hand, activated CD4+ T cells do not generally have a direct cytotoxic 
function, but produce cytokines and provide direct stimulation (via receptors) 
to cells of the innate immune system, such as macrophages, to enhance their 
host-defence mechanisms (14). Another important role of CD4+ T cells is to 
aid in progression of the CD8+ T cell response by providing stimulatory signals 
that enhance the stimulation provided by DCs, a process referred to as “T cell 
help”. CD4+ T cells perform a similar process to induce the production of 
antibodies by B cells. CD8+ T cells are the main lymphocyte of the adaptive 
immune response discussed in this thesis, because of their superior ability to 
kill tumour cells. 
 
The aim of the research in this thesis was to develop a greater understanding 
of the interactions between DCs and CD8+ T cells in eliciting anti-tumour 
immune responses. As will be established over the course of the introduction, 
there are many subsets of DCs, and it has been hard to elucidate the different 
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roles of these subsets. The availability of a mouse strain that enables the 
specific deletion of one DC subset, the langerin+ CD8α+ DCs in the spleen, 
enabled an analysis of this subsets function. Importantly, the information 
generated from this study could aid in the rational design of novel and more 
effective immunotherapies for the treatment of tumours. 
 
1.2 The structure and immune function of the spleen 
This thesis consists of an examination of the function of a specific DC 
population found within the marginal zone of the spleen. Therefore, a general 
understanding of the anatomy and function of the spleen is necessary to 
understand the function of this DC subset and how it has access to antigens 
from the blood. Immune cells and antigens within the blood enter the spleen 
through the splenic artery and travel trough the central arterioles, which are 
surrounded by the periarteriolar lymphoid sheath (a T cell rich area). The 
central arterioles branch into arterioles that transverse the periarteriolar 
lymphoid sheath and form capillaries in the marginal sinus and red pulp. The 
marginal sinus is surrounded by the marginal zone, which contains DCs, 
macrophages and lymphocytes. Blood within the marginal sinus enters the 
trabecular vein to exit the spleen, however there are small gaps in the 
marginal sinus that allows blood to pass into the marginal zone before 
entering the surrounding red pulp and then re-joining the circulation via 
venous sinuses (15). Blood passing through the marginal zone enables 
resident APCs to acquire antigens within the blood. 
 
1.3 Dendritic cells 
1.3.1 Antigen processing and presentation 
The classical pathways of antigen presentation 
To appreciate the importance of DCs in developing an immune response 
against tumours a deeper understanding of how they process and present 
antigens is required. There are two classical pathways of antigen presentation 
and each drives a different response by activating either CD8+ T cells (the 
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MHC class I presentation pathway) or CD4+ T cells (the MHC class II 
presentation pathway). 
 
MHC class I presentation pathway 
Antigens acquired by DCs, or derived from within the cell as a consequence 
of infection, are processed into peptide fragments, some of which are 
ultimately presented on the cell surface in the context of major 
histocompability complex (MHC) molecules for presentation to T cells. The 
class of MHC molecule that the peptide is presented on determines whether a 
CD4+ or CD8+ T cell can recognize it (16, 17); the T cell receptor (TCR) of 
CD8+ T cells recognise antigens bound to MHC class I and the TCR of CD4+ 
T cells recognise antigens bound to MHC class II, as demonstrated in figure 
1.1A. In the classical model of MHC class I antigen presentation, proteins 
found within the cell itself (“endogenous” antigens), such as those originating 
from a virus, are processed and presented on MHC class I. These 
endogenous proteins enter the core of the proteasome within the cytosol, 
where they are proteolytically cleaved into short peptides, 2 to 25 amino acids 
long (18, 19). After degradation, the peptide fragments then enter the lumen 
of the endoplasmic reticulum (ER) via molecules called transporters 
associated with antigen processing 1 and 2 (TAP1 and TAP2) (20, 21). The 
peptides are then cleaved into smaller fragments within the ER by peptidases, 
such as ER-associated amino peptidase 1 (ERAP1). Within the repertoire of 
peptides generated will be sequences that can be inserted in the peptide 
groove of MHC class I molecules (22-24).  
 
The MHC class I complex is composed of both a heavy chain and a beta-2 
microglobulin component. Initially following development in the ER, the heavy 
chain binds to the protein calnexin, which aids in folding of the heavy chain. 
The folded structure enables binding of ERp57 with calnexin further promoting 
folding of the heavy chain. Once folded, the heavy chain can form a complex 
with beta-2 microglobulin, allowing the dissociation of calnexin, and the 
binding of calreticulin and the TAP complex via tapasin. This creates an 
unloaded MHC class I molecule receptive to peptides that translocate into the 
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ER via TAP (25). Binding of a peptide into the peptide binding groove of MHC 
class I releases the MHC class I/peptide complex from ER proteins, thereby 
allowing the complex to migrate to the cells plasma membrane via the golgi 
cisternae for presentation (26). Antigens presented on MHC class I are 
recognized by TCRs of CD8+ T cells, which when activated provide a 
cytotoxic response against cells that express that specific antigen (27). 
 
MHC class II antigen pathway 
Antigens destined for expression on MHC class II for presentation to CD4+ T 
cells are exogenous antigens that are captured by APCs and internalized into 
endosomes (Figure 1.1B). The acquired proteins are then degraded into 
peptide fragments by proteases within the endosome, creating peptide 
fragments between 12 and 24 amino acids long that can bind to MHC class II 
(28-30). The MHC class II molecule is synthesized in the ER. The antigen 
binding groove ligates to a chaperon protein called the invariant chain (Ii) for 
stabilization (31). Following stabilization, the MHC class II complex is 
transported to the endosome where the Ii chain is cleaved by active 
proteases. A short fragment of the Ii chain remains bound to the MHC class II 
binding groove and is called the class II associated invariant chain peptide, 
which can then be displaced by a peptide with higher affinity for MHC class II 
(32). Once a peptide has bound, the complex migrates to the cell surface to 
present antigens to CD4+ T cells via a transport vesicle that buds from the 
endosome (33). 
 
Cross-presentation 
The classical pathways do not provide a mechanistic explanation for the 
observation that CD8+ T cell responses can be stimulated against infectious 
agents that do not infect DCs. Similarly, tumour antigens would need to 
access DCs to elicit an anti-tumour CD8+ T cell response. In fact, mice 
immunized with exogenous antigens have been shown to be capable of 
developing a cytotoxic CD8+ T cell response, suggesting cross-presentation of 
these antigens (34). In addition, CD8+ T cell-mediated responses can be 
generated against injected tumour antigens (35, 36). An explanation for these 
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observations is that exogenous antigens can be diverted into the MHC class I 
presentation pathway. The general presentation pathway involved in this 
process is called cross-presentation, and CD8+ T cell-mediated responses 
stimulated in this manner are said to have been “cross-primed”. A significant 
amount of data supports the concept of cross-presentation, and cross-
priming, although a variety of different pathways have been proposed. The 
various theories and their supporting evidence are described below. 
 
 
Figure 1.1: Classical models of antigen presentation on MHC class I and MHC 
class II molecules. (A) Antigens found within the cytosol are processed and 
presented on MHC class I for the stimulation of CD8+ T cells. (B) Antigens acquired 
from outside of the cell are acquired into an endosome where they are degraded. 
The antigens then bind to MHC class II for the stimulation of CD4+ T cells. Adapted 
from Heath (37). 
 
Endosome to cytosol pathway 
One proposed pathway of cross-presentation involves the release of 
internalized proteins from an endosome into the cytosol where they can be 
cleaved into fragments by the proteosome. The peptide fragments can then 
follow the classical MHC class I pathway where they enter the ER via the TAP 
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complex (Figure 1.2A). Studies have shown that exogenous antigens are 
present within the cytosol, indicating that the exogenous antigens are able to 
leave the endosome after acquisition. For example, sub-cellular fractionation, 
which separates the cytosol from vesicular organelles, has been used to 
detect exogenous chicken ovalbumin (OVA) protein within the cytosol of DCs 
following culture with OVA (38). Another study found that the administration of 
cytochrome C into mice led to a reduction in the amount of CD8α+ DCs. This 
is because when cytochrome C is present within the cytosol, it will activate the 
apoptotic protease-activating factor 1 (Apaf-1) molecule, which initiates 
apoptosis. Therefore, any cell that is able to transport exogenous cytochrome 
C into the cytosol (which might otherwise enter the MHC class I pathway) will 
undergo apoptosis. This experiment indicated that CD8α+ DCs are the most 
efficient cross presenters, which will be discussed in more detail below (39). It 
has not yet been determined how the antigen is able to leave the endosome 
but it has been postulated that peptide fragments may simply be able to 
migrate across the endosome membrane (39) or that the endosome itself 
ruptures, releasing its contents into the cytosol (27). Regardless of the 
process, there is strong evidence that DCs can transport exogenous antigens 
from an endosome into the cytosol for processing on MHC class I. 
 
ER phagosome fusion pathway 
When an endosome fuses with part of the ER an ergosome is formed. The 
development of an ergosome brings together the antigens from the endosome 
with the machinery from the ER, which enables exogenous antigens to be 
processed and loaded onto MHC class I within the ergosome. For this to 
occur the proteins must first exit the ergosome to enter the cytosol and be 
cleaved by the proteosome, before re-entering the ergosome to bind to MHC 
class I (Figure 1.2B). Evidence for this pathway has been found by looking for 
ER proteins within DC phagosomes. The ER proteins TAP, tapasin, ERP57 
and Sec61 have been detected within endosomes, indicating that ergosomes 
had been formed (40). The presence of Sec61 within an ergosome identifies a 
possible way in which peptides may enter the cytosol. Sec61 is a transporter 
that shuttles misfolded or mutated proteins from the ER into the cytosol for 
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destruction as part of the ER-associated destruction pathway (ERAD). Sec61 
could therefore also transport peptides from an ergosome into the cytosol for 
cleavage by the proteosome (41). Sec61 is further implicated in the process of 
cross-presentation as removing the Sec61 complex with ribonucleic acid 
(RNA) interference reduces the amount of cross-presentation that occurs (41). 
After peptides have been degraded in the cytosol they re-enter the endosome 
via the TAP complex and bind to MHC class I before being exported to the 
plasma membrane for CD8+ T cell stimulation (40). 
 
Endosome to ER pathway 
Another possible method by which cross-presentation occurs is based on 
studies demonstrating that internalized soluble proteins can exit the 
phagosome and directly cross the ER membrane to enter the ER lumen (42). 
Here the peptides can enter the ERAD pathway where they are transported 
back into the cytosol to be cleaved by the proteosome. The peptide fragments 
can then re-enter the ER via TAP and be loaded onto MHC class I as part of 
the normal MHC class I pathway (Figure 1.2C). 
 
Proteosome and TAP independent pathway 
It is possible that cross-presentation can occur by a process that does not 
involve the TAP complex, migration of the exogenous protein into the cytosol 
or degradation by the proteosome (43). In this pathway, exogenous proteins 
are degraded into peptides within the endosome, thereby bypassing the 
requirement to leave the endosome for degradation by the proteosome. It is 
not known exactly how the peptide encounters MHC class I in his model; 
however, it is thought to occur after the MHC class I molecule has been 
exported from the ER and through the Golgi cisternae, as inhibition of protein 
transport from the ER to the Golgi does not inhibit cross-presentation (44). 
The antigen; therefore, is likely to be loaded onto MHC class I molecules that 
have been recycled from the cell surface. In this case, the peptides that were 
digested in the endosome bind to the recycled MHC class I molecules and are 
then presented on the plasma membrane for presentation to CD8+ T cells 
(Figure 1.2D) (45). 
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Figure 1.2: Pathways of antigen cross-presentation. (A) The endosome to cytosol 
pathway involves the exogenous protein leaving the endosome and entering the 
cytosol, where it is degraded by the proteosome. The antigens then enter the ER via 
the TAP complex and are loaded onto MHC class I. The MHC I/antigen complex is 
transported via the Golgi to the cell surface. (B) The ER-phagosome fusion pathway 
involves the formation of an ergosome by fusion of the endosome and part of the ER. 
The proteins exit the ergosome and enter the cytosol via the ERARD system to be 
cleaved by the proteosome. The cleaved antigens then re-enter the ergosome via the 
TAP complex and are loaded onto MHC I molecules. The MHC I/antigen complex 
then transits to the cell surface. (C) In the endosome to ER pathway, the acquired 
exogenous proteins within the endosome enter the cytosol and directly enter the ER. 
The proteins then enter the ERAD pathway and leave the ER for cleavage by the 
proteosome. The antigens then re-enter the ER via the TAP complex, are loaded 
onto MHC I and then the MHC I/antigen complex transits to the cell surface. (D) The 
proteosome and TAP independent pathway involves the exogenous proteins being 
cleaved within the endosome and loaded onto MHC I molecules that are recycled 
from the cell surface. The MHC I/antigen complex then transits to the cell surface. 
Adapted from Petersen (27). 
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1.3.2 Dendritic cell activation 
The following paragraph is an introduction into the activation and function of 
DCs, which will be covered in detail below. The presentation of antigenic 
peptides via MHC molecules are able to stimulate T cells that can recognise 
the peptide/MHC complex by TCR binding. Depending on the activation status 
of the DC, the interaction between the TCR and MHC/peptide complex can 
activate the T cell, cause its deletion, or divert its activity, thereby initiating or 
preventing a specific immune response (46, 47). Activation is commonly used 
to describe the phenotypic changes DCs undergo in response to 
environmental signals that indicate a danger to the host, such as proteins 
released from dying or damaged cells (48-50). Proteins released from dead or 
dying cells that activate APCs are called danger associated molecular 
patterns (DAMPs). Because tumour cells arise from healthy tissue they are 
not associated with danger signals like bacteria and viruses are. As a result 
DCs in cancer patients are often not activated effectively and subsequently 
DCs presenting tumour antigens often inhibit tumour specific T cells instead of 
activating them (51). 
 
The terms maturation, activation and licensing are used to describe different 
stages of DC activation. In this report the term ‘maturation’ will be used to 
describe any process that induces the upregulation of co-stimulatory 
molecules on the DC plasma membrane, which are essential for T cell 
activation. ‘Activation’ will be used to describe any process that renders a DC 
capable of stimulating naïve T cells into proliferating and differentiating into 
effector T cells. For this to occur the DC must express co-stimulatory 
molecules and produce cytokines such as interleukin (IL)-12 (49). The term 
‘licensing’ will be used to describe the process by which a cell, such as a 
CD4+ T cell or iNKT cell, activates a DC through receptor binding and cytokine 
production (52, 53). The maturation of a DC can occur by binding to 
proinflammatory cytokines, DAMPs or pathogen associated molecular 
patterns (PAMPs), whereas for a DC to become activated it typically requires 
licensing in combination with DAMP or PAMP ligation (54, 55). 
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In the naïve state, DCs express low levels of MHC class I and II and low 
levels of the co-stimulatory molecules CD40, CD80 and CD86 making them 
poor T cell activators (56, 57). Naïve DCs are efficient at acquiring antigens in 
their resident tissues and this is their main function in this state (58). Activated 
DCs develop a phenotype consisting of a more circular shape, increased 
cytokine production and increased expression of MHC molecules and co-
stimulatory molecules (59, 60). This phenotype provides DCs with the three 
stimuli required to induce T cell activation, antigen presentation, co-
stimulatory molecules and cytokine production. A T cell presented with these 
stimuli will be activated into inducing an immune response against the 
presented antigen. Activated DCs also upregulate lymphoid homing 
molecules such as chemokine (C-C motif) receptor (CCR) 7 and chemokine 
(C-X-C motif) receptor (CXCR) 4, which allow peripheral DCs to migrate from 
their resident tissues to T cell areas of lymphoid tissues. Activated DCs are 
therefore able to interact with and activate T cells in lymphoid tissues (61, 62).  
 
PAMPs and DAMPs  
Pattern recognition receptors (PRR) are expressed by innate immune cells 
and are involved in the detection of pathogens and initiating an immune 
response. If a DC encounters a PAMP that can be recognised by PRRs then it 
will develop a more activated phenotype in order to initiate an adaptive 
immune response (63, 64). Similarly, damage to host cells caused by 
pathogens can result in DAMPs being released from damaged cells into the 
extracellular environment, which can also induce DC maturation through 
recognition by PRRs. Importantly, DAMPs are not released when a healthy 
cell dies as a consequence of normal cell turnover, because of a controlled 
form of cell death called apoptosis (65). However, if a cell dies because of 
immune attack, or as a result of stress associated with rapid growth or a 
hypoxic environment (perhaps within a tumour), then the dying cell releases 
DAMPs into the cell environment (66). An example of a DAMP is extracellular 
adenosine triphosphate (ATP) (67, 68), which in the healthy setting is a 
source of energy and is found in high intracellular concentrations. However, 
cell damage can cause ATP to be released into the extracellular environment 
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where it can induce DC maturation (69). A variety of classes of PRRs are 
found in DCs, often differentially expressed depending on the DC subtype. 
The best described are the Toll-like receptors (TLRs), which recognise a 
broad range of prokaryotic structures, such as glycolipid components of 
bacterial cell walls, double stranded RNA from some virus species, and 
unmethylated DNA. They can also recognise some DAMPs, such as HMGB1 
(70). Thus, in general, DCs recognising PAMP or DAMP structures via PRRs 
are induced to mature, and as a result have greater T cell stimulatory 
capabilities. 
 
Licensing dendritic cells 
Although DAMPs and PAMPs have the ability to mature DCs, in many cases 
this stimulation isn’t strong enough to enable them to activate T cells. To 
activate DCs sufficiently to enable CD8+ T cell activation, licensing is often 
required. Licensing a DC induces the DC to produce cytokines such as IL-12 
and upregulate co-stimulatory molecules that are essential for T cell activation 
(71). Maturation of a DC by PRR binding results in the upregulation of CD40 
on the DC plasma membrane, which can then be ligated by CD40L expressed 
by the licensing cell (Figure 1.3) (71, 72). Thus, a synergistic effect occurs 
between PRR binding and licensing (73).  
 
CD4+ T cell licensing 
There is ample evidence indicating that CD4+ T cells can regulate the 
activation status of DCs, aiding in the stimulation of CD8+ T cells. CD8+ T cells 
primed by DCs in the absence of CD4+ T cell licensing are termed ‘helpless T 
cells’ and it was initially believed that helpless T cells were unable to 
proliferate and differentiate into effector T cells. However, recent studies 
indicate that helpless CD8+ T cells have a functional effector compartment but 
a reduced ability to respond to a secondary infection (74). IL-2 is essential 
during CD8+ T cell priming to develop T cells that can respond to secondary 
challenge and the absence of IL-2 during priming generates helpless CD8+ T 
cells (75-77). Interestingly, the IL-2 is not produced by the licensed DC or the 
helper CD4+ T cell but by the CD8+ T cells themselves (76). The licensing of a 
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DC by a CD4+ T cell therefore provides DCs with the ability to activate CD8+ T 
cells, inducing them to produce IL-2 during priming, thereby enabling effective 
responses to secondary challenges (which will be discussed later). 
 
iNKT cell licensing 
As noted earlier, the T cell repertoire includes cells that do not fit into the 
“conventional” categories of CD4+ or CD8+ T cells. Included are populations 
that have largely invariant TCR structures, such as iNKT cells, mucosa-
associated invariant T (MAIT) cells, and Vγ2Vδ2 T cell in humans. The iNKT 
cells have been studied in considerable detail, and like CD4+ T cells have 
been shown to be capable of licensing DCs, which increases their ability to 
activate CD8+ T cells by inducing co-stimulatory marker expression and 
cytokine production (53, 73, 78). The invariant TCR alpha chain expressed by 
iNKT cells (Vα24-Jα18 in humans, Vα14-Jα18 in mice) recognises glycolipids 
presented by the MHC class I-like molecule CD1d. The glycolipid agonist α-
galactosylceramide (α-GalCer) is able to provide activation of host iNKT cells 
in all individuals (in humans and many other mammals), thus making it a 
useful agent to induce DC licensing in immunotherapies. Using α-GalCer to 
activate iNKT cells has been shown to drive a strong cytotoxic T cell response 
against the OVA protein in a CD40L-dependent manner, thereby providing 
mice with increased protection against an OVA-expressing subcutaneous 
tumour (E.G7-OVA) (53, 79). In addition to the CD40L-dependent stimulation 
of DCs by iNKT cells, iNKT cells produce IFN-γ and tumour necrosis factor 
(TNF) α both of which aid in DC maturation (80, 81). 
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Figure 1.3: Activation of a DC by licensing. The ligation of CD40 on the DC 
membrane by CD40L on a licensing cell results in the DC upregulating co-stimulatory 
molecules such as CD40 and CD86 and producing cytokines such as IL-12. This 
provides the DCs with stronger T cell stimulatory capabilities. 
 
 
Interestingly there are a few differences in the DC licensing provided by iNKT 
cells and CD4+ T cells. Following licensing by CD4+ T cells, DCs produce 
ligands that bind to CCR5 expressed by cytotoxic CD8+ T cells, thereby aiding 
in the interaction between licensed DCs and CD8+ T cells (82). On the other 
hand, DCs licensed by iNKT cells express the chemokine CCL17, which 
recruits cytotoxic T cells expressing the receptor CCR4, which also aids in the 
interaction between licensed DCs and CD8+ T cells (83). Of note, these two 
recruitment methods work independently of each other and can therefore be 
used together to provide a synergistic effect on CD8+ T cell recruitment (73). 
The combination of CD4+ T cell and iNKT cell licensing could be used in 
immunotherapeutics to provide enhanced CD8+ T cell stimulation. Because 
iNKT cells are an important component of this thesis they require their own 
section and will be discussed in detail at a later point. 
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1.3.3 Dendritic cell subsets 
The DC subsets described in this section refer to those found in mice, as this 
is the model used in the experiments conducted for this thesis. While there 
are many similarities with human DCs, and some conclusions can be 
extrapolated across species, in general it is recognised that there are 
phenotypic differences, and any functional activities observed in the mouse 
would ultimately have to be validated in human systems.  
 
It is increasingly becoming apparent that DCs are a heterogeneous cell type 
with different subsets having distinct locations and functions within the body. 
The different DC subsets have presumably evolved to have differing antigen 
acquisition and presentation abilities to respond to different forms of 
pathogenic insult. They may also have differing roles in inducing and 
maintaining tolerance to self-antigens. As mentioned above, the important DC 
subsets involved in developing a CD8+ T cell-mediated immune response 
against tumours are likely to be those that have the strongest ability to cross-
present tumour antigens. It is therefore important to define endogenous DCs 
with cross-presentation capability, as these may be exploited in the design of 
immunotherapies. This is a major theme of the thesis. 
 
A major division between DC subsets is the division into conventional DCs 
(cDCs) and plasmacytoid DCs (pDCs). These cells have differing 
developmental programs, with pDCs developing in the bone marrow and 
circulating in the blood as developed pDCs; whereas, cDCs either migrate to 
tissues in a precursor form and then differentiate into cDCs, or have a long-
term precursor in resident tissues that develop cDCs (84). Circulating pDCs 
are an important combatant against viruses as they are a strong producer of 
type I IFNs (85, 86). These cells will not be discussed further in this thesis. 
cDCs can be divided into two groups based on their position within the body, 
they either reside within secondary lymphoid tissues (the lymphoid resident 
DCs) or within tissues peripheral to the secondary lymphoid organs (tissue-
resident DCs) (Figure 1.4). 
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Tissue-resident conventional dendritic cells 
Tissue resident DCs are also known as migratory DCs as they function as 
sentinels or scavengers, continuously searching for and acquiring antigens 
within their resident tissues. Once acquired these DCs can migrate into the 
lymphoid organs for antigen presentation. The best-characterised tissue 
resident DC subsets are those found within the skin and these will be used as 
an example of the different DC populations in peripheral tissues. The skin DC 
subsets can be differentiated based on their expression of the markers CD11b 
and langerin (CD207) (87). In the dermis there are two populations of DCs, 
the CD11b+ langerin- dermal DCs and the CD11b- langerin+ dermal DCs (88, 
89). The epidermis contains a single subset of DC called Langerhans cells, 
which expresses both CD11b and langerin (90). The three DC subsets in the 
skin differ significantly in their functions, for example the langerin+ dermal DCs 
are the main skin-resident subset involved in antigen cross-presentation (91) 
and the CD11b+ dermal DCs are more involved in the presentation of antigens 
on MHC class II to CD4+ T cells. Conversely, the Langerhans cells in the 
epidermis extend out dendritic processes that allow the acquisition of antigens 
from surrounding keratinocytes and from the external surface of the skin (92, 
93). While they can migrate with antigens to the secondary lymphoid organs, 
they do not present antigens directly to CD8+ T cells (94-96). 
 
Lymphoid Resident conventional dendritic cells 
Lymphoid resident DCs, as the name suggests are found within the 
secondary lymphoid organs. In lymph nodes they acquire antigens draining 
through the lymphatic system (97) and in the spleen they acquire antigens 
circulating within the blood (96, 98). Lymphoid resident DCs can also acquire 
antigens through a process called antigen transfer, which involves a migratory 
DC transferring an antigen that was acquired in a peripheral tissue to a 
lymphoid resident DC (99, 100).  
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Figure 1.4: Dendritic cell subsets. The lymphoid resident DCs consist of CD4- 
CD8α- DCs, CD4+ CD8α- DCs, langerin- CD8α+ DCs and langerin+ CD8α+ DCs. The 
tissue resident DCs of the skin consist of the Langerhan cells in the epidermis and 
the CD11b+ langerin- DCs and CD11b+ langerin+ DCs of the dermis. The tissue 
resident DCs can acquire antigens in the peripheral tissues and then migrate to the 
lymphoid tissues for T cell stimulation. Adapted from Heath (87). 
 
The lymphoid resident DCs can be further divided into several groups, based 
on their function and expression of CD4 and CD8α. Thus, within the spleen 
there are CD4+ CD8- DCs, CD4- CD8α+ DCs (hereafter referred to as CD8α+ 
DCs) and a CD4- CD8- DCs (101). The potent ability of the CD8α+ DCs to 
cross-present makes them a vital component in the stimulation of CD8+ T 
cells against exogenous antigens. A major component of this thesis is 
involved in determining the importance of cross-presenting DCs in generating 
CD8+ T cell responses against tumours. While CD8α+ DCs have the ability to 
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present antigens on MHC class II for the stimulation of CD4+ T cells, the 
CD8α- DCs (which includes CD4+ CD8- DCs and CD4- CD8α- DCs) are much 
more proficient at this process (102). Recently it has been shown that 
separate populations within the CD8α+ subset can be identified. These 
include the langerin+ CD8α+ and the CX3CR1+ DCs (103, 104). The remaining 
DCs within the CD8α+ population that do not express langerin or CX3CR1 are 
referred to as CD8α+ DCs. CX3CR1+ DCs lack the hallmark features 
associated with the other CD8α+ DC subsets, such as IL-12 production and 
the ability to cross-present. Interestingly, their gene expression profile is more 
similar to the CD8α- DCs than the CD8α+. Due to the importance of langerin+ 
CD8α+ DCs in the thesis they require their own section and will be discussed 
in detail below. 
 
Langerin+ CD8α+ dendritic cells 
Langerin+ CD8α+ DCs can be found within the marginal zone, which 
surrounds the arteries entering the spleen. This places them in direct contact 
with blood circulating the body as it drains into the spleen (105). The langerin+ 
CD8α+ DCs are therefore in an ideal position to scan the blood for antigens 
and danger signals. These DCs are very competent at phagocytosing 
apoptotic cells that have been administered intravenously (106). It is therefore 
likely that dead or dying cells circulating in the blood will be acquired 
preferentially by the langerin+ CD8α+ DCs. It is also possible that blood-borne 
tumour cells will similarly be acquired and processed by these DCs, which is a 
major theme of this thesis.  
 
Within the CD8α+ DC population as a whole, it has been shown that langerin+ 
DCs are also the most effective subset at cross-priming CD8+ T cells. This 
was found by injecting mice intravenously with OVA, and then isolating the 
different DC subsets in vitro to determine which subset could most effectively 
stimulate OVA specific CD8+ T cells (107). If langerin+ CD8α+ DCs do indeed 
acquire dying tumour cells that are circulating in the blood, it is possible that 
they will effectively cross-present exogenous tumour antigens to cross-prime 
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CD8+ T cells. It is also possible that these DCs initiate immunotherapy-
induced immune responses that are administered intravenously. 
 
1.3.4 Dendritic cell subsets and cross-presentation 
Over decades, research determining which specific APCs are the most 
efficient at cross-presenting has progressively narrowed the specific cell down 
from all APCs (17, 55, 108), to CD11c+ DCs (38, 109), to only DCs expressing 
CD8α+ (45, 110) and finally to the langerin+ CD8α+ DC subset (107). The 
experiments involved are outlined below. 
 
Although earlier studies indicated that DCs are not the sole cross-presenting 
APCs it was found that when culturing DCs or macrophages with fluorescent 
horseradish peroxidase, the fluorescent signal was detected in the cytosol of 
DCs but not macrophages, a transportation feature that is central to many of 
the theories of the cross-presentation pathways presented earlier (38). This 
indicates that macrophages were unable to transport peptides from 
exogenous proteins into the MHC class I pathway. In addition, this study 
demonstrated that DCs could present peptides from exogenous OVA protein 
to stimulate CD8+ T cells, whereas macrophages could not (38). A similar 
study demonstrated that macrophages infected with the influenza virus were 
unable to activate CD8+ T cells, however when uninfected DCs were cultured 
with infected macrophages a significant CD8+ T cell response was induced. 
This indicates that DCs are more efficient at cross-presentation than 
macrophages. A further study ruled out the cross-presenting ability of other 
APCs by depleting all cells expressing CD11c (a commonly used DC marker) 
in mice. The results from this study revealed that CD8+ T cell proliferation in 
response to intravenously administered bacteria was ablated in me depleted 
of CD11c+ cells. This indicates that DCs are required for effective cross-
priming of CD8+ T cells (111).  
 
In more recent years, the specific DC subset involved in cross-presentation 
was identified as CD8α+ lymphoid resident DCs, as only this DC subset 
activated OVA-specific T cells in vitro when isolated from the spleens of mice 
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that were injected with OVA protein (102, 112). Furthermore, depleting the 
CD8α+ DC subset with an anti-CD8α antibody resulted in significantly reduced 
CD8+ T cell priming in response to cell-associated OVA protein (113). 
Similarly, the CD8α+ DCs were implicated as the most efficient cross 
presenting DCs by administering cytochrome C into mice, which induced 
apoptosis in cells that could effectively transport the pro-apoptotic protein from 
the endosome into the cytosol (110). It was found that following cytochrome C 
administration a majority of DCs expressing CD8α were depleted, although 
the fact that some remained pointed to some heterogeneity in the CD8α+ 
population as a whole (39). This group subsequently found that the CD8α- 
DCs did not contain the same ability to present exogenous OVA peptide to 
CD8+ T cells as the CD8α+ DCs (39).  
 
Research from my own laboratory has provided strong evidence that the most 
potent cross-presenting DCs are a subset within the CD8α+ DCs that express 
langerin (107). This conclusion was drawn from studies using a transgenic 
mouse strain in which all langerin-expressing cells can be specifically ablated 
(114). It was found that cross-presentation of OVA peptides was significantly 
reduced when the langerin+ DCs were ablated (107). Together these results 
indicate that a population of DCs expressing both langerin and CD8α are the 
main cross-presenting cell. 
 
What makes some dendritic cell subsets better at cross-
presentation than others? 
It remains to be established what specific features enable a DC to be efficient 
at cross-presentation, however several hypotheses have been developed. It is 
possible that cross-presenting DCs harbour specialized machinery for cross-
presentation or that they have greater access to proteins for cross-
presentation (115-117). The former idea is supported by studies that indicate 
that the CD8α+ lymphoid resident DCs have enriched levels of proteins 
involved in MHC class I presentation, such as TAP1, TAP2, Sec61 and ERAP 
(117), which would enable more acquired antigens to enter the MHC class I 
pathway. Additionally, it has been proposed that cross-presenting cells have 
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reduced levels of antigen degradation in the phagosome due to alkalinisation 
of the phagolysosome lumen by the nicotinamide adenine dinucleotide 
phosphate NADPH oxidase (NOX2). This prevents proteins within the 
phagolysosme being rapidly degraded, thereby leaving sufficient antigens for 
effective presentation. DCs that do not recruit NOX2 have increased 
acidification of the phagolysosome resulting in increased antigen degradation, 
thereby reducing the amount of antigens remaining for cross-presentation 
(118). 
 
It has also been suggested that a factor that determines whether an antigen is 
cross-presented or not is the method by which the antigen is taken into the 
cell. In this model, antigens that are acquired by specific receptors are 
directed towards the cross-presentation pathway and the cross-presenting 
DCs either express these receptors at higher concentrations than other cells 
or the receptors are specific to cross-presenting DCs (119). There are several 
known receptors with a putative antigen acquisition function expressed on the 
cross-presenting langerin+ CD8α+ DCs that are not expressed on the CD8α- 
DCs, such as DEC205 and DEC207. In particular, CLEC9A which is 
expressed by CD103+ DCs, including CD8α+ DCs, recognises an intracellular 
ligand that is only expressed by a cell upon it’s death. It has been 
demonstrated that necrotic cells acquired by DCs via CLEC9A avoid being 
rapidly degraded and favours the entry of cell antigens into the MHC class I 
pathway. In support of this, deficiency in CLEC9A also results in reduced 
cross-presentation of antigens derived from dead cells (120). 
 
1.3.5 Models of dendritic cell subset depletion 
As mentioned above, an effective way to elucidate the roles of specific DC 
subsets is by determining how an immune response is altered in the absence 
of that subset. The aim of this thesis was to determine the role of the langerin+ 
CD8α+ DCs in activating anti-tumour CD8+ T cells and this was determined by 
analysing anti-tumour T cell immunotherapies in mice depleted of their 
langerin+ CD8α+ DCs. Therefore, to understand the model used in this project 
an understanding is required of how the langerin+ CD8α+ DCs can be 
Chapter 1: Introduction 26 
depleted in healthy mice. Specifically, a description is provided of a transgenic 
mouse model called the langerin-diphtheria toxin receptor (DTR) mice (lang-
EGFPDTR) in which it is possible to specifically deplete the langerin+ cells 
(114). 
 
Diphtheria toxin receptor 
Diphtheria toxin (DT) produced by the bacteria Corynebacterium diptheriae, is 
able to effectively kill human cells by gaining access cell cytoplasm via the 
human DTR, where it blocks the cells ability to synthesize proteins. The 
mouse DTR is structurally different from the human counterpart, which 
significantly reduces the ability of DT to bind to the receptor and thereby enter 
the cell (121). This renders the murine cell 103–105 times more resistant to DT 
than human cells. This three amino acid difference between the murine and 
human DTRs has been exploited to permit the ablation of specific cell types 
within mice by genetically engineering the high affinity human DTR to be 
associated with specific cell markers. This approach has enabled the human 
DTR to be expressed by the promoters of specific DC markers, thereby 
associating the human DTR with those markers and permitting the selective 
ablation of specific cell subsets (122). Cells that internalise DT die through the 
steady and controlled cell death called apoptosis, thereby preventing the 
induction of an inflammatory response against debris from the dying cells. The 
DT depletion model is an inducible and temporary depletion, which gives it 
advantages over other DC depletion models, such as the Batf3 knock out 
(KO) mouse (123), which have the Batf3 transcription factor deleted from 
hosts, resulting in ablated development of the CD8α+ DCs. The DT model 
therefore allows the mice to develop and grow as normal, healthy mice, and 
the specific DC subsets can then be depleted on demand.  
 
CD11c-DTR 
The first DTR-based DC depletion model was developed by associating the 
human DTR to the integrin receptor CD11c, which is expressed on murine 
DCs (111). By administering 100 ng of the DT intraperitoneally it became 
possible to deplete all CD11c+ DCs for a period of 24–48 hours, at which point 
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the cells began to repopulate within the host. This depletion model enabled 
analysis of the specific functions of DCs as a whole, and as a result the 
importance of DCs in priming cytotoxic T cells was determined (111). The 
CD11c-DTR ablation model does have some limitations however, the most 
significant of which is the inability of these mice to survive for long periods of 
time following multiple DT treatments. This is likely due to the expression of 
DTR on non-haematopoietic cells, as the lethality can be overcome by 
generating bone-marrow chimeras where DTR expression is restricted to 
haematopoietic cells (124). 
 
Langerin-EGFPDTR 
Two separate groups initially developed the lang-EGFPDTR mouse model in 
2005, by inserting the human DTR into the langerin locus. The aim of these 
studies was to deplete the epidermal derived Langerhans cells in order to 
determine their function (125, 126). However, the development of these mice 
provided a means to deplete all langerin expressing cells including CD11b- 
langerin+ DCs found in the dermis, lung, liver, kidneys, small intestine, lymph 
nodes and also the langerin+ CD8α+ DCs in the spleen. Cells expressing 
langerin could be depleted in the lang-EGFPDTR mice within 24–48 hours by 
a single intraperitoneal administration of DT, reducing the percent of CD11c+ 
DCs expression both CD8α and langerin from 9.5% to <0.5% (114). No 
detectable inflammation was detected following DT treatment and unlike the 
CD11c-DTR model these mice can withstand multiple DT treatments. 
 
In this thesis the langerin+ CD8α+ DCs in the spleen were analysed using the 
lang-EGFPDTR mouse model. However, due to the depletion of all langerin+ 
cells following DT treatment, the function of the langerin+ CD8α+ DCs needs 
to be differentiated from those other subsets. For this reason, the tumour 
models and immunotherapies were administered intravenously, as it has been 
demonstrated that the activation of CD8+ T cells with TLR ligands and OVA 
protein is significantly ablated in mice with surgically removed spleens, 
relative to mice that had sham surgeries (unpublished data from our 
laboratory, with permission from T. Osmond). This indicates that DCs in the 
Chapter 1: Introduction 28 
spleen were required to activate CD8+ T cells with intravenously administered 
vaccines. Therefore, immunotherapies administered intravenously in the 
absence of langerin cells enable the analysis of the functions of langerin 
expressing cells in the spleen. In addition, the tumour cells were also 
administered intravenously in this thesis so that the tumour antigens would be 
preferentially acquired by APCs in the spleen. 
 
1.4 T Cells and the anti-tumour response 
The aim of many cancer immunotherapies is to provide tumour-bearing hosts 
with effector CD8+ T cells capable of targeting and killing tumour cells. T cells 
are part of the adaptive immune response, which already noted, is slower but 
much more specific than the innate immune responses. Prior to activation, T 
cells are said to be in a naïve state, in which they are presented antigens by 
DCs to determine if the TCR can bind to the peptide/MHC complex. Once an 
antigen that can be recognised by a T cells TCR is found the T cell is 
stimulated into immunity or tolerance. Naive T cells remain circulating within 
the secondary lymphoid organs due to their expression of the lymph node 
homing receptors CD62L and CCR7, which bind to receptors found at high 
concentrations in the secondary lymphoid organs (127-129). The importance 
of sequestering naïve T cells within the lymphoid tissues is to aggregate rare 
T cells within a specific area so that they are easily accessible to migrating 
APCs (130).  
 
1.4.1 T cell development 
During the development of T cells a rigorous selection process is performed to 
remove T cells that respond to self-antigens, thereby preventing the 
development of autoimmune T cells. As noted earlier in the chapter, the 
implication of removing self-reactive T cells from the immune system in the 
tumour context is that T cells with TCRs specific for self-antigens that might 
have served as targets in tumour tissue have also largely been removed 
during selection. This limits the repertoire of antigens that can be used to 
generate an anti-tumour immune response. An overriding feature is that 
tumour antigens must be presented in some way that is unique and 
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distinguishable from healthy cells. The specific types of tumour antigens will 
be discussed at a later point. 
 
Following development in the bone marrow, progenitor T cells migrate to the 
thymus expressing neither CD4 nor CD8 co-receptors (131, 132). The 
progenitors develop a unique TCR typically composed of an α and β chain. 
Each chain consists of a variable (V) amino-terminal region, a joining (J) and 
a constant (C) region. In addition, the β chain has a diversity (D) region. Each 
region has numerous gene segments and the assembly of these genes 
through V(D)J recombination creates a unique gene sequence and as a result 
a unique TCR (133). Following successful recombination, the thymocytes then 
express both CD4 and CD8. At this stage of development thymocytes 
undergo a selection process to ensure that the T cells that ultimately enter the 
circulation can recognise peptides in the context of self-MHC molecules, but 
do not have high affinity for self-antigens (132, 134). The thymus can be 
divided into two main regions, the peripheral cortex and the central medulla. 
Positive selection occurs in the cortex where epithelial cells present MHC 
class I and II molecules (135, 136). Thymocytes that have TCR receptors that 
can recognise the MHC molecules are able to survive. The remaining cells 
are removed from the population due to lack of stimulation (“death by 
neglect”) (137, 138). The surviving cells down-regulate either CD4 or CD8 to 
become single positive cells, and the marker that remains depends on 
whether the TCR recognises MHC class I or II. The single positive cells then 
move into the medulla were negative selection occurs. Self-peptide/MHC 
molecules are presented to the thymocytes by APCs and those that bind too 
strongly are killed, thereby removing autoimmune T cells (139). The remaining 
T cells bind to self-MHC ligand with a mild affinity and these constitute around 
1% of the initial T cell population, however this still provides the host with 
enough T cells to recognize around 108 different antigens (140). At this point 
the T cells leave the thymus and enter secondary lymphoid organs. 
 
A subset of T cells that bind to self-MHC ligand with high affinity survives 
positive selection and is programmed to have suppressor function. These 
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regulatory T cells (Tregs) suppress anti-self T cells that have escaped negative 
selection, thereby providing another barrier to avoid an autoimmune response 
(141, 142). These cells have be defined on the basis of constitutively 
upregulated expression of the IL-2 receptor α chain (CD25), although a more 
accurate correlate with suppressor function is expression of the transcription 
factor forkhead box P3 (Foxp3). This subset of T cell will be described in 
greater detail at a later point. 
 
1.4.2 T cell activation 
In order for a DC to induce the activation of a naïve T cell, it must present an 
appropriate MHC/peptide complex in combination with co-stimulatory 
molecules, and also provide the T cell with cytokines, such as IL-12 (130, 143, 
144). The CD4 or CD8 co-receptors expressed by the T cell bind to the MHC 
molecule presented by the DC, thereby stabilizing the TCR/MHC/peptide 
interaction (145).  
 
An important factor that determines if the T cell is activated or rendered 
anergic by this interaction is the presence or absence of co-stimulation 
provided by the APC (146). The best-characterised co-stimulatory molecule 
interaction is the binding of the T cell molecule CD28 to either CD80 or CD86 
on a DC (56). A specialized form of co-stimulation called bidirectional co-
stimulation activates both the APC and the T cell. For example, ligation of 
CD40 on a DC by CD40L presented by a T cell results in co-stimulatory 
signals provided to the T cell, thereby aiding T cell activation and it also 
induces the upregulation of CD80 and CD86 on the APC (59, 80).  
 
Naïve T cells undergo a series of changes as they differentiate into effector T 
cells that allow them to leave the lymph node, enter inflamed tissue, and 
perform effector functions, which for CD8+ T cells includes a cytotoxic 
response. The T cell undergoes proliferation to provide a significantly 
increased population of antigen-specific cells (143). The high affinity IL-2 
receptor, CD25, is also upregulated on activated T cells, allowing the cells to 
respond more effectively to IL-2, which drives the proliferative response (147). 
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Activated T cells develop a phenotype that allows them to leave the lymphoid 
tissues by down-regulating the expression of CD62L and CCR7. The markers 
CD44, CCR2 and CCR5 are upregulated on effector T cells allowing them to 
migrate into inflamed tissues from the blood where they perform their effector 
functions (147-149). Effector capabilities are developed in a manner that is 
specific to the T cell subset, for example CD8+ T cells produce cytotoxic 
molecules, such as perforin and granzyme B, and upon activation the genes 
that encode these proteins are expressed (147). These activated CD8+ T cells 
are now fully differentiated CTLs, and are now equipped to migrate to target 
tissues, such as tumours, and eliminate antigen-expressing cells. 
  
A T cell response generated against a pathogen must at some point be turned 
off as an uncontrolled immune response can lead to tissue damage. Following 
T cell activation, the pool of effector cells enter a programmed response that 
dictates when the T cell population will reduce in number (150, 151). This 
reduction is called the contraction phase of the T cell response, with 
approximately 95% of the effector T cells undergoing apoptosis. The 
remaining T cells develop into memory cells that initiate a faster adaptive 
immune response if the antigen is encountered again (152). Memory cells will 
be discussed below. 
 
1.4.3 T cell functions 
Cytotoxic T cells 
Perforin and granzyme 
CD8+ T cells cause apoptosis upon TCR binding to an antigen/MHC complex 
on target cells by releasing lytic granules that contain cytotoxic proteins. The 
cytotoxic proteins are maintained in an inactive form within the lytic granules 
and only upon their release do they develop cytotoxic potential (13, 153). 
Cytotoxic proteins called granzymes, particularly granzymes A and B are able 
to induce apoptosis of a target cell in a caspase dependent or independent 
pathway (13). Granzyme A induces deoxyribonucleic acid (DNA) damage 
independent of caspase activity and functions by activating a complex of 
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molecules containing endonucleases and exonucleases. Once the complex 
has migrated into the nucleus, the endonuclease cleaves DNA and the 
endonuclease expands the break by removing bases from the fragment, 
thereby reducing the chance of DNA repair (154-156). Granzyme B, on the 
other hand, induces apoptosis via caspase dependent pathways. It can 
directly activate caspase 3, which also results in DNA fragmentation (157, 
158). Granzyme B can also induce mitochondria damage, thereby decreasing 
mitochondrial function and causing cell death. Mitochondrial damage can also 
cause the release of cytochrome C, which enters the cytosol and induces 
activation of the Apaf-1 complex, which in turn induces the activation of 
caspases 3, 6 and 7, all of which trigger apoptosis (158, 159).  
 
Granzyme A and B are significantly less effective at inducing target cell 
apoptosis when released alone due to a decreased ability to enter the cell. 
Granzyme A and B are therefore secreted with another protein called perforin, 
which forms pores in membranes between 5 to 20 nM in size (160, 161). 
Following endocytosis of the granzymes and perforin molecules, perforin 
forms a pore in the endosome, thereby allowing granzyme A and B to enter 
the cytosol and mediate apoptosis of the target cell (162, 163).  
 
FasL 
Cytotoxic CD8+ T cells express FasL (CD178), which can interact with target 
cells that express Fas (CD95) to induce apoptosis of the target cell in a 
caspase dependent manner (164, 165). The Fas receptor is expressed on 
most tissues and also has non-apoptotic functions. The tissue in which Fas is 
expressed and the presence of other proinflammatory mediators are likely to 
determine the effect of Fas ligation (166, 167). In the apoptotic inducing 
setting, the caspase cascade that results from Fas-FasL interaction results in 
the activation of caspase 8, which activates caspases 3, 6 and 7 directly, 
thereby resulting in apoptosis (168). Caspase 8 activation also results in 
damage to the mitochondrial outer membrane, allowing cytochrome C to enter 
the cytosol and activate the Apaf-1 complex resulting in the induction of 
apoptosis (169, 170). 
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Cytokine production 
Following activation, CD8+ T cells begin producing cytokines such as IFN-γ, 
TNF-α and TNF-β (171). There are several functions of IFN-γ that can aid in 
protection against tumour development. These include promoting apoptosis of 
tumour cells by upregulating both Fas and FasL on tumour cells, thereby 
inducing the interaction of these two molecules between tumour cells (172, 
173). Furthermore, IFN-γ is able to damage blood vesicles that supply 
tumours with nutrients, resulting in necrosis of the tumour cells (174). It also 
aids in the ability of CD8+ T cells to recognize tumour cells by increasing the 
expression of MHC class I on tumour cells, thus increasing the expression of 
antigens that CD8+ T cells use to identify their targets (175, 176). The activity 
of IFN-γ also includes the inhibition of tumour cell proliferation (177, 178) and 
the activation of macrophages (which will be discussed in the next section). 
The targets of TNF-α and TNF-β are not tumour cells directly but host cells; 
however, at high concentrations they can cause haemorrhagic necrosis (179). 
Both of these cytokines promote tumour destruction by activating DCs, 
increasing the tumour killing functions of macrophages and NK cells and by 
promoting the functions of T cells (180, 181). The adhesion molecules E-
selectin, intracellular adhesion molecule-2 and vascular cell adhesion 
molecule-1 are upregulated on endothelial cells in response to TNF 
interaction, thereby aiding leukocyte recruitment and enhancing the 
inflammatory response (182). In addition, vascularisation caused by TNFs, 
increase local blood flow, also aiding immune cell recruitment. 
 
T helper cells 
Antigen-specific CD4+ T cells constitute an essential component to immune 
responses against a variety of pathogens or abnormal cells, including tumour 
cells. In addition to licensing DCs (as mentioned earlier), CD4+ T cells can 
mediate tumour protection independent of CD8+ T cells by activating other 
immune cells. CD4+ T cells have recently been found to also produce 
cytotoxic molecules such as granzyme B (183-185). The importance of the 
cytotoxic functions of CD4+ T cells is poorly understood, however it is 
receiving increased attention. 
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There are several different subsets of CD4+ helper T cells, each of which is 
unique in their cytokine repertoire and type of infection that they are 
specialised to control. The cytokines within the environment during CD4+ T 
cell priming and the strength by which the TCR binds to the antigen 
determines the class of helper cell that is generated (186). The helper T cell 
subsets include T helper (Th) 1, Th2, Th9, Th17, Th22, follicular helper T cells 
and Tregs. The functions of the Th1 cells and Tregs are the most relevant 
subsets in this thesis and the other subsets will not be mentioned further. 
 
Th1 cells 
When stimulated in the presence of IL-12, naïve CD4+ T cells are driven into 
Th1 cells (187, 188). In addition, IFN-γ can likewise drive the differentiation of 
CD4+ T cells into Th1 cells (189). Activated Th1 cells produce IL-2, IFN-γ, TNF-
α, IL-3 and granulocyte macrophage colony stimulating factor (GM-CSF) and 
contribute to anti-tumour immunity by recruiting phagocytic cells such as 
macrophages into the tumour bed (190-192). Once within a tumour, the 
macrophages are activated by two signals produced by Th1 cells, the ligation 
of CD40 on the macrophage, and IFN-γ (193). Activated macrophages rapidly 
degrade material engulfed from the environment, such as tumour material, 
and begin producing reactive nitrogen species such as nitric oxide and 
superoxide that can be toxic (191). In addition, activated macrophages can 
secrete CXCL9 and CXCL10, which can inhibit tumour growth by preventing 
angiogenesis (192).  
 
In addition to aiding in tumour destruction by recruiting macrophages, Th1 
cells can also kill tumour cells directly by ligating the Fas receptor on the 
tumour cell, thus inducing apoptosis (194). Licensing DCs is also a critical 
function of Th1 cells as it aids in CD8+ T cell priming. In addition, Th1 cells that 
enter tumour tissue play a useful role in producing IFN-γ, which has anti-
angiogenic properties, and also causes tumour cells to increase the 
expression of MHC class I, thereby making a better target for the effector 
CD8+ T cells (176). 
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Although the research in this thesis is aimed at analysing the role of the 
langerin+ CD8α+ DCs in stimulating CD8+ T cells against tumours, the direct 
anti-tumour activity of Th1 cells and their ability to aid in the function of CD8+ T 
cells must be acknowledged. In addition, langerin+ CD8α+ DCs may play an 
important role in activating naive CD4+ T cells and aiding their differentiation 
into Th1 cells. 
 
Regulatory T cells 
As mentioned earlier Tregs can develop during the normal process of CD4+ T 
cell maturation in the thymus. These cells are referred to as natural Tregs. 
However, similar cells with suppressor function can also differentiate from 
naïve Foxp3-/- CD4+ T cells, when activated in the presence of TGF-β These 
are called inducible Tregs (195). The general function of Tregs is to suppress 
immune responses. This can be to limit responses against self-antigens, or to 
shut down an immune response against pathogens once they have been 
cleared. The suppressive nature of Tregs has severe implications on tumour 
immunity and this will be discussed in detail at a later point. 
 
1.4.4 Memory T cells 
When the levels of antigen used to generate an effector T cell population has 
reduced within the host, the T cells with TCRs specific for that antigen will 
enter the contraction phase (196, 197). A small population of T cells remain 
following contraction that have developed into long-lived memory T cells to 
ensure that a strong immune response can be generated if the pathogen to 
which the antigen derives is detected again.  
 
Memory cells are able to survive within a host through the contraction phase 
and for a significant period of time thereafter, due to the ability of memory T 
cells to self-renew in response to IL-7 and IL-15. For this purpose, the 
receptors IL-7Rα (CD127) and the IL-15Rβ (CD122) are upregulated on 
memory cells and these markers can be used to identify memory cells (198, 
199).  
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When antigens are encountered a second time, the resulting “secondary” 
response that is initiated is faster and stronger than a primary response due to 
the greater number of antigen-specific memory T cells within the host 
repertoire. In addition, memory cells reside in a primed state that enables a 
quicker response (200-202). Memory CD8+ T cells also respond to lower 
levels of antigen than naïve T cells (203, 204) and require less co-stimulation 
(205). 
 
Memory T cell subsets 
The T cells that remain after the contraction phase are divided into distinct 
subsets of memory cells whose functions cooperate to provide protection 
upon reinfection. The first two memory subsets discovered are central 
memory (TCM) and effector memory (TEM) cells (127). The lymphoid homing 
receptors CD62L and CCR7 are expressed by TCM cells and subsequently 
they recirculate through the secondary lymphoid organs, like naïve T cells 
(206). As the most likely sites of secondary infection are in the peripheral 
tissues, the TCM cells function not as the first line of defence but as a means 
to repopulate a host with effector T cells when antigen is encountered. This is 
supported by the high proliferative potential of TCM cells and their ability to 
produce large quantities of IL-2 upon antigen stimulation (127, 207, 208). On 
the other hand, TEM cells express low levels of CD62L and CCR7 allowing 
them to circulate within the blood and enter peripheral sites of inflammation 
(208). Upon antigen stimulation, TEM cells undergo very little proliferation 
relative to TCM, but rapidly produce cytokines such as IFN-γ and cytotoxic 
molecules, such as perforin and granzymes (127, 209).  
 
Recently a subset of memory cell very similar to TEM has been discovered that 
does not recirculate through the blood like TEM cells but reside solely within 
tissues. This subset is called resident TEM (rTEM) cells (210). The benefit of the 
rTEM cells is that they reside within tissues and can therefore respond faster to 
secondary infection within their resident tissues. They respond to antigen 
encountered by both attacking the infected or abnormal cells and by recruiting 
TEM cells circulating in the blood. The overall memory response therefore 
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consists of three waves, beginning with an attack by the rTEM, followed by 
recruitment of the migrating TEM cells and ending with the migration of effector 
T cells that were generated by TCM cells in the lymphoid organs. 
 
Recently, a population of long-lived T cells has been identified that has stem 
cell-like qualities and these have being termed “memory stem cells” (TSCM) 
(211). This memory cell subset arises after antigenic stimulation and they 
have a phenotype similar to that of naïve T cells. In addition, TSCM and naïve T 
cells are located in the same area of the secondary lymphoid organs. Similar 
to TCM, TSCM have enhanced proliferative abilities relative to the other T cell 
populations and are able to generate effector T cells and all memory subsets. 
It is therefore possible that the generation of TSCM is essential to maintain 
memory T cell populations. 
 
CD8+ T cells generate in the absence of CD4+ T cell help can develop an 
effector T cell response, however the memory response generated in the 
absence of help is significantly impaired (212, 213). Memory cells generated 
in the absence of help have a reduced ability to produce cytotoxic molecules, 
such as interferon (IFN)-γ, perforin, granzyme A and B and FasL, and they 
express more regulatory molecules such as IL-10Rα, TGF-β and TGF-βRII 
(214). Therefore, although memory cells can be developed in the absence of 
help, they are unable to respond to secondary challenges (212, 215, 216). 
 
1.5 Invariant Natural Killer T cells 
T cells that react with CD1d were termed iNKT cells because of their 
expression of NK cell and T cell markers. However, it has now been 
determined that not all iNKT cells express NK markers (217). The discovery of 
α-GalCer and development of α-GalCer-loaded CD1d tetramers has enabled 
significant developments in the identification and analysis of iNKT cells (217, 
218). These cells are an innate-like cell found in high numbers in the spleen, 
liver and bone marrow and are able to rapidly produce cytokines in response 
to stimulation, similar to TEM cells (219). The TCR of iNKT cells is invariant, 
consisting of an α-chain restricted to the Vα14-Jα18 gene rearrangement in 
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mice and a limited number of β-chains (218, 220, 221). The TCR recognizes 
glycolipids, both self and pathogen derived, that are presented on the MHC 
class I-like molecule CD1d, which is expressed at high levels by DCs (222, 
223). 
 
The development of iNKT cells begins the same as for conventional T cells, 
but differentiate during the double positive stage mentioned earlier (224). 
Current evidence indicates that the development of the invariant TCR, Vα14-
Jα18 is through the random selection of genes during V(D)J recombination as 
with conventional T cells (225). However, T cells with the invariant TCR bind 
to CD1d molecules presented with an internally derived antigen by other 
double positive thymocytes, as opposed to MHC molecules presented by 
epithelial cells during conventional T cell development (226, 227). The binding 
of an iNKT cells TCR to CD1d is thought to initiate the iNKT cell 
developmental program, involving the expansion of the precursor cells and 
the development of the iNKT cell phenotype. There is evidence indicating that 
dendritic cells can induce negative selection of iNKT cells in the thymus, as 
mice that over expressed the CD1d molecule had a significantly decreased 
population of iNKT cells (228). The increase in CD1d likely caused by 
stronger binding between the DC and iNKT cell, resulting in more iNKT cells 
removed during negative selection. Some iNKT cells migrate from the thymus 
in an immature state and develop further in the periphery. Others remain 
within the thymus and mature before entering the peripheral tissues (229, 
230). 
 
The evolutionary reason why a population of T cells with an invariant TCR 
exist is unknown, however several theories have been developed. One idea 
involves the development of iNKT cells as a result of evolutionary selection for 
a TCR that recognises multiple antigens deriving from pathogens in the 
ancestral environment (231). Another suggestion involves the fact that iNKT 
cell activation following infection with LPS-positive bacteria was mediated 
indirectly via DC activation of T cells following TLR stimulation, whereas LPS-
negative bacteria directly activated iNKT cells with cell wall gycolipids. Thus it 
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is possible that iNKT cells evolved as a defence against bacteria that do not 
have cell wall ligands that TLRs can recognise (232).  
 
The invariant TCR, in combination with their potent licensing ability, makes 
iNKT cells an attractive target for immunotherapies, as a single ligand can be 
used to activate iNKT cells irrespective of an individuals MHC tissue type. An 
example of a glycolipid that provides a blanket iNKT cell activation stimulus is 
α-GalCer, which activates iNKT cells in a CD1d-dependent manner. Following 
administration, α-GalCer rapidly activates iNKT cells enabling them to license 
DCs in a CD40L-dependent manner (53, 78). Licensed DCs produce IL-12, 
which stimulates the release of IFN-γ by iNKT cells. The IFN-γ produced by 
iNKT cells activates NK cells, inducing them to also produce IFN-γ (233). The 
resulting IFN-γ significantly contributes to an anti-tumour response, including 
through its anti-angiogenic properties (234, 235). In addition, the activated 
iNKT cells are able to induce direct killing in a CD1d dependent manner. This 
was demonstrated by the iNKT cell-mediated killing of CD1d+ AML cells that 
were pulsed with α-GalCer, largely through the ligation of FasL on the iNKT 
cell with Fas on the target cell (236, 237). The importance of iNKT cells in 
mediating an immune response against tumours was made evident by using 
CD1d and Jα18 KO mice (mice that cannot develop iNKT cells), which were 
significantly more susceptible to chemically induced tumours, such as 
prostate and sarcoma tumours (238, 239). Manipulating iNKT cells for the 
benefit of mediating anti-tumour protection will be discussed in detail later. 
 
1.6 Tumour development and the immune system 
Tumours develop when cells escape from various control mechanisms that 
limit cell-cycle progression. This occurs via genetic and epigenetic mutations 
that result in the activation of oncogenes and inactivation of tumour 
suppressor pathways (240, 241). Thus, the cell is able to proliferate without 
control enabling an exponential increase their population. This results in a 
significant propagation of these tumour cells, either as a solid node within 
tissues or as circulating cells within the blood. The difficulty for the immune 
system to prevent the progression of tumours is largely due to the inability of 
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the immune system to differentiate between healthy and tumour cells. Ideally 
an immune response generated against a tumour will not attack healthy cells 
and for this to occur the tumour antigens used to stimulate the adaptive 
immune response must be presented in a tumour-specific context. This 
makes it difficult for the host to develop an endogenous immune response 
when a malignancy is first initiated, and also makes it difficult to devise 
immunotherapies directed against established tumours. This difficulty is 
exacerbated by the immune suppression generated by a tumour, which not 
only suppresses endogenous responses, but can also be a significant barrier 
to anti-tumour immunotherapies (242). The interaction between a tumour and 
the immune system is complex and can range from the immune system being 
completely ignorant of the tumour to providing complete tumour rejection. A 
better understanding of this interaction is required to improve immunotherapy. 
 
1.6.1 Tumour immunoediting 
Evidence demonstrating that the immune system is capable of identifying 
tumours as dangerous is indicated by the fact that tumour-specific CD8+ T 
cells can migrate into tumours. In many cancers, including breast (243), colon 
(244), ovarian (245) and skin cancers (246), the presence of tumour infiltrating 
lymphocytes (TILs) is correlated with a better prognosis, thus the immune 
system is to some degree able to attack tumours. For an effective anti-tumour 
adaptive immune response, tumour cells and not healthy cells must primarily 
express the antigen used to activate T cells so as to avoid autoimmunity. 
Examples of the types of antigens that can be expressed by tumours and 
recognised by the immune system, are indicated below. 
 
Tumour antigens 
Tumour-specific antigens 
Tumour specific antigens arise from the genetic instability associated 
neoplastic transformation, with mutations causing neo-antigens that are 
expressed by the tumour cell alone (247). The formation of tumour-specific 
antigens is unpredictable and therefore their detection is rare, making their 
use as targets for immunotherapy difficult (248). The host’s own immune 
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system is likely to be capable of developing a strong T cell response against 
this type of antigen, as neo-antigens are effectively ‘foreign’ and therefore T 
cells recognising these antigens are unlikely to have been deleted through the 
process of central tolerance. An example of a tumour-specific antigen is the 
mutated peptide p53210-223, with a missense mutation causing an amino acid 
change from tyrosine to cysteine at position 220 (249). All cells express p53, 
as it functions as an inhibitor of cell growth by controlling cell cycle 
progression and apoptosis (250). When mutated, loss of p53 function can 
contribute to uncontrolled cell growth resulting in tumour development. 
Importantly, mutated sequences from the p53 protein can be presented on 
MHC molecules to T cells, providing unique antigens that severe as targets 
for tumour elimination (251).  
 
Tumour-associated antigens 
Tumour-associated antigens are tumour antigens that are typically only 
expressed in a select number of healthy tissues. For example, expression of 
cancer/testis antigens (such as NY-ESO-1) is restricted to the testis and 
ovaries (252, 253). In these healthy tissues the immune system is mildly 
suppressed, thereby preventing an autoimmune response against these 
antigens (253). When NY-ESO-1 is expressed on a tumour outside of the 
testis or ovaries an immune responses that targets the tumour can be 
generated, while generally avoiding autoimmunity due to the suppressive 
environment in their original tissues (253).  
 
Other tumour-associated antigens are those that are expressed in a wider 
variety of healthy cells, but are over expressed by tumour cells (27, 254). For 
example, the expression of the wild-type p53 protein, which as mentioned, is 
expressed in all cells, is often over expressed in tumour cells (254). In order to 
initiate an effective anti-tumour response, the immune system would have to 
differentiate the tumour cells from healthy cells based not on the presence of 
the antigen but on the level of expression. 
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Stromal antigens 
Another type of antigen that is an effective target for tumour immunotherapy 
belongs to the cells that support a tumour and not to the tumour cells 
themselves (255). These cells are called stromal cells and include fibroblasts, 
vascular endothelial cells and macrophages. An example is fibroblast 
activation protein (FAP), which is highly expressed by tumour-associated 
fibroblasts that often make up a significant portion of the stroma (256). Using 
a DC-based vaccine to develop an immune response against FAP antigens 
has proven to be effective in the treatment of colon cancer in mice (257). 
 
1.6.2 Host immune responses to tumours; the elimination 
phase 
The complex interaction between the immune system and a tumour has 
broadly been differentiated into three different states that are based on the 
success of the immune system at eradicating a given tumour. These three 
states consist of elimination, equilibrium and escape. Elimination occurs when 
the immune system mounts a successful attack on tumour cells. This occurs 
frequently in healthy individuals by preventing tumour growth and 
development. This is made evident by experiments involving the treatment of 
immunodeficient mice with the chemical carcinogen 3-methylcholanthrene to 
induce sarcomas. Immunodeficient mice developed significantly more 
tumours following 3-methylcholanthrene treatment compared to wildtype mice, 
indicating that the immune system is capable of preventing tumour 
development (258, 259). In addition, the cytotoxic protein perforin has been 
demonstrated to be essential in protecting mice from developing a 
spontaneous lymphoma, which further demonstrates that the immune system 
has the potential to protect a host from tumour development (260). 
 
1.6.3 Host immune responses to tumours; the equilibrium 
phase 
Equilibrium (also known as immune mediated tumour dormancy) is where the 
immune system and the tumour have reached a state of equilibrium and the 
rate of tumour growth is equal to the rate that the tumour is being removed by 
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the immune system. The tumour size within the host is therefore constant due 
to the immune attack. However, if the host is immunocompromised the tumour 
will begin to expand (261, 262). An excellent example of the controlled state in 
which the immune system can hold tumours is seen in cases where a 
secondary melanoma develops in hosts due to receiving a renal transplant 
from someone who once had melanoma (263). Some recipients remained 
tumour-free after transplantation for 16 years before the secondary melanoma 
developed. This indicates that the tumour cells were present for 16 years, 
without being able to grow or be eradicated by the immune system (263). 
Similarly, mice with a dormant B cell lymphoma were symptom free for 60 
days but developed tumours rapidly following suppression of the immune 
system with a CD8 depleting antibody. In addition, inactivating IFN-γ on day 
60 of symptom-free survival also induced tumour growth at the original 
injection site (264). This indicates that CD8+ T cells were actively attacking the 
tumour cells by producing IFN-γ, which was preventing the tumour from 
growing but not eradicating the tumour cells completely. 
 
A constant attack on a tumour by the immune system can have the undesired 
effect of sculpting the tumour to become more immunoresistant. This occurs 
as the immune system attacks the tumour cells it can recognize, leaving the 
immune resistant tumour cells behind to grow and repopulate the tumour, 
thereby developing a more immunoresistant tumour (Figure 1.6) (261). 
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Figure 1.5: Sculpting an immunoresistant tumour by the immune system. The 
difference between the ability of the immune system to recognize given tumour cells 
can result in the development a more immunoresistant tumour. This occurs when the 
immune system attacks and kills the immunosensitive tumour cells while being 
unable to attack the more immunoresistant tumour cells. The immunoresistant 
tumour cells are therefore left to grow and repopulate the tumour resulting in a more 
immunoresistant tumour. 
 
1.6.4 Host immune response to tumours; the escape phase 
When the innate and adaptive immune systems cannot eliminate or contain 
tumour growth, the tumour cells effectively “escape” leading to tumour growth 
and development. Tumour cells can avoid being attacked by the immune 
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system by cell modifications that enable the tumour cells to avoid detection or 
effective attack. In addition, tumours can generate a suppressive environment 
that is able to shut down or prevent the development of an effective immune 
response (262). 
 
Tumour cell modification 
As mentioned above, cells that survive immune mediated attack are left to 
grow, thereby developing an immunoevasive tumour. Some tumour cells 
develop defects in antigen processing or presentation pathways that can 
result in loss of MHC class I proteins (265, 266), immunoproteosome subunits 
(267, 268) or downregulation of the TAP complex (269, 270). These mutations 
impair the ability of the tumour cell to present tumour antigens, thereby 
making it unrecognizable by the adaptive immune response. In addition, 
tumour cells can downregulate the IFN-γ receptor, making them resistant to 
direct killing with IFN-γ (271). Tumour cells can also actively suppress an 
immune response by upregulating molecules on their surface such as PD-L1, 
which interacts with receptors on the surface of T cells and dampens their 
functions or induces apoptosis (272). The secretion of soluble factors can also 
have a significant immune suppressing function. Sterol metabolites secreted 
by tumour cells prevent DCs from upregulating CCR7, impairing the ability of 
DCs to migrate to the lymph nodes for antigen presentation (273). 
Furthermore, vascular endothelial growth factor (274), and TGF-β (275) 
produced by tumour cells can suppress DC activation and function. The 
expression of Indolamine 2, 3-dioxygenase (IDO) by tumour cells also has a 
variety of suppressive effects, which will be discussed later. 
 
Immunosuppression 
The immunosuppressive environment generated by tumours makes it a very 
difficult disease to treat with immunotherapy. The highly suppressive tumour, 
AML, provides an appropriate example for tumour-associate immune 
suppression, due to its clinical implications and due to its use during the 
research performed for this thesis. Patients with AML, have been found to 
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have DCs with impaired maturation and functional capabilities in their 
peripheral blood, and these DCs can drive tolerance in response to leukemic 
antigens instead of immunity (276). A greater understanding of the immune 
suppression generated by a tumour would greatly help understand why some 
current immunotherapies are failing and would aid in the development of new, 
more effective anti-tumour immunotherapies. 
 
Indolamine 2, 3-dioxygenase 
One way that tumour cells can induce immune suppression is by expressing 
IDO, which the majority of AML cells express (277). IDO is a tryptophan 
catabolising enzyme that functions by reducing the amount of tryptophan in a 
host, which is required for T cell proliferation (278). The importance of 
tryptophan in T cell proliferation is made evident by in vitro studies 
demonstrating that IDO-induced T cell suppression can be reversed by the 
addition of tryptophan during priming (279). During inflammation, DCs 
upregulate IDO in response to IFN-γ, as a method to prevent an exaggerated 
inflammatory response within a host (280). 
 
The metabolites of tryptophan degradation by IDO are called kynurenines and 
they also generate immunosuppression by inducing apoptosis of thymocytes 
and functional Th1 cells (281). The combination of tryptophan deprivation and 
the presence of kynurenines result in the down-regulation of the CD8+ T cell 
TCR ζ-chain, causing decreased functionality of cytotoxic T cells (282). 
Kynurenines also have a distinct effect on CD4+ T cells during priming, driving 
them to differentiate into immunosuppressive Tregs (283). Furthermore, IDO 
can activate and induce the migration of Tregs to a tumour site (283-285). 
Therefore, IDO suppresses immune responses directly, but can also 
exacerbate the suppressive environment by activating other suppressive cells. 
 
Regulatory T cells 
The immune suppressor cell, Tregs, prevent the generation of an immune 
response in unwarranted situations, thereby decreasing the chance of 
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developing autoimmunity (286). Some tumours have the ability to inhibit an 
anti-tumour immune response by activating tumour-antigen specific Tregs and 
thereby evade the immune system. As a result the number of Tregs within a 
tumour-bearing host can be directly correlated to their prognosis (287). 
Production of the cytokines IL-10 (288) and TGF-β (289) and expression of 
the inhibitory molecule CTLA-4 (290) are tools by which Tregs mediate immune 
suppression. They also regulate the CD8+ T cell population by absorbing free 
IL-2, thereby limiting the amount of IL-2 available for CD8+ T cells to utilize for 
population maintenance and expansion (291). The suppressive capabilities of 
tumour-induced Tregs were demonstrated by showing that mice with AML 
responded better to the transfer of anti-tumour effector CD8+ T cells when 
host Tregs were depleted prior to transfer (292). The transferred CD8+ T cells 
in these mice proliferated more and produced more IFN-γ when the Tregs were 
depleted. 
 
As mentioned above Tregs can develop directly from the thymus or can be 
generated by CD4+ T cell differentiation, the Tregs generated are called natural 
and induced Tregs, respectively. The type of Treg found in tumours is poorly 
understood largely due to the difficulty in differentiating them (293). The 
distinction between the two subsets is important as the method required to 
deplete tumour-infiltrating Tregs may depend on the type infiltrating the tumour. 
Methods to differentiate between these two subsets are currently being 
investigated. Initially, expression of the Ikaros family transcription factor 
‘Helios’ was used to identify the natural Tregs (294, 295); however, it was later 
found that Helios could be expressed by both natural and induced Tregs (296, 
297). It has subsequently been suggested that Helios is upregulated on 
activated and proliferating Tregs. The implication of Helios expression and 
methods to differentiate between natural and induced Tregs are up for debate. 
 
Myeloid derived suppressor cells 
Another suppressive cell subset involved in maintaining and controlling an 
immune response is called the myeloid derived suppressor cells (MDSC). 
MDSCs constitute a population of progenitor myeloid cells, including immature 
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DCs, macrophages and granulocytes that are unable to progress into a 
mature phenotype. There are, broadly speaking, two different subsets of 
MDSCs in mice that are called the granulocytic and monocytic MDSCs, which 
express the markers Ly6G and Ly6C, respectively (298). The specific 
differences between these two subsets are not well understood, however both 
subsets are able to suppress T cells, with some studies demonstrating 
different mechanisms of T cell suppression (299). Tumours can increase the 
number of MDSCs within a host and these can aid the tumour in evading the 
immune system. Many tumours upregulate both the granulocytic and 
monocytic population of MDSC but it is the granulocytic population that 
typically expands the most (298).  
 
The immune suppression generated by MDSCs occurs via several different 
pathways and most of these are contact dependent. One suppressive process 
is similar to the tryptophan ablation mediated by IDO, in which MDSCs 
increase the activity of arginase-1, which catabolises L-arginine, an amino 
acid also essential for T cell proliferation (300). MDSCs also have upregulated 
NADPH oxidase and inducible nitric oxide synthase, which results in 
increased production of ROS and nitric oxide, respectively (301). The 
production of ROS also suppresses immune responses as indicated by 
ablation of the suppressive activity of MDSCs that were removed from 
tumour-bearing mice when ROS production was inhibited (302-304). In 
addition, MDSCs can exacerbate the immuneosuppressive response of a 
tumour by increasing the Treg population (305). 
 
1.7 Tumour immunotherapy 
The current treatments for tumours largely consist of surgery, radiotherapy 
and chemotherapy. While these treatments are effective to some degree, in 
many situations the clinical benefit is short-lived, and is often associated with 
considerable treatment-related morbidity. The invasiveness of surgery and the 
non-specific mode of action of radiotherapy and chemotherapy make them 
significantly harmful, often resulting in severe morbidity or even mortality 
(306). These therapies have had significant success in treating some 
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tumours, however many still remain extremely difficult to treat, often only 
receiving mild benefits from these harmful therapies (307). 
 
Immunotherapy, on the other hand, can be designed to specifically attack 
each host’s individual tumour, thereby limiting the healthy tissue damage that 
is associated with conventional treatments. In addition, a successful 
immunotherapy will develop immunological memory to produce long-term 
protection from tumour relapse. However, there are still many aspects of anti-
tumour immunotherapy that need to be fine-tuned to maximise anti-tumour 
protection. Some of these aspects will be discussed below for the therapies 
used in the research of this thesis. 
 
1.7.1 Adoptive T cell therapy 
The history of adoptive cell therapy 
Adoptive T cell therapy is the process of removing tumour-specific T cells 
from a tumour-bearing host, and then inducing their proliferating in vitro to 
produce large numbers of tumour-specific T cells that can be readministered 
back into the host (308). The aim of this treatment is to administer a 
significantly large, and appropriately activated population of antigen-specific 
effector T cells that can directly attack the tumour. The first model of adoptive 
T cell therapy involved removing a tumour from mice with pulmonary 
micrometastasis and culturing the resulting single cell suspension in IL-2. The 
tumour antigens in combination with IL-2 activated the tumour infiltrating 
lymphocytes, thereby inducing their proliferation and causing them to attack 
the tumour cells within the culture (309). By day fifteen the tumour cells had 
been eradicated leaving behind only the lymphocytes within the culture. 
Injecting 5x106 of the remaining CD8+ T cells into mice with the same 
pulmonary micrometastasis resulted in eradication of the established tumour 
in 96% of the tested mice (309).  
 
There are still many factors that limit the development of an effective adoptive 
T cell therapy that can readily be adapted to the clinic. These include the 
difficulty in isolating and expanding tumour infiltrating lymphocytes, the 
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inability of the T cells to persist for an extended period of time following 
administration, and the barrier to effective therapy caused by tumour-
associated immune suppression. Research to increase the effectiveness of 
adoptive therapy has included determining the differentiation status and 
number of T cells that provide the most effective anti-tumour T cell population, 
in addition to the most suitable environment for the transferred cells (310). 
 
Increasing the number of transferred CD8+ T cells has been shown to have a 
significant impact on the protective benefit provided by adoptive therapy, with 
most experiments demonstrating a direct correlation between the number of 
CD8+ T cells administered and the protection provided to the recipient (310, 
311). However, some studies also observed no difference between two 
significantly different doses of the same transferred CD8+ T cells (312). It was 
suggested that an immune cascade initiated following T cell transfer was 
central to tumour killing and therefore increased numbers did not produce a 
significant difference in survival. The differentiation status of the CD8+ T cells 
also had significant consequences to the protection provided by adoptive cell 
therapy. This was made evident by an experiment that involved transferring 
either CD62Lhigh (naïve T cells) or CD62Llow (effector T cells) CD4+ and CD8+ 
T cells into hosts. While 5x106 CD62Llow cells were sufficient to protect mice 
from a three-day-old fibrosarcoma, 50x106 CD62Lhigh cells provided no 
protective benefit against the same tumour (313, 314). However, once again 
the expression of CD62L and the state of differentiation of the transferred T 
cells have had contradicting results in terms of their ability to provide 
protection following transfer. Another study demonstrated that CD8+ T cells 
that have reached an advanced stage of effector cell development had 
reduced anti-tumour activity, whereas naïve CD8+ T cells, as well as the “early 
effectors”, which are CD62Lhigh had significant protective capabilities (315). It 
is thought that the effector CD8+ T cells in this experiment are terminally 
differentiated and therefore not as effective at providing protection. 
 
Transferring memory cells instead of effector cells may be more effective for 
adoptive therapy, as they can self-renew and have heightened recall 
responses (310, 316, 317). Studies examining the most effective memory 
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subset to transfer have also developed contradicting results. Culturing T cells 
in vitro with IL-15 and/or IL-21 develops a CD62Lhigh TCM phenotype and the 
transfer of TCM cells provided mice with superior anti-tumour protection 
compared to TEM cells, possibly due to the stronger ability of TCM cells to 
proliferate in response to restimulation (318-320). In contrast, the 
development of TEM cells by culturing T cells with IL-2 has also been found to 
provide greater anti-tumour protection than TCM cells, possibly due to the 
expression of adhesion molecules by TEM cells that allow them to migrate to 
and infiltrate a tumour, thereby providing rapid tumour destruction (313, 314). 
 
Depleting the host immune system with either irradiation or a lymphodepleting 
chemotherapy prior to adoptive cell therapy has been shown to extend the 
persistence of T cells following transfer, thereby resulting in more objective 
response rates in melanoma patients (321). Lymphodepletion aids in T cell 
persistence both by depleting the regulatory cells generated by a tumour and 
also by depleting the endogenous T cells that compete with the transferred 
cells for homeostatic cytokines, such as IL-7 and IL-15 (322, 323). 
 
Determining how to provide the best protection against tumour development 
with adoptive cell therapy is still under debate and it is likely that the most 
effective method depends on the type and stage of tumour and the specific 
immune system of the patient. It is possible that the interaction between the 
transferred T cells and the endogenous APCs may determine how effective 
the transferred cells are at providing protection against tumours. 
 
1.7.2 Cancer vaccines that exploit NKT cells 
Using a vaccine to generate effector CD8+ T cells against a tumour requires 
appropriate activation of DCs, particularly DC licensing, which is required to 
optimally activate CD8+ T cells against a tumour. A single dose of the iNKT 
cell ligand α-GalCer, administered intravenously, results in a significant 
activation of splenic DCs within 24 hours due to licensing by the α-GalCer 
activated iNKT cells (53, 78). In addition, the administration of free α-GalCer 
provides significant protective benefits to mice with either a melanoma or 
Chapter 1: Introduction 52 
thymoma (324, 325). However, the experiments using free α-GalCer in the 
clinic did not show as much success as the pre-clinical results (326-328). 
 
The limitation of vaccinating with free α-GalCer is the dependency on the 
effector functions of the innate immune response (325). Studies have now 
demonstrated the potential of co-administering α-GalCer with a target antigen 
to induce an effective CD8+ T cell response that is dependent on the 
stimulation of DCs by iNKT cells (53, 78). To enable this vaccine to generate 
lymphocytes directed against tumours, whole tumour cells were administered 
in combination with α-GalCer to provide a source of tumour antigens. This 
vaccine provided a significant protective benefit to mice with a plasmacytoma 
(J558) or a thymoma (A20) and the immune response was dependent on the 
irradiated tumour cells being taken up by DCs in the spleen (329). 
Subsequent studies have demonstrated that a vaccine consisting of irradiated 
tumour cells pulsed with α-GalCer provided mice with superior protection 
against the A20 lymphoma than mice that received irradiated tumour cells 
with free α-GalCer (330). Interestingly, this immune response was dependent 
on CD4+ T cells and not CD8+ T cells. Vaccinating mice with irradiated tumour 
cells pulsed with α-GalCer has subsequently been demonstrated to be an 
effective treatment for a murine model of glioma (331), melanoma (332), 
lymphoma (330) and also a model of AML (which differs from the model used 
in this thesis) (333). 
 
A vaccine consisting of irradiated tumour cells loaded with α-GalCer has the 
advantage of inducing response to undefined antigens within the autologous 
whole tumour cells, rather than having to determine if a patient’s tumour 
expresses a given tumour antigen (334). In addition, a vaccine based on 
whole tumour cells can be used to activate a broad immune response 
involving CD4+ and CD8+ T cells against a variety of different targets. This 
greatly decreases the chance of developing a more immunoevasive tumour 
due to tumour escape. In general, the utility of whole-tumour vaccines will be 
largely determined by how relatively simple they are to prepare. There is 
some evidence to suggest that this form of vaccine (regardless of the adjuvant 
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used) may be more effective in the clinic than therapies targeting defined 
antigens. An analysis of 1601 patients from 75 published trials in advanced 
metastatic melanoma showed that 12.6 % of patients that received some form 
of vaccine with undefined whole tumour antigens had an objective response, 
compared to 6 % of those that received a vaccine using a defined antigen 
(335). 
 
When α-GalCer is pulsed onto irradiated tumour cells as an immune adjuvant, 
in vivo DCs will phagocytose the cellular material and the α-GalCer will be 
presented on the non-classical MHC molecule CD1d for simulation of iNKT 
cells (336). Activated iNKT cells will then provide a link between the innate 
and adaptive immune response by licensing DCs (73). The matured DCs will 
use the tumour antigens acquired from the irradiated tumor cells to induce the 
activation of naïve T cells into anti-tumour effector T cells (81). The research 
in this thesis investigates the in vivo events that follow administration of such 
a vaccine designed to treat AML. The availability of lang-EGFPDTR made it 
possible to specifically investigate what role, if any, was played by langerin+ 
CD8α+ DCs. 
 
1.8 Hypotheses tested in this thesis 
It is now evident that DCs are a heterogeneous cell population, with 
phenotypically distinct subsets that may have different functions in immunity. 
The role that specific endogenous DC subsets play in different forms of 
immunotherapy is largely unknown. Due to evidence indicating that langerin+ 
CD8α+ DCs are efficient at cross-priming CD8+ T cell responses using 
circulating antigens, it is possible that these cells provide an essential function 
during in vivo immune responses generated by an intravenously administered 
immunotherapy. With the recent availability of lang-EGFPDTR mice, where 
langerin+ CD8α+ DCs can be depleted from the spleen, it became feasible to 
study how CD8+ T cell responses are affected in the absence of this subset of 
DC. The aim of this thesis, therefore, was to anaylse the function of langerin+ 
CD8α+ DCs in stimulating T cells, in both the naïve and effector settings, 
following immunotherapy for the treatment of intravenously administered 
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tumours. For this purpose, two models of immunotherapy were developed, 
one that utilises effector cells directly (adoptive CD8+ T cell therapy) and 
another that generates effector cells in vivo (tumour/α-GalCer vaccination). 
With these two models it was possible to determine if langerin+ CD8α+ DCs 
stimulate transferred effector CD8+ T cells in vivo (following transfer) and if 
they generate effector T cells during a vaccine-induced immune response 
(Figure 1.6). 
 
 
 
Figure 1.6: Immunotherapy models to determine if langerin+ CD8α+ DCs 
stimulate and/or generate effector CD8+ T cells. Adoptive therapy is used to 
determine if langerin+ CD8α+ DCs stimulate effector CD8+ T cells administered for 
the treatment of intravenous tumours (Top). A vaccine consisting of irradiated tumour 
cells loaded with α-GalCer is used to determine if langerin+ CD8α+ DCs are involved 
in generating effector CD8+ T cells during a vaccine-induced immune response for 
the treatment of intravenously administered tumours. 
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Adoptive transfer of activated CD8+ T cells has shown promising results in the 
clinic. However, methods to prolong the survival and function of the 
transferred T cells are likely to enhance the resulting anti-tumour response. 
Investigating whether endogenous DCs are involved stimulating adoptively 
transferred effector CD8+ T cells may provide insight into new methods to 
improve responses. If endogenous DCs are found to provide stimuli to the 
transferred T cells it may be possible to enhance the transferred T cell 
response by either promoting or deterring this interaction. In addition, if the 
specific stimuli associated with this interaction were determined then it may be 
possible to enhance tumour elimination by artificially producing or blocking 
these stimuli. Therefore, in the first part of the thesis, a model of adoptive T 
cell transfer-based immunotherapy was established, and the following 
hypothesis was tested “that resident langerin+ CD8α+ DCs in the spleen 
stimulate adoptively transferred effector CD8+ T cells, thereby promoting 
effective anti-tumour activity of the immunotherapy”. 
 
Vaccination is another immunotherapeutic strategy that relies on the function 
of T cells, with many models showing that CD8+ T cells are particularly good 
anti-tumour effector cells. The challenge is to develop simple vaccines with a 
known mode of activity in order to translate this form of therapy to routine 
cancer treatment. In this context, resident DCs are likely to play a very 
significant role. Over the course of this thesis, a novel vaccine consisting of 
irradiated tumour cells loaded with α-GalCer was developed for the treatment 
of AML. One of the features of this vaccine is that it required intravenous 
administration to access splenic iNKT cells, and hence elicit potent activity. 
With this vaccination model, it was possible to examine the specific role of 
langerin+ CD8α+ DCs in the spleen in initiating generating anti-tumour effector 
T cells. Determining whether this specific DC subset has a role in vaccine-
induced responses may significantly contribute to the future design of more 
potent vaccines. Therefore, in the second part of the thesis, a vaccine-based 
immunotherapy of AML was used to test the hypothesis “that resident 
langerin+ CD8α+ DCs in the spleen activate naïve T cells following 
intravenous vaccination, resulting in effective anti-tumour activity”. 
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1.9 Aims 
• Generate two immunotherapy models for the treatment of intravenously 
administered tumours that use either effector T cells directly or 
generates effector T cells in vivo 
 
• Determine if langerin+ CD8α+ dendritic cells are required to promote an 
immunotherapy-based effector CD8+ T cell response 
 
• Determine if langerin+ CD8α+ dendritic cells are required to generate 
effector CD8+ T cells following vaccination 
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2.1 Materials 
2.1.1 Labware 
 
Product Supplier/Distributor 
Acrodisc 13 mm Syringe filters with 
0.2 µM membrane 
PALL LifeSciences, Cornwall, U.K 
Axygen Microtubes 1.7 mL Axygen Scientific Inc., Union City, CA, 
U.S.A 
BD 25 ml Syringes 
BD 10 ml Syringes 
BD 5 ml Syringes 
BD Biosciences, Bedford, MA, U.S.A 
Falcon Tissue culture plates: 
6-well plates, 24-well plates & U-
bottom 96-well plates 
BD Biosciences, Bedford, MA, U.S.A 
Falcon™ Polypropylene conical 
flasks: 
50 ml, & 15 ml 
BD Biosciences, Bedford, MA, U.S.A 
Falcon Tissue culture flasks: 
750 ml & 250 ml 
BD Biosciences, Bedford, MA, U.S.A 
Falcon Nylon cell strainers 70 µM BD Biosciences, Bedford, MA, U.S.A 
Pre-Seperation filter 30 µm Miltenyi biotec, Bergisch Gladbach, 
Germany 
PrecisionGlide Needles 25 gauge BD Biosciences, Bedford, MA, U.S.A 
 
Titertube Microtubes Biorad, Hercules, CA, U.S.A 
Ultra-Fine Insulin syringes 1 ml 29 
gauge 
BD Biosciences, Bedford, MA, U.S.A 
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2.1.2 Reagents and Buffers 
 
BD Cytofix/Cytoperm 
Purchased from BD Bioscience (CA, U.S.A) and stored at 4 °C. 
 
Bioplex Buffer 
• 1 L PBS 
• 4 ml EDTA (0.5 M) (Sigma-Aldrich, MO, U.S.A) 
• 1 g BSA 
• 0.5 ml Tween20 (Sigma-Aldrich, MO, U.S.A) 
• 50 µl NaN3 (Sigma-Aldrich, MO, U.S.A) 
 
Bovine Serum Albumin (BSA) 
BSA with low endotoxin levels and no IgG was purchased from ICPbio Ltd 
(Auckland, New Zealand) in powder form and stored at 4 °C. 
 
5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
Ten 500 µg vials of CFSE were purchased from Molecular Probes, Invitrogen 
(OR, U.S.A). It was reconstituted in DMSO and stored at -20 °C. 
 
Cell Separation Running Buffer 
• 1 L PBS 
• 2 mM EDTA (Sigma-Aldrich, MO, U.S.A) 
• 10 ml FCS 
 
Cell Tracker Orange (CTO) (5-(and-6)-(((4-
chloromethyl)benzoyl)amino)tetramethylrhodamine) 
1 mg of CTO was purchased from Molecular Probes, Invitrogen (OR, U.S.A). 
It was reconstituted in DMSO and stored at -20 °C. 
 
Collagenase I 
10 mg/ml of collagenase was purchased from Gibco Invitrogen (OR, U.S.A). It 
was reconstituted in IMDM and stored at -20 °C. 
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Complete Iscove’s Modified Dulbecco’s Medium (cIMDM) 
• 500 ml iIMDM 
• 25 ml FBS 
• 5 ml Penstrep (Gibco, Invitrogen) 
• 500 µl 2-ME 
 
Cytarabine 
Purchased from Pifzer (Perth, Australia) and stored at room temperature. 
 
DNase I 
DNase I was purchased from Roche (IN, U.S.A) and stored at -20 °C. 
 
Dulbecco’s Phosphate Buffered Saline (dPBS) 
Purchased from Gibco Invitrogen (OR, U.S.A). 
 
Diphtheria toxin 
1 mg DT in powder form was purchased from Sigma-Aldrich (MO, U.S.A). It 
was reconstituted in H20 and stored at -20 °C. 
 
Doxorubicin 
10 mg of doxorubicin in a 5 ml vial was purchased from EBEWE Pharma 
(Unterach, Austria). 
 
Endograde OVA 
Low endotoxin chicken OVA was purchased from Profos AG (Regensburg, 
Germany). 
 
FACS Buffer 
• 1 L PBS 
• 10 ml FBS 
• 5 ml NaN3 
• 4 ml EDTA (0.5 M) 
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Foetal Bovine Serum (FBS) 
Purchased from SAFC Biosciences Sigma-Aldrich (MO, U.S.A) and stored at    
-20 °C. 
 
α-Galactosyl-ceramide (α-GalCer) 
The iNKT cell ligand α-GalCer was manufactured by Industrial Research Ltd 
(Wellington, New Zealand) as previously described (337). 
 
Incomplete Iscove’s Modified Dulbecco’s Medium (iIMDM) 
Purchased from Gibco Invitrogen (OR, U.S.A). 
 
Liberase 
Purchased from Roche (IN, U.S.A) and stored at -20 °C. 
 
Lipopolysaccharides (LPS) 
1 mg was purchased from Sigma-Aldrich (MO, U.S.A). It was reconstituted in 
PBS and sonicated for 30 minutes before being stored at 4 °C. 
 
2 Mercaptoethanol (2 ME) 
Purchased from Gibco, Invitrogen (OR, U.S.A) and stored at 4 °C. 
 
Percoll 
Purchased from GE Healthcare Biosciences (Uppsala, Sweden). 
 
Phosphate Buffered Saline (PBS) 
• 1 sachet of PBS (Gibco, Invitrogen) 
• 1 L MilliQ water 
 
Red Blood Cell Lysis Solution 
Purchased from Qiagen Sciences (MD, U.S.A) and stored at room 
temperature. 
 
Chapter 2: Materials and Methods 62 
Running Buffer 
• 1 L PBS 
• 10 ml FBS 
• 4 ml EDTA (0.5 M) 
 
SIINFEKL 
The peptide deriving from the OVA protein SIINFEKL (OVA257-264) was 
purchased from Genscript (NJ, U.S.A). It was reconstituted in H20 and stored 
at -20 °C. 
 
2.1.3 Antibodies 
 
Specificity Fluorophore Clone Manufacturer 
CD3 FitC 145-2C11 eBioscience (CA, 
U.S.A) 
CD3 PECy7 145-2C11 eBioscience 
CD4 A488 GK1.5 eBioscience 
CD4 APC GK1.5 eBioscience 
CD4 PE GK1.5 eBioscience 
CD8 Fitc 53-6.7 BioLegend (CA, 
U.S.A) 
CD8 PE 56-6.7 BioLegend 
CD8 PerCP 53-6.7 BD Bioscience 
CD8 A700 56-6.7 eBioscience 
CD8 Pacific Blue 53-6.7 BD Bioscience 
CD11b APC M1/70 eBioscience 
CD11b Biotin M1/70 eBioscience 
CD11c PECy7 N418 eBioscience 
CD11c APC N418 BioLegend 
CD25 FitC 7D4 BD Pharmingen 
CD25 PE PC61 eBioscience 
CD40 Biotin 3/23 BD Bioscience 
CD44 PECy5 IM7 BD Bioscience 
CD44 PerCP Cy5.5 IM7 eBioscience 
CD45.1 FitC A20 eBioscience 
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CD45.1 PE A20 eBioscience 
CD62L Biotin MEL-14 BD Bioscience 
CD86 PE GL-1 eBioscience 
CD122 FitC TM-β1 BioLegend 
B220 PercP RA3-6B2 BD Bioscience 
FoxP3 PE FJK-16s eBioscience 
IFN-γ PE - BD Bioscience 
IFN-γ PECy7 XMG1-2 eBioscience 
IgG APC - BD Bioscience 
KLRG1 PECy7 2F1 eBioscience 
Ly6G PE 1A8 eBioscience 
NK1.1 Bio PK136 eBioscience 
Vα2 APC B20.1 eBioscience 
Vα2 V450 B20.1 BD Bioscience 
 
 
2.1.4 Fluorophores 
 
Fluorophore Manufacturer 
DAPI Invitrogen 
Live Dead Fixable Blue (LDFB) Invitrogen 
Propidium Iodide (PI) Invitrogen 
Streptavidin PECy7 BD Bioscience 
 
 
2.1.5 Cytokines 
Granulocyte-macrophage colony stimulating factor (GM-CSF) 
Recombinant murine GM-CSF was produced using stationary phase cultures 
of the murine X63 cell line, modified to secrete the dull length murine GM-CSF 
protein. 
 
Interleukin 4  
Recombinant murine IL-4 was produced using stationary phase cultures of a 
Chinese Hamster Ovary cell line, modified to secrete full-length murine IL-4 
protein. 
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Concentration of GM-CSF and IL-4 
To determine the concentration of GM-CSF and IL-4 isolated from the cultures 
mentioned above, bone marrow derived DCs (BMDCs) were cultured in 
different concentrations of the cytokines. The BMDC phenotypes were then 
compared to BMDCs cultured with known concentrations of GM-CSF and IL-
4. The concentrations of GM-CSF and IL-4 that produced BMDCs with similar 
phenotypes to the control samples were chosen for future experiments. 
 
Interleukin 2  
Recombinant human IL-2 was purchased from PeproTech, (NJ, U.S.A). 
 
2.1.6 Tumour Cell Lines 
E.G7-OVA 
E.G7-OVA is a genetically altered version of the C57BL/6 derived murine 
lymphoma called EL-4. The genetic manipulation consists of the insertion of 
DNA coding for the OVA protein into the genetic material of EL-4. E.G7-OVA 
is therefore EL-4 that expresses OVA (338). E.G7-OVA was obtained from 
ATCC (VA, U.S.A). EG.7-OVA was grown in cIMDM and cultured in 37 °C 
with 5 % CO2. 
 
C1498 
C1498 is a murine AML that developed spontaneously in a C57BL mouse at 
the Jackson Laboratories (ME, U.S.A) in 1941 (339). C1498 was obtained 
from ATCC (VA, U.S.A) C1498 was grown in cIMDM and cultured in 37 °C 
with 5 % CO2. 
 
2.1.7 Mice 
Ethics Approval and Housing 
All mice were bred and housed at the Biomedical Research Unit of the 
Malaghan Institute of Medical Research. Groups of age and sex matched 
mice were used in each experiment. All experiments were carried out within 
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the provisions of the Animal Welfare Act of New Zealand (1999) and approved 
by the Victoria University of Wellington Animal Ethics committee. 
 
Mouse Strains 
The C57BL/6 inbred mouse strain was obtained from Jackson Labratories 
(ME, U.S.A). C57BL/6 cells express CD45.2. 
 
Intercrossing C57BL/6 mice with SJL/J mice developed the B6-Sj ptprca 
congenic model. The cells from these mice therefore express CD45.1 instead 
of CD45.2. The B6-Sj ptprca mice were imported from the Jackson 
Labratories (ME, U.S.A) 
 
OT-I mice are from a C57BL/6 origin that have been backcrossed onto B6-Sj 
ptprca making the OT-I cells express both CD45.1 and CD45.2. The CD8+ T 
cells from these mice express a transgenic TCR specific for the H-2 Kb–
binding peptide of OVA, OVA257–264 also known as SIINFEKL (137). 
 
FoxP3-GFP mice are on a C57BL/6 background and have had eGFP knocked 
into the FoxP3 gene so that the eGFP is produced when FoxP3 is expressed 
(340). These mice were imported from the University of Washington, U.S.A. 
 
Lang-EGFP mice are on a C57BL/6 background and have eGFP knocked into 
the langerin gene. eGFP is therefore under the control of the langerin 
promoter (126). 
 
Lang-EGFPDTR mice are on a C57BL/6 background and have eGFP and the 
human diphtheria toxin receptor knocked into the langerin gene. The langerin 
gene is still transcribed without fault and when it is eGFP and DTR is also 
expressed (126). 
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2.2 Methods 
 
2.2.1 Immunotherapy development and tumour challenge 
Adoptive transfer of effector CD8+ T cells 
OT-I lymph node cells were stimulated in vitro with DCs loaded with SIINFEKL 
peptide. To generate DCs, bone marrow from the femur of a C57BL/6 mouse 
was removed by squirting PBS into one end of the femur and collecting the 
liquid and bone marrow from the other. The bone marrow was then filtered 
through a 70 µM cell strainer to remove debris and the cells were centrifuged 
at 552 x g (Heraeus Multifuge 3 S-R, Kendro Laboratory Products, CT, U.S.A) 
for 4 minutes. The cells were resuspended in cIMDM and 2x106 cells were 
added to each well of a six-well plate, in a final volume of 5 ml. Each well 
received 100 U/ml of IL-4 and GM-CSF and the cells were cultured for seven 
days. On days three and five of culture another 100 U/ml of IL-4 and GM-CSF 
were added. After culture the DCs were harvested from the six-well plate and 
centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four minutes. The cells 
were resuspended at 1x106 cells/ml and were cultured for four hours with 0.1 
µM/ml of SIINFEKL. The DCs were then centrifuged at 552 x g (Heraeus 
Multifuge 3 S-R) for four minutes and resuspended in cIMDM for culture with 
the T cells. 
 
The naïve OT-I T cells to be activated for adoptive transfer were acquired 
from the lymph nodes of OT-I mice. The mice were culled by CO2 
asphyxiation and the inguinal, brachial, axillary and mesenteric lymph nodes 
were removed, placed into PBS and stored on ice. The lymph nodes were 
then grinded through a 70 µM cell strainer to acquire a single cell suspension. 
The cells were then centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four 
minutes to pellet the cells and the supernatant was removed. The cells were 
resuspended in cIMDM and 5x105 OT-I cells were cultured in a six-well plate 
with 6.25x104 DCs in a total volume of 5 ml. Four days later the OT-I cells 
were collected into a single vial and centrifuged at 552 x g (Heraeus Multifuge 
3 S-R) for four minutes. The cell pellet was resuspended in cIMDM and the 
cells were placed into a 750 ml flask at 2.5x105 cells/ml with 100 U/ml of IL-2. 
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The T cells were cultured for 48 hours with new IL-2 administered both days. 
The following day the cells were collected in 50 ml falcon tubes and 
centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four minutes. The cells 
were resuspended in iIMDM and washed two more times. The cells were then 
resuspended at 25x106 cells/ml and 200 µl (5x106 cells) were injected into the 
lateral tail vain of mice. 
 
Irradiated tumour cells loaded with α-GalCer 
C1498 cells were cultured in cIMDM at 37 °C with 5 % CO2. The cells were 
harvested from the flask, centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for 
4 minutes and the cell pellet was resuspended in cIMDM. 10x106 C1498 cells 
were then added to a 250 ml flask in a total volume of 10 ml and 200 ng of α-
GalCer was added. The cells were cultured with the α-GalCer overnight 
before being harvested from the flask, centrifuged at 552 x g (Heraeus 
Multifuge 3 S-R) for four minutes and washed three times with iIMDM. The 
cells were resuspended at 3.75x106 cells/ml in iIMDM and irradiated for 32 
minutes with gamma radiation (Gammacell 3000 Elan, Best Theratronics Ltd, 
Ontario, Canada) giving a total of 11,700 grays. The cells were then 
administered into the lateral tail vein of mice in 200 µl (7.5x105 cells/mouse). 
 
Cytarabine treatment 
Mice treated with cytarabine received three intraperitoneal doses, 24 hours 
following tumour challenge. Each dose consisted of 3 mg, injected ten hours 
apart. 
 
Doxorubicin treatment 
Mice treated with doxorubicin received a single 240 µg intravenous injection, 
either 24 hours before or at the same time as adoptive therapy. 
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E.G7-OVA challenge 
E.G7-OVA was cultured in cIMDM at 37 °C with 5 % CO2 until confluent. The 
cells were then removed from the flask and placed into a 50 ml falcon tube 
before being centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four 
minutes. The cell pellet was resuspended in iIMDM and this was repeated 
twice to wash the cells, which were then suspended at 5x106 cells/ml. Mice 
were injected with 200 µl (1x106 cells) of cells into the lateral tail vain. 
 
C1498 challenge 
C1498 was administered similar to E.G7-OVA. It was cultured in cIMDM at 37 
°C with 5 % CO2 until enough cells had grown for the required challenge. The 
cells were then removed from the flask and placed into a 50 ml falcon tube. 
The cells were centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four 
minutes and the cell pellet was resuspended in iIMDM. This was repeated 
twice to wash the cells, which were then suspended at 5x105 cells/ml and 200 
µl (1x105 cells) was administered into the lateral tail vain of mice. 
 
 
2.2.2 Tissue preparation 
Specific tissues were removed from mice for analysis of the cells within them. 
The way in which these tissues were prepared is indicated below. The mice 
were culled by CO2 asphyxiation and the tissues in question were removed 
and placed in iIMDM on ice. 
 
Spleen 
The spleens were grinded through a 70 µM cell strainer to get a single cell 
suspension and the cells were centrifuged at 552 x g (Heraeus Multifuge 3 S-
R) for 4 minutes. The supernatant was discarded and the cells were 
resuspended in 1 ml of iIMDM and 1 ml of red blood cell (RBC) lysis buffer for 
two minutes. The cells were then centrifuged again and resuspended in 5 ml 
of iIMDM. 
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Liver 
To isolate cells from the liver, excess blood had to first be drained from the 
liver. To do this, mice were culled and a 25 g needle with a 5 ml syringe was 
inserted into the hepatic portal vein. The vena cava was then cut with scissors 
and 5 ml of PBS was then forced into the hepatic vein, thereby forcing blood 
within the liver to be pushed out the vena cava. This changes the colour of the 
liver from a dark red to a pale yellow. The liver was removed and placed in 
iIMDM on ice. The livers were then grinded through a 70 µM cell strainer into 
a 50 ml falcon tube to get a single cell suspension. The tube was filled with 
PBS, centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four minutes and 
the supernatant was aspirated off, leaving behind the cell pellet. The cells 
were resuspended in a 33% Percoll mix, which was made by diluting Percoll 
in PBS and 45 ml was added to each liver sample. The cells were then 
centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for ten minutes without a 
brake to allow the centrifuge to stop without mixing the cell layers. The 
supernatant was again aspirated leaving behind the cell pellet, which was 
resuspended in 2 ml of RBC lysis buffer and incubated for five minutes at 37 
°C. The cells were then centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for 
four minutes and resuspended in iIMDM. 
 
Blood 
Blood was either removed from live mice by slicing the lateral tail vein 30 
minutes after applying the topical aesthetic ELMA (AstraZeneca Limited, 
Auckland, New Zealand) to the tails. Alternatively blood was drawn from mice 
that were recently culled by inserting an empty 1 ml tube into the heart and 
drawing blood into the syringe. For the analysis of cells within the blood, eight-
ten drops of blood were collected in a 1.7 ml microtube containing 200 µl of 
an anticoagulant consisting of PBS with 10 mM EDTA to prevent the blood 
from clotting. The cells were then incubated with 1 ml of RBC lysis buffer at 37 
°C for 30 minutes. The cells were spun at 664 x g (Sigma 1-14 Microfuge, 
John Morris Scientific Ltd, Auckland, New Zealand) for five minutes to remove 
the supernatant. For the analysis of blood serum, the blood was paced into an 
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empty tube to allow clotting. The blood was spun at 664 x g (Sigma 1-14 
Microfuge) for five minutes and the serum was removed. 
 
Viable cell counts 
To determine the concentration of cells within a single cell suspension, a 
small aliquot of cells was removed from the sample, which was then diluted 
with Trypan Blue (Gibco, Invitrogen). A total of 10 µl of the cell mix was then 
placed on a haemocytometer and the cells were counted under a microscope. 
The total number of cells could be determined using the following equation: 
 
Total cells/ml = average number of cells within a quadrant x dilution factor 
x104 
 
2.2.3 Flow Cytometry 
Cell surface staining 
Molecules expressed by a cell can be used to identify the specific type of cell 
and its functional capabilities. The molecules can be identified on a cell by 
using an antibody that has an affinity for specific regions of the desired 
molecule. A fluorophore attached to the antibody can be detected by flow 
cytometry, thereby indicating cells that the antibody has bound to and 
therefore which cells express the marker to which the antibody will bind. To 
attach the antibody/fluorophore to the cells, a 200 µl aliquot of the sample 
single cell suspension, containing between one and ten million cells, were 
transferred into the wells of a 96-well plate. The cells were then spun down at 
863 x g (Heraeus Multifuge 3 S-R) for two minutes, the supernatant was 
tipped off and the cells were washed twice in FACS buffer. Non-specific 
binding of the antibodies to the FcR was blocked by incubating the cells with 
anti-CD16/32 clone 24G2 (prepared in house from hybridoma supernatant), 
for ten minutes at 4 °C. The cells were then centrifuged and the supernatant 
was removed. The desired antibodies, diluted in PBS, were then added to 
each cell sample at the required concentrations and the cells were then 
cultured for 20 minutes at 4 °C. Following this, the cells were washed twice in 
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FACS buffer, resuspended in 200 µl of FACS buffer and transferred into 
Titertube microtubes. All flow cytometry was performed on a FACSCalibur or 
an LSRII (both from BD Bioscience) and analysed using FlowJo software 
(TreeStar Inc. OR, U.S.A). 
 
Intracellular staining 
Prior to intracellular labelling of cytokines the cells were restimulated for 20 
hours in 24-well plates (5x106 cells/well) with anti-CD3 and anti-CD28 
antibodies (prepared in house from hybridoma supernatant) at 37 °C. After 
this incubation 1 µg/ml of monensin was added at to each well and the 
samples were incubated for a further four hours. Surface markers were then 
stained as indicated above and the cells were washed with 2 ml of FACS 
buffer. The samples were then incubated with 1 ml of fixation/permeabilization 
buffer (BD Bioscience) for 30 minutes at 4 °C before being washed twice with 
2 ml of 1 x permeabilization buffer (BD Bioscience). Non-specific binding was 
again blocked with 24G2 in 1 x permeabilization buffer. Intracellular antibodies 
were then added in 100 µl of 1 x permeabilization buffer and the cells were 
incubated for 30 minutes at room temperature. The samples were then 
washed twice with 2 ml of 1 x permeabilization buffer and suspended in 200 µl 
of FACS buffer for collection on a FACSCalibur or LSRII (both from BD 
Bioscience). The data obtained was analysed using FlowJo software 
(TreeStar Inc.). 
 
Antibody titrations 
To determine the concentration at which each antibody should be used, 
splenocytes were processed and stained as mentioned above, with the 
antibody diluted in a variety of different volumes including 1:100, 1:200, 1:500 
and 1:1000. Each sample was collected on a FACSCalibur or LSRII (both 
from BD Bioscience). The highest antibody dilution that produced a clear 
positive stain was used in future experiments. An example of an antibody 
titration can be found in appendix 1, where the antibody CD8 A700 was 
titrated. A 1:200 dilution was deemed the appropriate concentration to use. 
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2.2.4 Proliferation of naïve T cells 
To determine the amount of proliferation adoptively transferred naïve T cells 
undergo in vivo, the T cells were stained with CFSE prior to administration. 
When cells proliferate the cells contents are divided between the daughter 
cells. If a cells surface is stained with CFSE and the cell divides, the daughter 
cells receive half of the CFSE stain each. Thus, by using flow cytometry to 
quantify the fluorescence of CFSE on the transferred T cells it is possible to 
determine which T cells have proliferated a single time by looking at which 
cells that have halved their concentration of CFSE. Furthermore it is possible 
to determine which cells have proliferated up to several times before the stain 
has been divided to undetectable levels. 
 
Naïve CD8+ OT-I T cells were removed from the inguinal, brachial, axillary 
and mesenteric lymph nodes of OT-I mice that were culled by CO2 
asphyxiation. The lymph nodes were grinded through a 70 µM cell strainer to 
acquire a single cell suspension containing the lymphoid cells. The cells were 
then centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four minutes to form 
a cell pellet, the supernatant was removed and the lymphoid cells were 
resuspended at 5x106 in PBS. The CFSE (10 mM) was diluted in PBS to 50 
µM, and 25 µl was added to the sample for each ml of cells, which were then 
immediately vortexed and incubated in a 37 °C water bath for eight minutes. 
An equal volume of FBS was then added to the cells to stop the CFSE from 
killing the cells and the cells were then washed once with cIMDM, twice with 
iIMDM then resuspended in iIMDM at 25x106 cells/ml. Mice were 
administered 200 µl (5x106 cells) of cells into the lateral tail vain. 
 
2.2.5 Tumour scoring 
In figure 2.7 mice were challenged with 1x106 E.G7-OVA cells and 
administered different numbers of activated OT-I cells 10-days-later. On day 
20 following tumour-challenge, the mice were culled and were analysed for 
tumour development by necroscopy. The tumours were graded on a scale of 
0–2. If no tumour was detected in a particular tissue a zero score was given. 
In the lymph nodes and spleen, two points was given when the detected 
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tumour was over 25 mm2. If the tumour was under this size it was graded a 
one. In the kidneys and ovaries the tumour was graded two points if the 
tumour was over 100 mm2. Under this size and it was graded one point. For 
hind leg paralysis, a two was appointed if the paralysis involved a complete 
loss of hind leg movement. If only one leg was paralyzed or if some 
movement remained a one was appointed. In the liver a two was appointed if 
more than 10 nodes were detected or if a node was of 25 mm2 in size or 
larger. The detection of fewer than 10 nodes under 25 mm2 resulted in a 
score of one.  
 
2.2.6 Killing assay 
The ability of CD8+ T cells to find and kill cells in vivo can be determined by 
performing a killing assay (341). To do this, target cells expressing the T cells 
TCR cognate antigen were administered into mice and the amount of target 
cells that remained in the blood or spleen after 24 hours indicates how well 
the resident CD8+ T cells could kill those targets. To determine how many 
target cells were killed, a control cell population was also administered that 
did not contain the cognate antigen. These cells cannot be recognised by the 
T cells and therefore can be used as the baseline for 0% killing. Any reduction 
in the target cell population compared to the non-target control would indicate 
that killing had occurred. For example, if the non-target cell to target cell ratio 
is at 1:1 the day after administration then the T cells were unable to kill the 
target cells and if the ratio is 2:1 then the T cells were able to kill half of the 
target cell population, etc. 
 
Splenocytes from B6-Sj ptprca mice were used as the target cells as they are 
CD45.1+ and the experimental mice are CD45.2+. It is therefore possible to 
differentiate the administered target cells from the host cells based on the 
expression of CD45.1. Before administration, the target cells were divided into 
three groups, which were administered the target antigen SIINFEKL at three 
different concentrations (0.5, 5 and 50 ng). The cells were then incubated at 
37 °C for two hours. The non-target control splenocytes did not receive 
SIINFEKL. The three target populations were then stained with CFSE at a 
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high, intermediate and low concentration, which was used to differentiate the 
three target cell populations (not the amount of proliferation, as the 
splenocytes should not proliferate). The high SIINFEKL population received 
the strongest staining by being incubated with 1.25 µM of CFSE, the 
intermediate SIINFEKL population received 0.25 µM of CFSE and the low 
received 50 nM. The cells were incubated in a 37 °C water bath for eight 
minutes before an equal volume of FBS was added and the cells washed 
twice in iIMDM. The non-target control cells were stained with CTO, which is 
similar but distinguishable from CFSE. This was done by incubating the cells 
for fifteen minutes at 37 °C with 10 µM of CTO diluted in warm cIMDM. The 
cells were then centrifuged at 552 x g (Heraeus Multifuge 3 S-R) for four 
minutes, resuspended in warm cIMDM and incubated for 20 minutes at 37 °C. 
The four different populations were combined at a 1:1:1:1 ratio and 
resuspended at 1x108 cell/ml. 200 µl (20x106 cells) were injected into the 
lateral tail vein of each mouse. The following day mice were bled and the 
amount of killed target cells was determined by analysing the remaining 
transferred cell populations by flow cytometry. 
 
2.2.7 Microscopy 
All slides were analysed using an Olympus BX51 microscope (Precision 
Microscopy Equipment, Wellington, New Zealand) and photos were taken 
using an Olympus DP70 (Wellington, New Zealand). 
 
Bone marrow 
The femur of mice was removed and stored in 4% formalin solution (Sigma-
Aldrich, MO, U.S.A). The bones were then decalcified in 10 % formic acid for 
three days, changing the formic acid daily. Tissue was processed using an 
automated processor (Tissuetek VIP-5, Sakura Finetek U.S.A Inc, U.S.A). 
Specimens were fixed in formalin for two hours and dehydrated with 
increasing concentrations of alcohol for one hour at each concentration (70%, 
90% and 100%) before embedding in paraffin wax. Four micron sections were 
taken using a rotary microtome (model 2235, Leica, Nussloch, Germany), 
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which were then mounted onto glass slides and manually stained with 
haematoxylin for ten minutes. After washing with water, the slides were 
stained with eosin for four minutes (stains made in house). The slides were 
then cleared with xylene I and II for five minutes. A cover slip was then 
mounted using Di-N-Butyl Phthalate (DPX, Merck, Darmstadt, Germany). 
 
Blood 
Blood was collected in an empty eppendorf tube and one drop was placed on 
a slide. The drop was then smeared over the length of the slide with a clean 
cover slip. The blood was then allowed to dry before being stained with a 
Romanowsky stain variant (Diff-Quick staining) purchased from Siemens 
Healthcare (Erlangen, Germany). This Consisted of immersing slides in Diff-
Quick fixative reagent for five seconds, and blotting away the excess liquid 
before immersing the slides in Diff-Quick solution I for ten seconds. The slides 
were again blotted and then immersed in Diff-Quick solution II for seven 
seconds. The slides were then washed with water and left to dry at room 
temperature. A cover slip was then mounted using mounting medium 
(Kirkegaard & Perry Laboratories, Inc, MA, U.S.A). 
 
2.2.8 Cytokine production assay 
To determine the type and quantity of cytokines being produced in response 
to a treatment, a bead-based cytokine assay was performed (Bio-Plex Pro™ 
Cytokine, Chemokine, and Growth Factor Assay; Biorad Labratories, Inc.) 
following the distributer’s protocol, on either the serum from mice or the 
supernatant from a splenocyte culture. For the latter, a single cell suspension 
was made from the spleens of mice as indicated above and the splenocytes 
were resuspended at 10x106 cells/ml. Each well of a 24-well plate was 
transferred 1x106 splenocytes of a given sample, in a total volume of 500 µl. 
One set of the samples remained unstimulated and another was restimulated 
with 1x105 DCs loaded with C1498 tumour cell lysate (described below). The 
cells were then cultured at 37 °C for 24 hours, after which the liquid was 
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collected in a microtube, centrifuged at 616 g (Sigma 1-14 Microfuge) for five 
minutes and the supernatant was collected for cytokine analysis.  
 
To make the lysate loaded DCs, C1498 cells were freeze thawed six times in 
liquid nitrogen to lyse the cells. The cells were then filtered through a 40 µm 
filter to remove clumps. The lysate was then cultured for four hours with bone 
marrow derived DCs at a ratio of one DC to the lysate from six tumour cells. 
 
2.2.9 Suppression assay 
Processed spleens were resuspended in 5 ml of PBS and underlaid with 4 ml 
of a density separation medium designed to isolate lymphocytes (Lympholyte 
solution, Cedarlane, Ontario, Canada). The samples were centrifuged at 823 
x g (Heraeus Multifuge 3 S-R) for 20 minutes without a brake. The resulting 
cell pellet was resuspended in 10 ml of PBS and washed twice. The cells 
were resuspended in running buffer with CD11b-biotin antibody for fifteen 
minutes at 4 °C before being washed twice in PBS. The cells were 
resuspended in 200 µl of running buffer per 1x107 cells and this was run 
through a 30 µm pre-separation filter. For every 1x107 cells, 10 µl of anti-biotin 
microbeads (Miltenyi biotec, Bergisch Gladbach, Germany) was added and 
the samples were then incubated at 4 °C for 30 minutes. The samples were 
run through an automated cell separator (Automacs, Miltenyi biotec, Bergisch 
Gladbach, Germany) and the positive fraction was washed twice in cIMDM. 
Lymph nodes were harvested from a C57BL/6 mouse and stained with CFSE 
as indicated in section 2.2.4. The cells were resuspended at 1x106 cells/ml 
and anti-CD3 and anti-CD28 were added to the lymphoid cells at 4 µg/ml and 
1 µg/ml respectively. Lymphoid cells were cultured in a 96-well plate with 
5x104 lymphoid cells per well and the same amount of MDSCs (1:1 ratio), in a 
total volume of 200 µl. The cells were then cultured for 72 hours before flow 
cytometry was performed to analyse the dilution of CFSE on both the CD4+ 
and CD8+ T cells. For the suppression assay with C1498 cells, 5x104 C1498 
cells were cultured with the T cells in place of the CD11b+ cells. 
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2.2.10 Statistical analysis 
The statistical significance between groups was determined with a one-way 
ANOVA followed by the Bonferroni post-test when there were more than two 
groups with one variable. This analysis was performed, as the sample 
population is parametric. To determine the statistical difference between only 
two groups a Mann Whitney test was performed. This test is non-parametric 
but was chosen as it is a more robust test compared to the unpaired T test, as 
it includes an analysis of the distribution within groups as well as between 
them. For the analysis of the statistic difference between two or more groups 
in a survival assay a Log-rank Mantel Cox test was performed. All statistics 
performed on a given figure display the standard error of the mean and the 
tests performed are indicated in the figure legends. Graphpad Prism 5 
software (Graphpad Software Inc., San Diego, CA, U.S.A) was used. five 
animals were chosen because there has been literature precedence for 
revealing statistically significant differences between groups in similar 
immunological experiments. Single representative experiments showing 
statistically significant results are presented throughout. However, to ensure 
robustness, the experiments were always repeated at least once, and again 
independently assessed for statistical significance.  In some cases, where 
less than 5 animals were used, again the robustness of the results was 
confirmed by repeating the experiment with independent statistical analysis. 
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3.1 Introduction 
Endogenous CD8+ T cells activated against tumours are often unsuccessful at 
preventing tumour progression. This is, in part, due to the development of an 
immune-suppressive environment by tumours. The ex vivo stimulation of T 
cells in adoptive therapy enables T cell activation in the absence of tumour-
associated suppression. Thus, tumour-bearing hosts can be administered a 
population of appropriately activated tumour-specific T cells. Clinical trials 
investigating the protective benefits of adoptive CD8+ T cell therapy for the 
treatment of melanoma found that as many as 70% of recipients developed 
objective responses, as determined by a decrease in tumour size (321). While 
the potential of adoptive therapy is evident, it is likely that enhanced protection 
would be provided if some current limitations could be overcome. One such 
limitation is the inability of the transferred cells to survive in high numbers for 
the extended periods of time required for effective anti-tumour activity (342-
344). A greater understanding of the interactions and stimuli received by 
transferred T cells in vivo may elucidate new strategies to improve longevity of 
the transferred cells and hence the level of anti-tumour protection (312, 344).  
 
As DCs are potent APCs, it is possible that transferred CD8+ T cells receive 
stimuli from endogenous DCs presenting tumour antigens. Evidence 
indicating the interaction between DCs and endogenous anti-tumour CD8+ T 
cells is found in studies demonstrating that anti-tumour CD8+ T cell responses 
within a host are strictly dependent on a match between the MHC haplotype 
of the host’s APCs and that of the host’s T cells (17). This suggests that 
activating anti-tumour CD8+ T cells in vivo is dependent on the presentation of 
tumour antigens by APCs. An Experiment specifically implicating DCs in the 
activation of anti-tumour CD8+ T cells utilized Batf3 KO mice. Batf3 KO mice 
are unable to develop CD103+ DCs, which includes the cross-presenting 
CD8α+ DCs in lymphoid tissues. These mice were unable to activate anti-
tumour effector CD8+ T cells and subsequently could not control the growth of 
a fibrosarcoma that was effectively controlled in Batf3+/+ mice, therefore 
indicating that CD103+ DCs are essential for anti-tumour CD8+ T cell 
responses in this model (123).  
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It remains to be determined if DCs presenting tumour antigens have an effect 
on transferred effector CD8+ T cells. However, the combination of adoptive 
CD8+ T cell therapy with a DC-based vaccine can provide a synergistic effect 
resulting in superior anti-tumour protection provided by the transferred CD8+ T 
cells (345-347). Endogenous DCs have also been demonstrated to stimulate 
transferred effector-CD8+ T cells in virally infected hosts, as anti-viral effector 
CD8+ T cells transferred into influenza-infected hosts proliferated significantly 
less when depleted of their CD11c+ DCs (348). However, the specific DC 
subset that stimulated the T cells to proliferate was not determined. It remains 
to be established if the same stimulatory function applies in a tumour model. 
Importantly in this context, it is possible that the suppressive environment 
associated with tumour development may maintain DCs in an immature state, 
thereby limiting their T cell stimulatory capability (349-351). 
 
The contact dependent interaction between transferred T cells and 
endogenous DCs was indicated by a study, in which, α-GalCer was loaded 
onto T cells prior to their transfer. The α-GalCer was transferred directly from 
the administered T cells to endogenous DCs (352). The anti-tumour activity of 
the transferred T cells was also enhanced when loaded with α-GalCer, 
possibly due to licensing of DCs by α-GalCer-activated iNKT cells and then 
superior stimulation of the transferred T cells by the licensed DCs. 
 
In this chapter, the role of endogenous DCs was investigated in a model of 
adoptive T cell therapy. Because the stimulation of adoptively transferred 
CD8+ T cells with tumour antigens requires the exogenous antigens to be 
cross-primed, the potent cross-priming langerin+ CD8α+ DCs were analysed 
(107). In addition to their cross-priming functions, their location in the marginal 
zone of the spleen places them in an ideal position to acquire antigens from 
the blood, such as those derived from circulating tumour cells. The langerin+ 
CD8α+ DCs were therefore examined in relation to their ability to stimulate 
adoptively transferred effector CD8+ T cells used for the treatment of an 
established tumours. For this purpose, the tumour challenge within the 
following experiments consisted of intravenously administered E.G7-OVA 
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cells. Intravenously administering the tumour enables the tumour cells to 
circulate in the blood and drain from circulation into the spleen. This provides 
a tumour model that enables the acquisition of tumour antigens by splenic 
DCs, including langerin+ CD8α+ DCs. In addition, E.G7-OVA expresses the 
OVA protein, peptides of which can be recognised by the TCRs of OT-I T 
cells. The tumour cells engraft in a variety of extrasplenic locations and 
antigens released from these sites are likely to reach the circulation and enter 
the spleen. Therefore, we have a tumour model that encourages acquisition of 
tumour antigens by splenic APCs and provides us with access to tumour-
specific CD8+ T cells for use in adoptive therapy. 
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3.1.1 Aims 
The aim of this series of experiments was to develop a model of adoptive 
therapy, consisting of CD8+ T cells used to treat an established tumour, and to 
determine if the presence or absence of recipient langerin+ CD8α+ DCs had 
an effect on the function of the transferred T cells, or the anti-tumour 
response. The hypothesis addressed is that “the effective anti-tumour activity 
of an adoptive transfer-based immunotherapy is dependent on the function of 
resident langerin+ CD8α+ DCs in the spleen.” 
 
Specific aims 
- To establish whether langerin+ CD8α+ DCs acquire and cross-present 
tumour-associated antigens in tumour-bearing animals 
 
- To develop a model of adoptive cell therapy using in vitro-activated 
antigen-specific CD8+ T cells to treat established tumours 
 
- To assess the role of langerin+ CD8α+ DCs in determining the 
functional response of effector CD8+ T cells transferred into tumour-
bearing animals 
 
- To assess the role of langerin+ CD8α+ DCs in the anti-tumour response 
mediated by transferred CD8+ T cells 
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3.2 Results 
3.2.1 Developing a Naïve T cell tumour challenge model 
To enable the analysis of langerin+ CD8α+ DCs in the stimulation of naïve 
CD8+ T cells, experiments were required to elucidate the number of naïve OT-
I T cells and E.G7-OVA cells that would generate an effective tumour-antigen 
specific CD8+ T cell response in vivo. E.G7-OVA is a murine thymoma cell 
line that has been modified to express OVA protein as a model tumour 
antigen. Different numbers of E.G7-OVA cells, 1x105, 1x106 or 6.5x106, were 
administered intravenously into hosts to identify a tumour challenge that 
develops within a timeframe suitable for experimentation. In all survival 
experiments, mice were culled at the initial onset of symptoms, as determined 
by weight loss, or a change in their behaviour as identified by hunching or 
reduced grooming, and presence of tumours was confirmed by necropsy. 
Hosts administered 1x105 E.G7-OVA cells began to develop symptoms 
associated with tumour burden at day 40 (Figure 3.1A). Hosts challenged with 
1x106 or 6.5x106 E.G7-OVA cells developed symptoms between days 20 and 
32 following tumour challenge. As mice challenged with the lower number of 
E.G7-OVA cells remained symptom-free for a long period and hosts 
challenged with the larger two numbers of tumour cells developed symptoms 
at similar times, the 1x106 E.G7-OVA cell tumour challenge was used as the 
model of tumour challenge throughout this chapter. 
 
Mice intravenously administered 1x106 E.G7-OVA cells developed tumours in 
multiple tissues. In initial experiments, tumour burden was verified by 
dissection at different times after tumour challenge. Tumours were observable 
to the naked eye in the liver, kidneys, ovaries, inguinal lymph nodes, spleen 
and lumbar lymph nodes (Figure 3.2 A–B). Interestingly around 40% of mice 
developed paralysis of their hind legs, most likely due to a tumour seeding in 
the spinal cord or brain.  
 
Naïve CD8+ T cells were initially used to ascertain whether tumour antigens 
could be cross-presented to stimulate tumour-specific CD8+ T cells in vivo. 
For adoptive transfer experiments, CD8+ T cells isolated from OT-I mice were 
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used, which are genetically altered such that the majority of CD8+ T cells 
express TCRs specific for the SIINFEKL antigen, which is a H-2Kb-binding 
peptide epitope from the OVA protein. As the tumour expresses the OVA 
protein, OT-I CD8+ T cells are essentially model “tumour-specific” CD8+ T 
cells. The number of naïve OT-I cells that would delay this tumour burden was 
analysed by intravenously administering different numbers, 500, 5x105 or 
5x106, of naïve OT-I T cells into hosts prior to challenge with 1x106 E.G7-OVA 
cells. Hosts that received either 500 or 5x104 naïve OT-I T cells exhibited no 
delay in the development of symptoms associated with tumour burden when 
compared to the tumour only control (Figure 3.3). However, hosts that 
received 5x106 naïve OT-I T cells remained symptom-free significantly longer 
than the other groups and therefore this number of OT-I T cells was used for 
the remaining naïve T cell experiments.  
 
To determine how many of the 5x106 lymphoid cells administered were OT-I 
CD8+ T cells flow cytometry was performed to analyse the proportion of total 
lymphoid cells that express CD8 and the OT-I T cell receptor component Vα2. 
Of the live cells within the lymphoid single cell suspension, 68 % were CD8+ 
Vα2+ cells and of the total lymphoid cell population, 37.0 % were OT-I T cells 
(Appendix 2). Therefore, when administering 5x106 OT-I lymphoid cells, 
1.9x106 OT-I T cells are being transferred. 
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Figure 3.1: Developing the E.G7-OVA tumour challenge model. (A) C57BL/6 
mice were intravenously administered 1x105, 1x106 or 6.5x106 E.G7-OVA cells and 
the symptom-free survival was analysed. This experiment was performed once with 
three mice per group. *P < 0.05 (Log-rank test for trend). 
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Figure 3.2: E.G7-OVA administered intravenously results in tumour 
development in a variety of tissues. Mice were administered 1x106 tumour cells 
intravenously and their symptom free survival was followed. Upon the development 
of symptoms arising from tumour burden the mice were culled. (A) The tissues in 
which a tumour was found by necropsy are indicated along with the number of mice 
that had a tumour in that tissue. (B) A photo is used to demonstrate the variety and 
severity of tumour-burden between mice. The tumours detected are outlined with 
blue circles. 
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Figure 3.3: Naïve OT-I CD8+ T cells protect mice from tumours in the blood. 
C57BL/6 mice were intravenously administered 500, 5x104 or 5x106 naïve OT-I T 
cells and the following day were challenged with 1x106 E.G7-OVA cells. The period 
that the mice remained symptom-free was determined, and is graphed. This 
experiment was performed once with five mice per group. However, the survival of 
tumour-challenged mice with 5x106 OT-I T cells has been performed twice. *P < 0.05 
(Log-rank test for trend). 
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3.2.2 Langerin+ CD8α+ dendritic cells in the spleen acquire 
and cross-present tumour antigens 
In the previous experiments, OT-I T cells were transferred into mice before 
tumour challenge, thereby maximizing the chance of interaction between the 
tumour-specific T cells and the tumour, either directly or perhaps with 
antigenic debris derived from the tumour. It was next investigated whether 
naïve OT-I T cells could be activated by tumour antigen once the tumour had 
been established. This may be more indicative that antigens derived from the 
tumour in its niche environment can be acquired and presented by host APCs. 
For this purpose, 5x106 lymphoid cells, containing naïve CD8+ T cells from 
CD45.1-expressing OT-I mice were stained with CFSE and administered into 
CD45.2 expressing mice that had tumours established for one or seven days. 
Proliferation of the transferred CD8+ T cells was assessed by monitoring 
CFSE fluorescence by flow cytometry, with a reduction in fluorescence 
indicative of proliferating cells that have contributed half of their labelled 
cellular contents to each daughter cell. Flow cytometry was performed on 
single cell suspensions prepared from the spleens of animals culled three 
days after T cell transfer, with fluorescent antibodies for CD45.1, CD8 and 
TCR Vα2 used to identify the transferred CD8+ T cells.  
 
When naïve CD8+ T cells were transferred into mice that had not been 
challenged with tumour cells, the intensity of the CFSE concentration 
remained high, indicating that these cells were not proliferating. However, 
when CD8+ T cells were transferred into mice with tumours established for 
one or seven days, a significant reduction of CFSE fluorescence was 
observed, indicating that these CD8+ T cells were receiving a tumour-derived 
stimulus resulting in their proliferation (Figure 3.4). These data therefore 
provide evidence that antigens can be presented to CD8+ T cells from 
established tumours. While it remains possible that the CD8+ T cells were 
stimulated directly by tumour cells, it was very likely that the antigen had been 
acquired by resident APCs, and then cross-presented for stimulation of the 
CD8+ T cells. This tumour model was therefore used in subsequent 
experiments to explore the possibility that resident APCs such as the splenic 
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langerin+ CD8α+ DCs were responsible for the acquisition of tumour antigens, 
and that these cells could play a role in adoptive T cell therapy with in vitro 
activated CD8+ T cells. 
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Figure 3.4: Naïve CD8+ T cells proliferate in the spleen of mice with established 
tumours. CFSE labelled CD8+ T cells were administered into the blood of mice with 
one or seven day-old tumours. Three days after transfer the spleens were removed 
and CFSE fluorescence on the transferred cells was analysed by flow cytometry, 
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using an antibody for CD45.1 to identify the transferred cells. The gating strategy 
used to identify the transferred CD8+ T cells from a single cell suspension of 
splenocytes is provided (A). Gating on FSC-A vs. FSC-H and SSC-A vs. SSC-H was 
performed for every flow cytometric analysis in this thesis but will no longer be 
displayed. An example of the CFSE dilution observed from each group (B). (C) The 
percent of transferred CD8+ T cells in the spleen that proliferated is compared 
between the various groups. This is the result of a single experiment, with five mice 
per group. *P < 0.05, ***P < 0.001 (One-way ANOVA with a Bonferroni’s Multiple 
comparisons Test). 
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To first determine if langerin+ CD8α+ DCs could acquire and cross-present 
tumour-derived antigens from established E.G7-OVA tumours, naïve CFSE 
labelled CD8+ OT-I T cells were transferred into lang-EGFPDTR mice that 
were then tumour challenged; DT was used to deplete the langerin expressing 
cells in some recipients prior to challenge. Proliferation of the transferred 
CD8+ T cells was determined by analysing their CFSE fluorescence by flow 
cytometry three days after transfer. The CD8+ T cells transferred into mice 
that were not tumour challenged maintained a high CFSE fluorescence 
indicating that the CD8+ T cells were not proliferating in the absence of 
antigen. In contrast, the CD8+ T cells transferred into mice that were then 
tumour challenged displayed a significant decrease in the concentration of 
CFSE, indicating that the transferred CD8+ T cells proliferated in response to 
tumour antigens. Mice depleted of langerin+ cells prior to transfer also 
maintained a high CFSE concentration indicating that the CD8+ T cells were 
not receiving the proliferation-inducing stimulus even when the tumour 
antigens were present (Figure 3.5). However, some proliferation was 
detected, indicating that another DC subset maybe able to induce T cell 
proliferation to a lesser degree. This experiment suggests that langerin+ 
CD8α+ DCs can acquire antigens from the tumour and cross-present them for 
stimulation of naive antigen-specific CD8+ T cells, thereby negating the idea 
that the tumour cells are stimulating naive CD8+ T cells directly. Importantly, 
this readout does not provide information on the quality of the interaction, and 
whether the outcome is an anti-tumour T cell response, or merely a 
proliferative response that precedes the induction of tolerance. 
 
 
 
 
 
 
 
Chapter 3: The role of langerin+ CD8α+ DCs in ACT 93 
 
Figure 3.5: Langerin+ CD8α+ DCs are required for naïve CD8+ T cells to 
proliferate in response to intravenously administered tumour cells. Naïve OT-I 
T cells labelled with CFSE were administered into Lang-EGFPDTR mice the day 
prior to challenge with 1x106 E.G7-OVA cells. Three days after challenge the spleens 
were removed and the amount of transferred naïve CD8+ T cells that proliferated was 
determined by CFSE dilution. One group of mice received two intraperitoneal doses 
of 350 ng of DT to deplete the langerin+ cells, beginning before OT-I transfer. (A) A 
histogram representative of CFSE dilution on CD8α+, Vα2+ and CD45.1+ OT-I T cells 
from each experimental group. (B) A graph comparing the percent of OT-I T cells 
found in the spleen that had undergone proliferation as determined by CFSE dilution. 
This data is a representative of three experiments, with five mice per group. ***P < 
0.001 (One-way ANOVA with Bonferroni’s Multiple Comparisons Test). 
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Having established that langerin+ CD8α+ DCs are required for activation of 
anti-tumour CD8+ T cells against an intravenous tumour challenge, it was next 
evaluated whether these DCs are essential for adoptive T cell therapy with 
activated CD8+ T cells. In order to accomplish this, it was first necessary to 
demonstrate the ability to activate naïve OVA-specific CD8+ T cells in vitro 
into useful effector T cells for adoptive therapy and then determine the most 
effective number of CD8+ T cells to transfer, as well as the optimum time to 
treat mice. The ability to effectively stimulate naïve CD8+ T cells into effector 
CD8+ T cells in vitro was determined by examining the CD8+ T cell phenotype 
before and after activation. Activation was induced by culturing naïve OT-I T 
cells for six days with SIINFEKL-pulsed BMDCs, in combination with IL-2 
treatment. Flow cytometry, with fluorescent antibodies for CD62L and CD25, 
was used to determine the activation status before and after the culture 
period. Before culture, the CD8+ T cells displayed a naïve phenotype with low 
CD25 and high CD62L expression. During this stimulation around 12x106 
naïve T cells could generate over 7.5x107 activated T cells. The T cells 
cultured with BMDCs, on the other hand, expressed an activated phenotype, 
with high CD25 and low CD62L expression (Figure 3.6). These studies 
demonstrate that the T cells were effectively stimulated by the BMDCs and 
were ready for administration. 
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Figure 3.6: CD8+ T cells stimulated in vitro express an effector T cell 
phenotype. Flow cytometry analysis was performed on both naïve and in vitro 
stimulated OT-I T cells to analyse the T cell phenotype after stimulation. The lymph 
nodes of an OT-I mouse was removed and the naive OT-I T cells were identified by 
CD8 and Vα2 expression. The same markers were used to identify activated CD8+ T 
cells removed from culture. (A) An example of the gating strategy used to isolate the 
OT-I T cells from both the naïve and effector T cell samples. (B) An example of the 
gating strategy used on both the naïve and stimulated T cells to determine the 
expression of the lymphoid homing receptor CD62L and the expression of the alpha 
chain of the IL-2 receptor, CD25. (C) A histogram comparing the expression of 
CD62L and CD25 on naïve and stimulated T cells. The effector CD8+ T cells are 
represented in brown in the histograms and naïve T cells are represented in green. 
This data is representative of three separate experiments. 
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Next the number of effector CD8+ T cells required to provide mice with 
effective therapy against the tumour model was determined. Three different 
doses of T cells were administered into mice ten days after tumour challenge 
and the development of tumours was assessed by necropsy eleven days 
later. These time-points were chosen as we needed a model where the mice 
had an established tumour burden before the administration of OT-I T cells, 
whilst giving the T cells time to prevent tumour development. In addition, the 
experiment needed to end before the tumour only control mice required 
culling. Therefore, day 20 was chosen as the end point and mice were 
allowed to develop tumours for only 10 days prior to adoptive therapy. After 
being culled, mice were thoroughly examined and the tissues that developed 
tumours were scored on a scale from zero to two depending on the severity 
and size of each tumour and the tumour score for each mouse is combined 
(Section 2.2.5). The tissues detected with tumours include the ovary, kidney, 
liver, spleen, inguinal lymph nodes (ILN), auxiliary lymph nodes (ALN), lumbar 
lymph nodes (LLN) and medistinal lymph nodes (MLN). Some mice 
developed hind leg paralysis, which was also graded from zero to two 
depending on the extent of paralysis (Figure 3.7). The results from this 
experiment indicate that 2x104 and 2x105 effector CD8+ T cells was 
insufficient to provide any protective benefit to mice, but the administration of 
2x106 effector CD8+ T cells resulted in the development of fewer tumours, 
with only a single, small tumour detected in one mice (Figure 3.7). However, 
because this was a statistically insignificant result, 5x106 CD8+ T cells were 
used in future experiments. 
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Mice Kidney 
 
Ovary  ILN ALN LLN Liver MLN Hind 
legs 
Spleen 
EG7 only 1      1  2  
2      1    
3  1        
4  2   2    1 
5   2       
2x104 OTI 
1 
1      2 2  
2   2   1    
3  1        
4          
5          
2x105 OTI 
1 
       2  
2        2  
3        2  
4 2         
5    2   2   
2x106 OTI 
1 
         
2  1        
3          
4          
 
Figure 3.7: Adoptively transferring 2x106 effector CD8+ T cells reduces the 
burden in mice with ten-day-old tumours. Lang-EGFPDTR mice were 
administered E.G7-OVA intravenously and ten days later were administered different 
doses of effector CD8+ T cells. On day 21 after tumour challenge mice were culled 
and their tissues were graded for tumour development by necropsy. The tumours in 
each tissue were graded on a scale of zero to two depending on the size of the 
tumour, when taking into consideration the size of the tissue itself. Hind leg paralysis 
was also detected in some mice and the severity was also scaled from zero to two. 
The score for each mouse is depicted in the table and the average score between 
groups is graphed. This represents a single experiment with five mice in each group 
except the group that received 2x106 OT-I cells, which had four mice. P = 0.1657 
Chapter 3: The role of langerin+ CD8α+ DCs in ACT 98 
3.2.3 Tumours induce the stimulation of adoptively 
transferred effector CD8+ T cells 
It was next investigated whether established tumours can provide an 
environment in which adoptively transferred effector CD8+ T cells can be 
stimulated. Timing of transfer was considered crucial to these experiments as 
leaving the tumour to grow in the host for too long may allow it to generate a 
suppressive environment capable of inhibiting the transferred cells, whereas 
smaller tumours may not provide sufficient antigen to stimulate the CD8+ T 
cells. Mice were therefore administered 5x106 effector OT-I T cells, four, eight 
or twelve days following tumour challenge. The CD8+ T cell population was 
analysed in the spleen and blood seven days later by flow cytometry, using 
fluorescent antibodies for CD45.1, CD8 and Vα2. Control mice were 
administered effector CD8+ OT-I T cells in the absence of tumour challenge. 
Interestingly, larger percentages of OT-I T cells were detected in the spleens 
when tumours were present for twelve days prior to transfer, compared to T 
cells administered in mice without tumours (Figure 3.8B). In addition, 
significant increases were observed in the blood of mice that had the tumour 
for eight or more days’ prior to transfer (Figure 3.8C). Furthermore, the ability 
of the T cells to produce IFN-γ was analysed by intracellular flow cytometry, 
with a fluorescent antibody for IFN-γ. This showed that a greater percentage 
of effector OT-I T cells produced IFN-γ when they were administered into mice 
with twelve-day-old tumours (Figure 3.8D). These results indicate that 
tumours can provide a stimulus to transferred effector CD8+ T cells, 
particularly when the tumours had more time to develop a larger mass. This 
stimulus resulted in accumulation of the transferred T cells in the tissues 
tested; whether this reflects a proliferative stimulus remains to be ascertained. 
 
Having established a model of adoptive therapy consisting of the 
administration of 5x106 activated CD8+ T cells for the treatment of twelve-day-
old tumours, the kinetics of the transferred cells were then assessed. For this 
purpose, 5x106 in vitro activated CD8+ T cells were administered into mice 
with twelve-day-old tumours and blood samples were collected from the mice 
three, seven and fourteen days after transfer. The percentage of transferred 
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cells detected by flow cytometry was compared to animals that were 
transferred effector CD8+ T cells but did not harbour any tumour. Mice that 
were administered T cells in the absence of tumours consistently maintained 
a low population of transferred CD8+ T cells in the blood at all time points 
tested. Mice transferred effector CD8+ T cells in the presence of twelve-day-
old tumours had a significantly larger population of transferred T cells in the 
blood on day seven, however by day fourteen this population had reduced 
significantly (Figure 3.9). This result indicates that the tumour provided a 
stimulus to the transferred effector CD8+ T cells that caused more 
accumulation of the transferred T cells in the blood. It is likely that the 
transferred T cells underwent proliferation between days three and seven in 
response to tumour antigens, although tumour induced changes in the 
recirculation of the transferred T cells between tissues cannot be ruled out. 
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Figure 3.8: Transferred effector CD8+ T cells respond more when the tumours 
have been allowed to develop for twelve days prior to transfer. Lang-EGFPDTR 
mice were administered 5x106 effector OT-I T cells four, eight or twelve days 
following tumour challenge. Seven days later the T cell populations were compared 
by flow cytometry by using CD45.1+, CD8+ and Vα2+ expression to identify the 
transferred effector CD8+ T cells. An example of the gating used to identify the OT-I T 
cells that are producing IFN-γ is displayed (A), with an isotype negative control 
antibody used on the left plot, and an IFN-γ antibody on the right. Graphs display the 
percent of CD8+ cells in (B) the spleen and (C) the blood that are OT-I T cells. The 
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presence of intracellular IFN-γ within the transferred CD8+ T cells was determined by 
performing intracellular flow cytometry on the splenocytes using an antibody for IFN-γ 
and the percent of transferred CD8+ T cells producing IFN-γ is presented (D). This 
represents a single experiment with four mice per group, however the data are 
repeated in following experiments. *P < 0.05, **P < 0.01, ***P < 0.001 (One-way 
ANOVA with a Bonferroni’s Multiple comparisons Test). 
 
 
 
 
 
Figure 3.9: Effector CD8+ T cells proliferate after transfer into mice with twelve-
day-old tumours. C57BL/6 mice were transferred 5x106 in vitro activated T cells 
either in the presence or absence of twelve-day-old tumours. Blood samples were 
collected three, seven and fourteen days following transfer to analyse the T cell 
population overtime. The transferred OT-I T cells in the blood were identified by 
expression of CD8, Vα2 and CD45.1. A line graph showing the percent of CD8+ cells 
in the blood that are OT-I T cells overtime. This represents a single experiment, with 
five mice per group, however the data are repeated in following experiments. A T 
Test with a Mann-Whitney post-test was performed at each time point between the 
two groups. **P = 0.01. 
 
 
 
 
 
 
Chapter 3: The role of langerin+ CD8α+ DCs in ACT 102 
3.2.4 Langerin+ CD8α+ dendritic cells are required for the 
stimulation of adoptively transferred CD8+ T cells in the 
presence of tumour 
Having shown that a tumour derived stimulus induced an increase of in vitro 
activated tumour specific CD8+ T cells in the blood after transfer, it was next 
investigated whether the potent cross-priming langerin+ CD8α+ DCs were 
essential for this stimulation to occur. To do this, lang-EGFPDTR mice were 
administered 5x106 effector CD8+ T cells for the treatment of twelve-day-old 
tumours, with or without DT treatment to deplete langerin+ cells. To ensure 
that DT treatment was not influencing T cell responses by a mechanism 
independent of langerin+ cells, DT was also administered into a group of 
C57BL/6 mice, which do not express the human DTR. Interestingly, in lang-
EGFPDTR mice depleted of the langerin+ cells prior to adoptive transfer, the 
accumulation of transferred cells seen in the spleen and blood of tumour-
bearing mice was ablated, approaching levels observed in mice that were 
administered CD8+ T cells in the absence of tumours (Figure 3.10 A–C). The 
accumulation of the transferred CD8+ T cells in the spleens of tumour-bearing 
mice was not altered by the administration of DT in C57BL/6 mice, which 
indicates that DT is not altering the CD8+ T cell response independently of 
langerin+ depletion (Figure 3.10D). These data demonstrate that the tumour-
derived stimulus that induced an increase of CD8+ T cells in the spleen and 
blood was dependent on langerin+ CD8α+ DCs. 
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Figure 3.10: The tumour induced increase of transferred effector CD8+ T cells 
in the spleen and blood is dependent on langerin+ CD8α+ DCs. Lang-EGFPDTR 
mice were transferred effector OT-I T cells twelve days after the intravenous 
administration of E.G7-OVA. One group of mice were depleted of the langerin+ cells 
with 350 ng of DT administered intraperitoneally. Seven days following adoptive 
transfer the blood and spleens were analysed by flow cytometry using CD8, Vα2 and 
CD45.1 to identify the transferred CD8+ T cells. The number of OT-I T cells per litre 
of blood was analysed and is depicted in (A). The proportion of OT-I T cells as a 
percent of the total CD8+ cell population was also analysed in the blood (B) and 
spleen (C). The adoptive transfer experiment performed in C57BL/6 mice, analysing 
the proportion of OT-I T cells as a percent of the total CD8+ cell population in the 
spleen (D). (A) is the combination of two experiments, (B) is representative of five 
experiments and (C) and (D) are a representative of four experiments with five mice 
per group. *P < 0.05, **P < 0.01, ***P < 0.001 (One-way ANOVA with a Bonferroni’s 
Multiple comparisons Test). 
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3.2.5 The phenotype of adoptively transferred CD8+ T cells is 
not altered in the absence of langerin+ CD8α+ dendritic 
cells 
In the absence of the tumour-associated stimulus from the langerin+ CD8α+ 
DCs, lower numbers of transferred T cells were found in the blood and spleen. 
As mentioned in the introduction, effector CD8+ T cells enter the contraction 
phase of the T cell response when the cognate antigen is reduced, resulting in 
apoptosis of a significant proportion of the T cell population. It was therefore 
possible that in the absence of the langerin+ CD8α+ DCs, the transferred T 
cells enter the contraction phase due to lack of stimulation. In this case, the 
CD8+ T cell population in the absence of the langerin+ CD8α+ DCs stimulation 
would be lower in number compared to when the langerin+ cells were present 
(as was observed) and the remaining population would display more of a 
memory phenotype. To determine if the transferred T cells entered the 
contraction phase in the absence of langerin+ cells, the phenotype of the 
transferred effector T cells in the spleen was analysed following transfer into 
hosts with twelve-day-old tumours, in the presence or absence of langerin+ 
CD8α+ DCs. As CD122 is upregulated on memory precursor cells we can use 
this marker in conjunction with CD62L to identify the different T cell 
phenotypes (127, 353, 354). TCM cells express CD122 and CD62L, TEM 
expresses CD122 but not CD62L and effector T cells express neither (354). In 
addition, KLRG1 can indicate the functional status of the CD8+ T cells, with 
KLRG1 upregulated on CD8+ T cells that have become terminally 
differentiated (355). While the effector and TEM and TCM subsets were 
discernable by this analysis, no significant differences in the proportion of any 
given phenotype were observed in tumour-bearing animals treated with 
adoptive therapy in the presence or absence of the langerin+ CD8α+ DCs and 
KLRG1 expression also did not differ between these two groups (Figure 3.11). 
However, CD8+ T cells that were transferred into mice that had not been 
challenged with tumours displayed more of a TCM phenotype than the CD8+ T 
cells that were transferred into mice with established tumours (Figure 3.11C). 
These results therefore indicate that although the absence of the langerin+ 
CD8α+ DC stimulus resulted in a reduced accumulation of transferred CD8+ T 
Chapter 3: The role of langerin+ CD8α+ DCs in ACT 105 
cells in the spleen and blood it does not significantly alter their phenotype, 
which suggests these T cells had not entered the contraction phase.  
 
 
Figure 3.11: The phenotype of transferred CD8+ T cells is unaltered when 
transferred into mice depleted of their langerin+ CD8α+ DCs. Lang-EGFPDTR 
mice were transferred effector OT-I T cells twelve days after the intravenous 
administration of E.G7-OVA. One group of mice were depleted of the langerin+ cells 
with 350 ng of DT administered intraperitoneally. Seven days following adoptive 
transfer the phenotype of the OT-I T cells in the spleen was determined by flow 
cytometry using CD8, Vα2 and CD45.1 to isolate the transferred cells. The gating 
strategy used to determine the expression of CD62L and CD122 can be found in (A), 
with naïve cells to demonstrate the negative populations (far left) and an example 
from each experimental group. (B) The proportion of the OT-I T cell population that is 
negative for CD122 and CD62L. (C and D) The proportion of the population that is 
CD122+ and CD62L+ and CD122+ and CD62L-, respectively. (E) The OT-I T cells 
from the spleen that express KLRG1. B–D are a representative of four experiments 
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and (E) is a representative of two, with five mice per group. *P < 0.05 (One-way 
ANOVA with a Bonferroni’s Multiple comparisons Test). 
 
 
3.2.6 The functional state of transferred CD8+ T cells is not 
altered in langerin depleted mice 
The studies to this point had shown that a tumour derived stimulus can induce 
adoptively transferred effector T cells to accumulate in the spleen and blood, 
however this stimulus did alter their phenotype. It was next investigated 
whether the langerin+ CD8α+ DC-dependent stimulation alters the function of 
the transferred CD8+ T cells in terms of cytokine production and their ability to 
kill antigen-specific target cells. Analysis of the ability of the CD8+ T cells to 
produce IFN-γ was determined by intracellular flow cytometry on the splenic 
OT-I T cell population. This showed that the percentage of transferred cells 
producing IFN-γ and the MFI of IFN-γ on OT-I T cells was unaffected by 
transfer into tumour-bearing mice depleted of their langerin+ cells (Figure 3.12 
A and B). However, this analysis did not take into account the increased 
population of transferred CD8+ T cells in the spleen where the differences 
were quite substantial. When taking into account the population size, there 
were significantly more transferred CD8+ OT-I T cells producing IFN-γ when 
the langerin+ cells were present (Figure 3.12C). 
 
The ability of transferred CD8+ T cells to recognize and kill cells loaded with 
their cognate antigen in tumour-bearing mice was analysed. Target cells 
consisting of fluorescently labelled splenocytes, loaded with or without 
peptide, were administered seven days after CD8+ T cell transfer and the 
following day a blood sample was removed to determine the proportion of 
target cells that were killed in each group using flow cytometry (Figure 3.13A). 
Three groups of target cells were used with each group pulsed with a different 
concentration of the cognate antigen SIINFKEL (0.5, 5 and 50 nM 
respectively). While peptide specific killing could clearly be observed, no 
statistically significant difference in the ability of the transferred CD8+ T cells 
to kill targets was observed when compared in the presence or absence of 
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langerin+ cells (Figure 3.13B). Of note, mice that received effector CD8+ T 
cells in the absence of tumours were significantly less effective at killing the 
50 nM target cells. This indicates that a tumour-derived stimulus independent 
of langerin+ cells increases the killing capacity of the transferred CD8+ T cells 
in this setting (Figure 3.13B). In conclusion, these results indicate that CD8+ T 
cells administered into tumour bearing mice in the absence of langerin+ cells 
have similar functional capabilities as those that are transferred in their 
presence, both in terms of IFN-γ production and their ability to find and kill 
antigen specific-cells. 
 
 
 
Figure 3.12: The proportion of transferred effector CD8+ T cells producing IFN-γ  
remains constant in langerin-depleted mice. Effector OT-I T cells were transferred 
into lang-EGFPDTR mice with twelve-day-old intravenously administered tumours. 
One group of mice were depleted of the langerin+ cells by intraperitoneal 
administration of 350 ng of DT. Seven days later the spleens were removed from 
each mouse and intracellular flow Cytometry was performed to determine the 
proportion of splenic OT-I cells producing IFN-γ, using CD8, Vα2 and CD45.1 to 
identify the transferred CD8+ T cells. (A) The proportion of OT-I T cells that are 
positive for intracellular IFN-γ in the spleen. (B) The proportion of total splenocytes 
that were IFN-γ producing OT-I T cells. (A) and (B) are representatives three 
experiments, with five mice per group. *P < 0.05, **P < 0.01 (One-way ANOVA with a 
Bonferroni’s Multiple comparisons Test). 
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Figure 3.13: Effector CD8+ T cells can effectively kill target cells when 
administered into tumour-bearing mice depleted of langerin+ cells. Lang-
EGFPDTR mice were transferred effector OT-I T cells twelve days after the 
intravenous administration of E.G7-OVA. One group of mice was depleted of 
langerin+ cells with 350 ng of DT administered intraperitoneally. Seven days following 
adoptive transfer, target cells were injected intravenously into mice loaded with 0.5, 5 
or 50 nM of SIINFKEL and stained with CFSE at a low, medium or high 
concentration, respectively. A control group of cells containing no target antigen and 
stained with CTO was also administered. The day after transferring target cells, a 
sample of blood was removed from each mouse and the three different CFSE+ target 
cell populations were compared to the non-target CTO+ control to determine how 
much of the target populations had been killed. The gating strategy used to identify 
the four different groups of target cells can be found in (A). The positive control group 
was administered OVA and α-GalCer to activate the transferred CD8+ T cells and the 
negative control group received no OT-I T cells or treatment. The graph displays the 
amount of target cells from each group that were killed by the different experimental 
groups. This figure is representative of two experiments, with five mice per group. *P 
< 0.05 (One-way ANOVA with a Bonferroni’s Multiple comparisons Test on each 
target cell population). 
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3.2.7 Anti-tumour activity provided by adoptive T cell transfer 
is dependent on langerin+ CD8α+ dendritic cells 
Although no significant differences were seen in the CD8+ T cells transferred 
in the presence or absence of langerin+ DCs with the functional assays 
assessed, it remained to be established whether the absence of the langerin+ 
cells would actually have any impact on therapy-induced protection. To 
determine this mice were administered 5x106 effector CD8+ T cells for the 
treatment of twelve-day-old tumours and the symptom-free-survival was 
analysed. Mice that were challenged with the tumour alone remained 
symptom-free for an average of 24 days after challenge (Figure 3.14). In 
contrast, mice that received adoptive T cell therapy had an extended 
symptom-free survival by an average of fourteen days, giving them an overall 
average of 38 days symptom-free after tumour challenge. Interestingly, mice 
depleted of their langerin+ cells prior to adoptive transfer therapy had an 
average symptom-free survival of only 28 days. To ensure that DT treatment 
was not altering the survival of mice independently of adoptive therapy an 
experiment was conducted comparing the symptom-free survival of mice 
challenged with E.G7-OVA and treated with or without DT (Appendix 3). In 
this experiment DT treatment did not alter the symptom-free survival and 
therefore the reduced protection seen in DT treated mice in figure 3.14 is due 
to a reduced function of the transferred T cells. This result indicates that the 
stimulation provided by the langerin+ CD8α+ DCs is required for the 
transferred effector CD8+ T cells to mediate effective killing of tumour cells. 
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Figure 3.14: Anti-tumour activity provided by adoptive T cell therapy is 
dependent on langerin+ CD8α+ dendritic cells. Mice were treated with 5x106 
effector OT-I T cells twelve days after receiving 1x106 E.G7-OVA cells intravenously. 
One group of mice received 350 ng of DT intraperitoneally two days before transfer 
and every two to three days to maintain depletion. The health of the mice was closely 
observed and when a mouse displayed a symptom of disease it was culled. The 
period of time that the mice remained symptom-free after tumour challenge was 
recorded and is compared between the groups. This is the combination of three 
experiments, with 15 mice in the treated groups and 10 in the E.G7-OVA only group. 
**P < 0.01 (Log-rank Mantel Cox Test). 
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3.2.8 Stimulating endogenous dendritic cells with α-GalCer 
prior to adoptive T cell therapy 
Having found that the treatment of established tumours with adoptive CD8+ T 
cell therapy was dependent on the stimulus provided by langerin+ CD8α+ 
DCs, we aimed to enhance the efficacy of the treatment by stimulating the 
endogenous DCs prior to transfer. Intravenously administering α-GalCer 
results in the activation of endogenous DCs through the activation of iNKT 
cells, which in turn license DCs. Therefore, hosts with twelve-day-old tumours 
were administered α-GalCer at the same time as the transfer of T cells or 24 
hours after. In addition one group received α-GalCer and OT-I T cells in the 
absence of a tumour challenge. Seven days following transfer the spleens 
were removed and the OT-I T cell population was analysed. As demonstrated 
earlier, more transferred T cells were found in the spleens of tumour 
challenged hosts. Hosts that were administered α-GalCer at the same time as 
adoptive transfer, with or without tumour challenge did not have the same 
increase in transferred T cells in the spleen (Figure 3.15). The administration 
of α-GalCer 24 hours after adoptive therapy had significantly fewer 
transferred T cells in the spleen compared to hosts that did not receive α-
GalCer. This result suggests that this method of DC activation was ineffective 
at enhancing the stimulus provided by langerin+ CD8α+ DCs to the transferred 
T cells. 
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Figure 3.15: Stimulation dendritic cells with α-GalCer prior to adoptive therapy. 
C57BL/6 mice were challenged with 1x106 E.G7-OVA cells and twelve days later 
were intravenously administered 5x106 activated OT-I cells. Two groups of mice 
received 200 ng of α-GalCer, one of which was not tumour challenged and another 
group received α-GalCer 24 hours after adoptive transfer. Seven days later the 
spleens were removed and the number of transferred OT-I T cells was analysed by 
flow cytometry using CD8, Vα2 and CD45.1 to isolate the transferred cells. The 
percent of CD8+ cells that expressed Vα2 and CD45.1 was analysed and is 
displayed. This is the combination of two experiments with five mice per group. *P < 
0.05 (One-way ANOVA with a Bonferroni’s Multiple comparisons Test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: The role of langerin+ CD8α+ DCs in ACT 113 
3.2.9 Increasing tumour debris for cross-presentation with 
chemotherapy 
As the stimulus provided by langerin+ CD8α+ DCs to the transferred T cells 
was dependent on the presence of tumours, it is possible that the stimulus will 
be enhanced by increasing the amount of tumour debris for endogenous DCs 
to acquire. To increase the amount of tumour debris within the host we treated 
tumour challenged mice with the chemotherapy doxorubicin. Doxorubicin was 
used as it is a relatively immunogenic chemotherapy. It has been found to 
increase the population of CD4+ T cells within hosts, which had also 
upregulated CD40L (356). In this study, the subsequent interaction of the 
CD4+ T cells with DCs resulted in enhanced activation and survival of DCs in 
vitro. Therefore, doxorubicin was of interest to enhance the function of the 
endogenous DCs in this model. Doxorubicin was administered either 24 hours 
before adoptive T cell transfer or at the same time. Seven days after transfer 
the spleens were removed and the OT-I T cell population was analysed by 
flow cytometry. An increase in the transferred T cell population was detected 
in tumour challenged hosts relative to non-tumour challenged controls. A 
similar increase was detected in hosts treated with doxorubicin 24 hours prior 
to adoptive transfer (Figure 3.16). Treating hosts with doxorubicin at the same 
time as adoptive therapy did not result in the same increase of transferred T 
cells in the spleen relative to the non-tumour challenged control. The use of 
doxorubicin in this setting, therefore did not improve the stimulus provided by 
langerin+ CD8α+ DCs to the transferred effector CD8+ T cells. 
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Figure 3.16: Increasing tumour debris for acquisition by endogenous dendritic 
cells. C57BL/6 mice were challenged with 1x106 E.G7-OVA cells and 12 days later 
received 5x106 activated CD8+ T cells. Two groups were treated intravenously with 
240 µg of doxorubicin, one group 24 hours before adoptive therapy and another on 
the same day. Seven days later the spleens were removed and the number of 
transferred OT-I T cells was analysed by flow cytometry using CD8, Vα2 and CD45.1 
to isolate the transferred cells. The percent of CD8+ cells that expressed Vα2 and 
CD45.1 was analysed and is displayed. This is the combination of two experiments 
with five mice per group. *P < 0.05 (One-way ANOVA with a Bonferroni’s Multiple 
comparisons Test). 
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3.3 Discussion 
The hypothesis of this study was that the effective anti-tumour activity of an 
adoptive transfer-based immunotherapy is dependent on the function of 
resident langerin+ CD8α+ DCs in the spleen. The data presented here support 
this hypothesis as the langerin+ CD8α+ DCs were found to be required for 
extended maintenance of the transferred T cell population in the spleen and 
blood, and the presence of the langerin+ CD8α+ DCs improved their ability to 
protect against tumour development. The langerin+ CD8α+ DCs are therefore 
contributing to maintaining effective immunotherapy, which suggests that the 
role of endogenous DCs should be taken into consideration during 
immunotherapy design. 
 
Following adoptive transfer, it is likely that the effector CD8+ T cells contact 
tumour cells and directly kill them, resulting in an incrfease in tumour debris in 
the blood. This debris could drain through the marginal zone of the spleen and 
be acquired by langerin+ CD8α+ DCs. Due to the potent cross-priming ability 
of the langerin+ CD8α+ DCs, antigens from acquired tumour debris could be 
presented on MHC class I and used to stimulate the transferred CD8+ T cells 
that enter the spleen. It is possible that the tumour model used provides a 
pool of circulating cells (although this was assessed and could not be 
confirmed). It is, however, also possible that within the twelve days prior to 
adoptive transfer the tumour cells had completely left the blood to seed in 
distant tissues. In this case, the langerin+ CD8α+ DCs could come into contact 
with tumour antigens that have either drained through the lymphatics from 
tumour tissue, or been transferred to langerin+ CD8α+ DCs by APCs that 
migrated from the tumour. It is also possible that the stimulus is independent 
of antigen presentation by langerin+ CD8α+ DCs, and that these DCs merely 
produce cytokines that transferred T cells acquire, such as those that aid in T 
cell proliferation or survival. 
 
As langerin+ CD8α+ DCs are efficient at cross-priming CD8+ T cells it is 
possible that the adoptively transferred CD8+ T cells are not the only CD8+ T 
cell population affected by the absence of the langerin+ CD8α+ DCs. It is likely 
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that endogenous CD8+ T cells are activated following tumour challenge and 
by depleting the langerin+ CD8α+ DCs they may not be receiving the same 
stimulus. However, as DT was administered into hosts 10 days following 
tumour challenge the depletion of langerin+ CD8α+ DCs may not be affecting 
the activation of endogenous naïve CD8+ T cells into effector CD8+ T cells, 
but preventing the effector cells from receiving a secondary stimulus, similar 
to the transferred effector CD8+ T cells. In this case, depletion of the langerin+ 
CD8α+ DCs is likely reducing the anti-tumour activity of both the transferred 
and endogenous effector CD8+ T cells. 
 
It was notable that CD8+ T cells that proliferated and developed an effector 
phenotype following in vitro activation appeared to undergo further 
proliferation following transfer into tumour-bearing mice. A preliminary 
experiment was conducted, in which CFSE labelled OT-I T cells were 
administered into mice with 12-day-old tumours. Blood samples were taken 
from these mice three and seven days following transfer to determine if there 
was any difference in the CFSE profiles of the transferred T cells in mice 
depleted of the langerin+ cells (Appendix 4). Because the entire population of 
transferred cells had significantly downregulated their CFSE, MFI was used to 
analyses the CFSE data in this experiment. From this preliminary experiment 
it appears that the T cells proliferate following transfer into tumour-bearing 
hosts independently of langerin+ cells, as no difference was seen in the CFSE 
profiles of the transferred T cells in tumour bearing hosts with or without 
langerin cell depletion. However, this experiment was only completed once 
and therefore the results have not yet been confirmed. The decrease of 
transferred T cells in the spleen and blood of mice depleted of langerin+ cells 
is therefore likely due to reduced survival of the T cells or altered homing. In 
either instance, the proliferation or accumulation of transferred cells in the 
spleen and blood indicates an interesting role for the langerin+ CD8α+ DCs in 
adoptive therapy.  
 
There is a significant amount of debate surrounding the subset of T cell that 
provides the most effective protection following transfer into tumour-bearing 
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hosts. In this study, the transferred CD8+ T cells displayed the phenotype of 
effector T cells, consisting of low expression of both CD62L and CD122. 
However, some studies have demonstrated that effector T cells used for 
adoptive transfer become terminally differentiated resulting in lower T cell 
survival rates and reduced anti-tumour protection (315, 357). In the current 
study; however, the effector CD8+ T cells transferred into mice expressed 
CD122 seven days after transfer (Figure 3.11), suggesting that they have 
developed into memory precursor cells. Furthermore, nearly 30% of the 
transferred cells developed CD62L expression, indicating that following 
transfer into tumour-challenged mice the effector CD8+ T cells can 
differentiate into both TEM and TCM cells, possibly providing the benefits of 
both subsets. Differentiation of the transferred cells into memory precursor 
cells within seven days is a curious finding, as at this point the transferred 
CD8+ T cell population is still at the peak of the T cell response, as 
determined by cell number, and the population is yet to enter the contraction 
phase (Figure 3.8). So the question arises whether the transferred cells are 
able to form a functional memory population. To test this, effector CD8+ T 
cells were administered into mice, which were then left for 28 days before 
being tumour challenged. Interestingly, the transferred cells at this time were 
able to provide significant protection against tumour development (Appendix 
5). This experiment indicates that the transferred effector CD8+ T cells used in 
this experiment were not becoming terminally differentiated but developed into 
memory cells, which could be restimulated in vivo to provide anti-tumour 
protection. However, this experiment has only been conducted once and 
therefore the observations have not been confirmed. 
 
Effector CD8+ T cells transferred into mice that do not have tumours displayed 
a greater expression of CD62L+ CD122+ cells (Figure 3.11), indicating that the 
absence of antigen drives the transferred cells into a TCM phenotype. The 
transferred population of T cells in mice without tumours also displayed a 
reduced killing ability than the population of cells transferred into mice with 
established tumours (Figure 3.13). This suggests that there is a tumour-
associated stimulus provided to the transferred cells in vivo that is 
independent of langerin+ CD8α+ DCs. The reduced killing seen in thenon-
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tumour challenged group may be attributed to the slower recall response of 
resting TCM cells compared to effector cells or TEM cells, which are potentially 
already attacking tumour cells (354). As the killing function was only analysed 
for a period of 24 hours this may not have been enough time to see significant 
activation of TCM cells in mice that were not tumour challenged. The T cells 
transferred into tumour-bearing mice retained more of a TEM phenotype, 
possibly due to the continued presence of tumour antigen and these cells may 
therefore be more primed to kill target cells, enabling a quicker killing 
response. While the killing function was analysed two and three days after the 
administration of target cells, the target cells with the highest concentration of 
SIINFEKL were no longer detectable, likely due to being removed by CD8+ T 
cell killing. Therefore, this model was not sufficient to analyse delayed killing 
function. 
  
Another question arising from this study is why the langerin+ CD8α+ DCs were 
essential to mediate the protective benefit associated with adoptive transfer 
when the absence of langerin+ CD8α+ DCs did not alter the function of the 
transferred T cells in the assays tested. It would be expected that two CD8+ T 
cell populations with no significant difference in ability to kill target cells would 
have a similar anti-tumour protective benefit, however this is not what was 
observed. It is likely that due to a lack of statistical power the smaller 
differences between these groups were missed. Another possibility is that the 
stimulus provided by the langerin+ CD8α+ DCs is essential to mediate 
trafficking of the effector CD8+ T cells to tumour sites or to enable infiltration 
into a tumour. Therefore, although T cell populations administered in the 
presence or absence of langerin+ CD8α+ DCs have the same ability to kill 
target cells, only the group administered in the presence of langerin+ CD8α+ 
DCs would be able to migrate to or invade a seeded tumour to mediate 
tumour killing. In addition, this could account for the increase of transferred 
cells observed in the spleen and blood of tumour-laden mice, as the langerin+ 
CD8α+ DC stimulus may induce the effector CD8+ T cells to accumulate at 
these sites, assuming this is where the tumour is situated at this point. 
Unfortunately, due to the nature of the tumour used, in particular the inability 
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of the tumour to develop consistent solid tumours, it was not possible to 
assess the ability of the transferred cells to enter a solid tumour. 
 
The implication of this work for immunotherapies is that the protection 
provided by a given therapy is likely influenced by the host’s network of APCs. 
This needs to be taken into consideration by researchers as the endogenous 
APCs may be significantly stimulating or inhibiting immunotherapies. By 
gaining a better understanding of the stimuli provided by host APCs to an 
immune therapy such as adoptive therapy, it may be possible to enhance or 
reduce the generated immune response in a manner that favours protection. 
For example, in this study it would be relevant to determine if the protection 
provided by the adoptive therapy can be further increased by enhancing the 
tumour-derived stimulus provided by the langerin+ CD8α+ DCs. This may be 
possible by increasing the amount of tumour debris circulating in the blood for 
the langerin+ CD8α+ DCs to acquire by treating tumour-bearing mice with 
chemotherapy (as attempted in figure 3.16) or irradiation or by directly 
administering irradiated tumour cells prior to transfer (358-361). This idea is 
supported by research demonstrating that treating tumour-bearing mice with 
whole-body irradiation activated the host’s innate immune system and 
subsequently adoptively transferred effector CD8+ T cells provided greater 
anti-tumour protection (362). In addition, mice adoptively transferred naïve 
CD8+ T cells were provided with greater anti-tumour protection when treated 
with chemotherapy and a combination of the TLR agonist poly(I:C) and 
tumour antigens. In these studies, chemotherapy developed a significant 
increase in the hosts DC population and by activating these cells at the peak 
of expansion with poly(I:C) and tumour antigens. The transferred anti-tumour 
CD8+ T cells, in this experiment, were induced to provide superior protection 
(363). This treatment regime was dependent on the endogenous DCs, as 
mice depleted of their CD11c+ cells, using the CD11c-DTR mouse model, had 
significantly reduced numbers of transferred CD8+ T cells in the spleen and 
lymph nodes. These studies provide evidence to the possibility of enhancing 
the protection provided by adoptive therapy through the manipulation of 
endogenous APCs. While figure 3.15 and 3.16 were performed to determine if 
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DC stimulation would improve the stimulation of the adoptively transferred T 
cells, these experiments were performed under specific conditions, such as 
the treatment time, and it is likely that further experiments with different 
chemotherapies, irradiation or different times of treatment may provide 
different results. In addition, the activation of the endogenous DCs under 
certain conditions has been demonstrated to shutdown the cross-presentation 
pathway, which in this experimental model, would likely lead to reduced 
stimulation of the transferred T cells (352, 364). The shutting down of the 
cross-presentation pathway may explain why in figure 3.15 lower proportions 
of transferred T cells were observed in the spleen when α-GalCer was 
administered following adoptive therapy. Therefore, to effectively activate DCs 
in order to enhance adoptive therapy, without shutting-down cross-
presentation, different treatments, concentrations and times of treatment 
would need to be tested. 
 
Tumours typically induce a strong suppressive environment capable of 
reducing the capacity of DCs to stimulate CD8+ T cells. This can occur by 
decreasing their co-stimulatory molecules (365), IL-12 production (366), or by 
inducing abnormalities in a DCs ability to acquire and present antigens (367, 
368). The suppressive effect tumours can have on DCs is evident in DCs that 
have infiltrated a solid melanoma tumour. These DCs display a phenotype 
consistent with immature DCs and are unable to stimulate CD4+ or CD8+ T 
cells in vitro (349, 369, 370). The langerin+ CD8α+ DCs have specifically been 
associated with the induction of CD8+ T cell tolerance in response to 
intravenously administered apoptotic cells expressing self-antigen (371). In 
light of this, it is possible that in certain situations the stimulus provided by 
langerin+ CD8α+ DCs to transferred effector CD8+ T cells may be reduced or 
have tolerizing effects. In this situation, the development of effective adoptive 
CD8+ T cell therapy may require activation of the host’s APCs prior to transfer.  
 
It is possible that some subtle differences in experimental results were missed 
due to small sample size causing type two errors. This may apply to 
experiments, such as figure 3.7, where a larger sample size may have 
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provided statistically significant results. Because of the increased cost 
associated with a larger sample size this was practical. 
 
3.4 Conclusions 
Activated CD8+ T cells stimulated in vitro for transfer into tumour-bearing 
hosts, are influenced by the endogenous network of APCs. The results 
presented in this chapter support this hypothesis as the anti-tumour protection 
provided by adoptive CD8+ T cell therapy was found to be reduced in the 
absence of resident langerin+ CD8α+ DCs. This suggests that langerin+ 
CD8α+ DCs have a role in stimulating effector CD8+ T cells. The interaction 
between the langerin+ CD8α+ DCs and the transferred T cells resulted in a 
larger T cell population in the spleen and blood and enhanced protection 
against tumour development. The endogenous network of APCs therefore 
needs to be considered when performing adoptive cell therapy in the clinic, 
and through their manipulation it may be possible to provide enhanced anti-
tumour protection. 
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4.1 Introduction 
Given the proposed role of langerin+ CD8α+ DCs in cross-presentation of 
circulating antigens and the stimulation of CD8+ T cell responses, it was 
possible that these DCs play a critical role in the generation of effector CD8+ T 
cells in anti-tumour vaccination strategies, particularly those where vaccines 
require access to the spleen. For example, “whole cell” vaccines that have 
been designed to exploit the helper activity of iNKT cells are currently under 
development, and are often administered intravenously to access the large 
populations of iNKT cells within the spleen. Colleagues in my laboratory have 
been engaged in research into this form of vaccine for a number of 
malignancies, including glioma (331), melanoma (372) and a variety of CNS-
associated tumours (Grasso, unpublished). Due to practical matters, such as 
collection of sufficient tumour tissue, and the ease with which the vaccines 
can be administered intravenously, haematological malignancies may be an 
obvious choice to translate this research into the clinic. For such patients, an 
obvious setting for vaccination will be in morphologic remission after 
conventional treatment, with the vaccines generated from leukaemic cells 
collected before treatment.  
 
Acute myeloid leukaemia (AML) is an aggressive haematological malignancy 
with a dire prognosis without treatment. Most patients achieve morphologic 
remission after induction chemotherapy, but the majority with poor-risk 
cytogenetic or molecular features, and most older patients subsequently 
relapse (373-375). Relapse may be mediated by a small population of 
chemoresistant leukaemia cells (376, 377) that fall below the threshold used 
to define remission clinically (374). Long-term disease-free survival can be 
accomplished in patients with advanced AML, by treating with a 
chemotherapeutic agent such as cytarabine, followed by allogeneic stem cell 
transplantation (allo-SCT). However, between 20 and 55% of treated patients 
relapse (378, 379). Allo-SCT also carries a high morbidity, mortality and cost, 
and is often precluded by age, co-morbidities or the lack of a suitable donor 
(380, 381). The low survival rates in combination with the risk associated with 
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allo-SCT, plainly indicate the necessity for a more effective and tolerable 
treatment for relapsing AML.  
 
In addition to overexpressing certain self-antigens (382), myeloblasts harbour 
numerous mutations (383), resulting in expression of tumour-specific antigens 
capable of eliciting autologous CD4+ and CD8+ T cell responses (384). In fact, 
expression of mRNA for some antigens has been associated with a 
favourable prognosis (385, 386), suggesting a level of immune-mediated 
control that can potentially be exploited in immunotherapy (387). Vaccines 
based on malignant cells from AML patients may be able to elicit immune 
responses against multiple leukaemia-specific antigens without needing to 
first define specific T cell epitopes, which is a drawback to other “targeted” 
vaccine approaches. 
 
AML may provide a challenge to immunotherapy due to its ability to generate 
an effective immunosuppressive environment (388-390). Patients suffering 
from AML have been found to develop DCs with impaired maturation and 
function that drive tolerance to leukemic cells rather than immunity (276). 
Similarly, patients with AML have been found to develop NK cells that are 
deficient in the expression of the activating receptors called the natural 
cytotoxic receptors. The presence of receptor deficient NK cells correlates 
with poor survival in AML patients (391). A significant contributor to 
suppression in AML is IDO, which is expressed on the majority of AML cells 
(277). This enzyme catabolises the amino acid tryptophan, which is essential 
for T cell proliferation, while the metabolites produced from this process are 
able to induce T cell apoptosis (282, 392). Furthermore, the metabolites 
produced can also cause naïve CD4+ T cells to differentiate into Tregs, which 
have been associated with a worse prognosis in AML (282, 393, 394). As 
described in the introduction to this thesis, Tregs can suppress T cell-mediated 
immune responses in a variety of different ways, including by producing 
suppressive cytokines, killing immune cells and reducing free IL-2 from the 
environment, which is a key cytokine involved in CD8+ T cell proliferation 
(288, 289, 291).  
Chapter 4: The role of langerin+ CD8α+ DCs in an α-GalCer-based vaccine 126 
A simple, whole cell vaccine was developed for the current study that 
consisted of irradiated murine AML cells loaded with α-GalCer (tumour/α-
GalCer). The specific aim of the study was to determine if langerin+ CD8α+ 
DCs were involved in the generation of vaccine-induced anti-tumour effector 
CD8+ T cells in a model of AML. However, as this was a newly developed 
vaccine that may be used to model a future clinical trial, the study includes an 
analysis of mechanism of activity, an exploration of the future impact of AML 
induced immunosuppression, and an attempt to overcome 
immunosuppression with chemotherapy.  
 
The rationale behind loading the vaccine with α-GalCer is that this specific 
ligand can be presented on CD1d to stimulate iNKT cells. It has been shown 
that following the administration of free α-GalCer, activated iNKT cells license 
DCs in a CD40L-dependent manner, providing them with a superior capacity 
to stimulate conventional T cells. Potent antigen-specific T cell responses can 
therefore be generated by administering an antigen in combination with α-
GalCer (53, 79-81). Of relevance to this thesis, the DCs involved in 
stimulation of antigen-specific CD8+ T cell responses to circulating soluble 
antigens were found to be langerin+ CD8α+ DCs (107). Once activated, iNKT 
cells can also stimulate DCs to produce IL-12, which drives the production of 
IFN-γ by NK cells (233) and may also contribute to anti-tumour activity. The 
specific DC subset producing IL-12 following iNKT cell stimulation was also 
found to be langerin+ CD8α+ DCs (107). 
 
As langerin+ CD8α+ DCs have been demonstrated to be able to effectively 
acquire apoptotic cells administered intravenously, it is possible that a vaccine 
incorporating intravenously administered irradiated tumour cells will be 
acquired predominantly by langerin+ CD8α+ DCs (371). In addition, the 
exogenous nature of the vaccine-derived irradiated tumour cells suggests that 
the activation of anti-tumour CD8+ T cells will require cross-priming, which is 
also a prominent function of langerin+ CD8α+ DCs. However, a colleague 
conducting research on a similar glioma vaccine showed that anti-tumour 
activity was independent of these DCs, and was in fact primarily dependent 
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on CD4+ T cell effectors (331). The outcome of the research outlined in this 
chapter was therefore of some interest. 
 
4.1.1 Aims 
A novel vaccine consisting of irradiated tumour cells loaded with α-GalCer 
was developed for the treatment of AML. This vaccine-based immunotherapy 
was used to test the hypothesis “that effective anti-tumour activity induced by 
an intravenously administered vaccine is dependent on the function of 
resident langerin+ CD8α+ DCs in the spleen”. Determining whether this 
specific DC subset has a role in vaccine-induced responses may significantly 
contribute to the future design of more potent vaccines.  
 
Specific aims 
- To develop and characterise a tumour/α-GalCer vaccine that provides 
anti-tumour activity in a mouse model of AML  
 
- To established whether langerin+ CD8α+ DCs are required for the anti-
tumour response elicited by the vaccine 
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4.2 Results 
4.2.1 The Tumour/α-GalCer vaccine completely protects 
against AML when given prophylactically 
An AML-specific vaccine was prepared by incubating the murine AML cell line 
C1498 with α-GalCer for 18 hours before irradiating them, and then rigorously 
washing the excess glycolipid off. Fresh vaccine was used for all of the 
experiments described. To determine if the tumour/α-GalCer vaccine had the 
capability to generate an immune response that could target and kill AML 
cells, the vaccine was administered into mice seven days prior to challenge 
with AML. Unvaccinated animals challenged with AML cells ultimately 
developed symptoms associated with AML-burden, such as weight loss, 
hunching or reduced grooming, at which point the mice were immediately 
culled. Significantly, mice that were prophylactically vaccinated were 
completely protected from developing symptoms of AML, indicating that the 
immune response generated was capable of targeting and killing AML cells 
(Figure 4.1). This experiment was repeated many times, with vaccinated mice 
remaining symptom-free for the duration of each experiment, with 100 days 
being the longest period tested.  
 
The detection of leukemic blasts in the peripheral blood is used as a 
diagnostic tool for AML and their presence causes an elevated white blood 
cell count. Blood samples where therefore collected from mice that were 
either vaccinated prior to AML challenge, or were challenged alone, to 
determine if leukemic blasts could be detected in the blood of AML challenged 
mice and if these blasts were absent from vaccinated mice. Blood was 
collected from the AML only control group on the day that they developed 
symptoms associated with AML burden, prior to being culled. Mice that were 
prophylactically vaccinated remained symptom-free and therefore blood was 
taken 40 days after AML challenge. Blood samples were depleted of RBCs 
and the white blood cells were counted manually with a haemocytometer. 
Mice that received AML cells alone were found to have significantly higher 
numbers of white blood cells in their blood compared to naïve mice (Figure 
4.2A). Prophylactically vaccinated mice did not have an elevated white blood 
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cell count and their count corresponded to that of naïve mice. Histology 
sections from blood and bone marrow samples collected from representative 
animals showed the expected accumulation of leukemic blasts in 
unvaccinated mice at the time of symptom onset, but not in those that had 
received the full α-GalCer-adjuvanted vaccine, suggesting a complete 
protective response had been induced (Figure 4.2 B–C). Arrows in the blood 
slides point to leukemic blasts. The tumour cells in the bone marrow slides are 
so prevalent that healthy cells cannot be identified. This result indicates that 
AML cells accumulate in the blood and bone marrow following administration, 
and that the tumour/α-GalCer vaccine prevented their development in these 
tissues.  
 
Having shown that the vaccine protects mice from AML development, it was 
then investigated which immune cells were being induced to prevent AML 
growth. For this purpose, mice were vaccinated prophylactically and either 
their CD4 or CD8 expressing cells were depleted before AML challenge using 
specific antibodies. Depletion of the CD4+ and CD8+ cells seven days 
following treatment is displayed in appendix 6. The vaccine was administered 
five days before CD4 or CD8 depletion to insure that the depletion removed 
the effector cells alone and did not interfere with the vaccines ability to 
generate an effector response. This experiment showed that both CD4+ and 
CD8+ cells were involved in the vaccine-mediated protection (Figure 4.3). 
Each depletion setting did not completely ablate the AML protection, likely 
indicating that the remaining T cell population was able to continue attacking 
the AML cells. These findings indicate that the tumour/α-GalCer vaccine is 
capable of preventing AML engraftment and growth in a CD4 and CD8 
dependent manner, suggesting CD4+ and CD8+ T cell dependence. 
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Figure 4.1: Tumour/α-GalCer vaccination protects mice from AML challenge. 
Mice were vaccinated intravenously with 7.5x105 irradiated AML cells loaded with α-
GalCer or the individual vaccine contents alone, seven days prior to intravenous 
challenge with 1x105 AML cells. The health of mice was observed closely and the 
time it took for disease symptoms to develop was recorded and is graphed. This 
graph represents four experiments with five mice per group. **P < 0.01 (log-rank 
Mantel-Cox test). 
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Figure 4.2: The tumour/α-GalCer vaccine prevents the development of 
leukemic blasts in the blood and bone marrow. One group of mice was 
administered 7.5x105 irradiated AML cells loaded with α-GalCer and seven days later 
1x105 AML cells were administered into mice. The group that received AML alone 
was monitored for symptoms associated with AML-burden and upon development a 
blood sample was taken, the mice were then culled and the femur was removed for 
histology. The vaccinated group remained disease-free and was culled 40 days 
following tumour-challenge. (A) The blood samples were depleted of RBCs, the white 
blood cells were counted with a haemocytometer and the counts graphed. (B) 
Peripheral blood smear with diff-quick stain and (C) bone marrow histology with 
hematoxylin and eosin stain taken from a representative naïve control mouse, AML-
challenged mouse and vaccinated then AML-challenged mouse. Arrows indicate 
leukemic blasts. (A) Represents a single experiment with five mice per group. *P < 
0.05 (one-way ANOVA with a Bonferroni post test). 
 
Chapter 4: The role of langerin+ CD8α+ DCs in an α-GalCer-based vaccine 132 
 
Figure 4.3: The vaccine-induced immune response is dependent on CD4+ and 
CD8+ cells. Mice were vaccinated intravenously with 7.5x105 irradiated AML cells 
loaded with α-GalCer, seven days prior to intravenous challenge with 1x105 AML 
cells. The health of mice was observed closely and the time it took for disease 
symptoms to develop was recorded and is graphed. The CD4+ or CD8+ cells were 
each depleted in one group of mice by intraperitoneal administration of the antibodies 
anti-CD8 (2.43; 250 µg per mouse) or anti-CD4 (GK1.5; 125 µg per mouse) five, 
twelve and nineteen days following vaccination and the symptom free survival was 
determined. This graph represents two experiments with five mice per group. *P < 
0.05 (log-rank Mantel-Cox test). 
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4.2.2 Langerin+ CD8α+ dendritic cells are essential for the 
Tumour/α-GalCer vaccine to protect against AML 
The requirement of CD8+ cells for full vaccine efficacy suggested that CD8+ T 
cells were cross-primed with cross-presented AML antigens. It was therefore 
analysed whether the potent cross-presenting langerin+ CD8α+ DCs were 
involved in the generation of the vaccine-induced protection against AML. To 
test this, lang-EGFPDTR mice were depleted of their langerin+ cells by 
intraperitoneal administration of DT two days prior to vaccination, and the 
mice were challenged with AML cells seven days after vaccination. 
Interestingly, depletion of the langerin+ cells prior to vaccination completely 
abrogated the protection provided by the vaccine and the mice developed 
AML-associated symptoms at a similar rate to the AML-only control group 
(Figure 4.4). To ensure that DT treatment was not reducing the symptom-free 
survival independently of the vaccine, an experiment was performed 
comparing the symptom-free survival of tumour-challenged mice, with or 
without DT treatment (Appendix 7). This experiment suggests that DT 
treatment does not alter the symptom-fee-survival of tumour-challenged mice. 
It is therefore likely that the function langerin+ CD8α+ DCs are performing 
following vaccination is the cross-priming of CD8+ T cells, which were shown 
in figure 4.3 to be essential for the vaccine to mediate effective anti-AML 
protection. 
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Figure 4.4: Langerin+ CD8α+ DCs are required for the tumour/α-GalCer vaccine 
to provide protection against AML. Lang-EGFPDTR mice were vaccinated 
intravenously with 7.5x105 irradiated AML cells loaded with α-GalCer seven days 
prior to challenge with 1x105 AML cells. One group of mice received 350 ng of DT 
administered intraperitoneally two days prior to vaccination and every two to three 
days after to maintain depletion. The symptom-free survival was analysed and is 
graphed. This represents two experiments with five mice per group. ***P < 0.001 
(log-rank Mantel-Cox test). 
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4.2.3 Established AML renders the tumour/α-GalCer vaccine 
ineffective 
In the prophylactic setting, the tumour/α-GalCer vaccine was highly effective 
at protecting mice from AML challenge, however generating an effective anti-
tumour immune response is often limited by tumour-mediated immune-
suppression. As AML is a particularly known for its ability to generate a strong 
suppressive environment, the ability of the tumour/α-GalCer vaccine to 
eradicate established AML was determined. AML cells were administered one 
week prior to vaccination and the symptom-free survival was analysed. In the 
therapeutic setting the vaccine was rendered ineffective and mice developed 
symptoms associated with AML-burden at a similar time as the AML only 
control mice (Figure 4.5). 
 
 
 
Figure 4.5: Established AML render the tumour/α-GalCer vaccine ineffective. 
Mice were administered 1x105 AML cells intravenously and the cells were allowed to 
grow and develop for one week before 7.5x105 irradiated AML cells loaded with α-
GalCer were administered. One group received irradiated AML cells without α-
GalCer. The symptom free survival of these mice was recorded. This graph 
represents three experiments each with five mice per group.  
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4.2.4 Vaccine-induced iNKT cell activation in hosts with 
established AML 
Having found that the vaccine was ineffective in the therapeutic setting it was 
necessary to determine whether the established AML had caused 
suppression of the various vaccine-activated immune cells. Each step of 
immune activation following vaccination in hosts with established AML was 
therefore analysed, beginning with iNKT cell activation and expansion, which 
in turn leads to DCs activation, providing them with enhanced T cell 
stimulatory capabilities (53, 80, 81, 329). As the langerin+ CD8α+ DCs are an 
essential component to the vaccine it was initially investigated whether the 
vaccine could induce the activation of iNKT cells for DC licensing in the 
presence of established AML. To test this, AML was allowed to develop in 
mice for either seven or fourteen days before vaccination and the spleens 
were removed from mice three days later. Flow cytometry was performed to 
determine the proportion of iNKT cells within host spleens, using an antibody 
specific for CD3 and a fluorescent α-GalCer-loaded CD1d tetramer (CD1d tet) 
to identify the iNKT cells; the gating strategy is indicated in figure 4.6A. Mice 
vaccinated in the absence of AML had a significant increase in the proportion 
of CD3+ cells that were iNKT cells three days after vaccination and a similar 
increase was observed in mice with seven-day-old AML prior to vaccination 
(Figure 4.6B). The vaccine-induced expansion of the proportion of iNKT cells 
was significantly lower in mice with fourteen-day-old AML when compared to 
the vaccine only control group, however the number of iNKT cells had still 
elevated significantly following vaccination. After being stimulated with α-
GalCer, iNKT cells rapidly produce IL-4 and IFN-γ, which can be detected in 
host serum by performing a multiplex bead-based cytokine assay and used as 
an indicator of iNKT cell activation and functionality. Mice with seven-day-old 
AML were found to have as much IL-4 and IFN-γ in their serum following 
vaccination as mice that received the vaccine alone (Figure 4.6 C and D). 
These results indicate that although the iNKT cells are being mildly 
suppressed in hosts with established AML, they are still being activated by the 
tumour/α-GalCer vaccination and therefore may still be able to effectively 
license langerin+ CD8α+ DCs. 
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Figure 4.6: iNKT cells can be activated by the tumour/α-GalCer vaccination in 
mice with established AML. Mice were administered 1x105 AML cells intravenously 
seven or fourteen days before vaccination with 7.5x105 irradiated AML cells loaded 
with α-GalCer. Mice were culled three days following vaccination and flow cytometry 
was performed on host splenocytes to determine the size of the iNKT cell population. 
An antibody for CD3 was used in combination with a fluorescent α-GalCer-loaded 
CD1d tetramer to identify the iNKT cells and the gating strategy used to identify them 
is displayed in (A). (B) The numbers of iNKT cells from the spleens of mice are 
graphed. Blood was taken two and five hours following vaccination and the serum 
was analysed for IL-4 (C) and IFN-γ (D), respectively, with a multiplex bead-based 
cytokine assay. The results are indicative of three experiments, each with five mice 
per group. *P < 0.05, **P < 0.01 (one-way ANOVA with a Bonferroni post test). 
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4.2.5 iNKT cells license dendritic cells following tumour/α-
GalCer vaccination in mice with established AML 
Having found that the vaccine could significantly activate iNKT cells in hosts 
with established tumours, the ability of the activated iNKT cells to license DCs 
was analysed. Mice were vaccinated seven or fourteen days after AML 
challenge and the spleens were removed 24 hours later for analysis by flow 
cytometry. An antibody specific for CD11c was used to identify all splenic 
DCs, with the gating strategy used displayed in figure 4.7A. The activation 
status of the DCs was determined by expression of CD40 and CD86, which 
are known to be upregulated in response to a variety of different activation 
stimuli, including licensing by iNKT cells. No significant difference in the size 
of the CD11c+ DC population was observed between any of the groups tested 
(Figure 4.7B). The DCs from vaccinated mice did however express 
significantly higher levels of the co-stimulatory molecules CD40 and CD86, 
even in the presence of established AML, which provides some indication that 
AML-associated suppression did not cause the general inhibition of CD11c+ 
DCs (Figure 4.7C-D).  
 
As shown in figure 4.4, langerin+ CD8α+ DCs are essential for the vaccine to 
generate an effective anti-AML immune response, therefore the suppression 
of this subset would likely have a significant affect on the vaccine-induced 
immune response. The activation status of langerin+ CD8α+ DCs was 
therefore analysed in therapeutically vaccinated lang-EGFP mice so that 
langerin-expressing cells could be detected. A decrease in the langerin+ 
CD8α+ DC population was found in the spleens of vaccinated mice (Figure 
4.8B), which corresponds to studies demonstrating that splenic langerin+ 
CD8α+ DCs are no longer detected in the spleen following activation with 
microbial agonists (105, 395). Similar to the total splenic DC population, the 
langerin+ CD8α+ DCs upregulated CD40 following vaccination, regardless of 
the presence of established AML (Figure 4.8C). However, there was less 
upregulation of CD86 on langerin+ CD8α+ DCs when the vaccine was 
administered into mice with well established AML, suggesting that AML-
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induced suppression was able to reduce the extent of langerin+ CD8α+ DC 
activation following tumour/α-GalCer vaccination (Figure 4.8D).  
 
Langerin+ CD8α+ DCs produce large quantities of IL-12 (over 500 pg/ml of 
blood) following activation, which can be detected in the serum of mice five 
hours following vaccination (107). A multiplex bead-based cytokine assay was 
performed on host serum to determine if the vaccine induced efficient IL-12 
production by langerin+ CD8α+ DCs in AML-bearing mice. The serum IL-12 
levels five hours after vaccination was not significantly different between mice 
with or without established AML (Figure 4.8E). These data suggest that the 
vaccine-induced activation of langerin+ CD8α+ DCs is suppressed in mice with 
established AML, however their function was not impaired.  
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Figure 4.7: Splenic DCs are activated by the tumour/α-GalCer vaccine in hosts 
with established AML. Lang-EGFP mice were administered 1x105 AML cells 
intravenously seven or fourteen days before vaccination with 7.5x105 irradiated AML 
cells loaded with α-GalCer. Mice were culled 24 hours following vaccination and the 
splenic CD11c+ DC population was analysed by flow cytometry using the gating 
strategy displayed in (A). The splenic CD11c+ DC populations in each group are 
compared in (B). CD40 (C) and CD86 (D) were used to determine the activation state 
of the CD11c+ DCs. The results are indicative of three experiments, with five mice 
per group. **P < 0.01, ***P < 0.001 (one-way ANOVA with a Bonferroni post test). 
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Figure 4.8: The presence of established AML on the vaccine-induced activation 
of langerin+ CD8α+ DCs. Lang-EGFP mice were administered 1x105 AML cells 
intravenously and were vaccinated with 7.5x105 irradiated AML cells loaded with α-
GalCer fourteen days later. Mice were culled 24 hours following vaccination and the 
splenic langerin+ CD8α+ DC population was analysed by flow cytometry. An anti-
CD11c antibody was used to isolate the DCs in the spleen and GFP expression was 
used to identify langerin+ DCs. The strategy used to isolate the CD11c+ langerin+ 
DCs is displayed in (A). The number of langerin+ CD8α+ DCs detected from the mice 
in each group is graphed in (B) and CD40 (C) and CD86 (D) was used to detect their 
activation status. Five hours following vaccination mice were bled and the serum was 
analysed for IL-12 (E). The results are indicative of two independent experiments, 
each with five mice per group. **P < 0.01, ***P < 0.001 (one-way ANOVA with a 
Bonferroni post test). 
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4.2.6 Established AML does not inhibit non-specific CD8+ T 
cell activation 
It was next examined if CD8+ T cells that are not specific for AML could be 
activated in hosts with established AML, as this would indicate whether AML 
induced a generalised suppression of T cell activity. Mice with AML for seven 
days, or AML-free controls were administered a small population of naive 
CD8+ T cells from OT-I mice. The OT-I T cells were then stimulated by 
intravenous administration of OVA protein, which contains the SIINFEKL 
peptide sequence that serves as the MHC class I binding epitope recognised 
by OT-I T cells, and α-GalCer to serve as an immune adjuvant. The 
proportion of CD8+ cells that were OT-I T cells and activation status of the OT-
I T cells was determined seven days later. Mice that were administered 
OVA/α-GalCer in the absence of AML displayed an increased proportion of 
CD8+ cells that were OT-I T cells in the spleen, compared to mice that were 
not vaccinated (Figure 4.9A). Treatment with OVA/α-GalCer also 
differentiated the naïve OT-I T cells into effector T cells as determined by the 
down-regulation of CD62L and the upregulation of CD44 (Figure 4.9 B–C). 
Importantly, the OT-I T cell population in mice with established AML also 
increased in size in response to OVA/α-GalCer vaccination and displayed a 
CD62L- CD44+ phenotype characteristic of effector T cells. However, the 
increase in OT-I T cells in the spleen was significantly lower when stimulated 
in the presence of AML and they expressed lower levels of CD44, indicating 
that some non-specific suppression was occurring at the point of T cell 
activation in the vaccine-induced immune response.  
 
To determine if OT-I T cells stimulated in the presence of established AML 
had the same ability to mediate antigen-specific killing, the ability of the OT-I T 
cells to kill target cells was assessed. Mice were vaccinated seven days after 
AML challenge, and then nine days later syngenic splenocytes were injected 
as target cells that had been loaded with SIINFEKL peptide and stained with 
the fluorescent dye CFSE. The following day blood was removed from each 
mouse to analyse, by flow cytometry, the proportion of target cells that were 
killed by the OVA/α-GalCer activated OT-I T cells (Figure 4.9D). Mice that 
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were vaccinated in the absence of AML challenge displayed a significant 
amount of target cell killing compared to the AML-bearing mice that did not 
receive OVA/α-GalCer vaccination. Interestingly, mice that were vaccinated 
seven days after AML challenge displayed a similar level of target cell killing 
as the AML-free controls. It has previously been demonstrated that the 
activation of OT-I T cells by OVA/α-GalCer vaccination is dependent on 
cross-priming by langerin+ CD8α+ DCs and therefore OT-I T cell activation 
can be indicative of langerin+ CD8α+ DC function (107). Overall, these results 
suggest that the presence of established AML does suppress general T cell 
activation, however langerin+ CD8α+ DCs were still able to significantly 
activate CD8+ T cells that are not specific for AML, into effective cytotoxic 
lymphocytes.  
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Figure 4.9: Established AML does not prevent T cell activation in an antigen-
independent manner. (A, B and C) Mice were administered 1x105 AML cells 
intravenously and six days later mice were injected intravenously with 5x106 naïve 
OT-I T cells. The following day mice were vaccinated with the OVA protein and α-
GalCer. Seven days later the spleens were removed and the OT-I T cell population 
was analysed by flow cytometry for (A) population number, (B) CD62L expression 
and (C) CD44 expression. OT-I T cells were identified based on cell expression of 
CD8, Va2 and CD45.1 using the gating strategy displayed in figure 3.7A. (D) Target 
cells, consisting of splenocytes loaded with one of three concentrations of SIINFKEL 
(0.5 ng, 5 ng and 50 ng) were administered nine days following vaccination. The 
groups of target cells could be differentiated based on different CFSE staining 
concentrations, using the gating strategy seen in figure 3.12. Blood was taken from 
each mouse the day after target cell administration, and the ratio of each target cell 
subset was compared to a non-target control to determine the proportion of target 
cells that were killed. A–C was completed once on spleens and twice on blood, each 
with five mice per group. (D) represents one experiment with five mice per group. *P 
< 0.05, ***P < 0.001 (one-way ANOVA with a Bonferroni post test). 
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4.2.7 Established leukaemia prevents AML-specific CD4+ but 
not CD8+ T cells from being activated by tumour/α-
GalCer vaccination 
Having found that non-specific CD8+ T cells could still be activated in the 
presence of established AML, it was next determined whether AML-specific T 
cells could also be activated in the same setting. This is relevant as Tregs can 
suppress T cells through antigen-dependent cell-to-cell contact, which 
enables them to inhibit tumour-specific T cells without hindering non-specific T 
cells (396). The ability of the vaccine to induce AML antigen-dependent IFN-γ 
production was therefore assessed in the presence or absence of established 
AML. The tumour/α-GalCer vaccine was administered seven days following 
challenge with AML cells and the vaccine-induced immune response was left 
to develop for one week to ensure that the vaccine had ample time to 
generate effector T cells. Mice were then culled, the spleens were removed 
and the splenocytes were cultured for 24 hours with or without DCs loaded 
with lysate from AML cells for an antigen-dependent restimulation. After 24-
hours of culture the supernatant was removed and a multiplex bead-based 
cytokine assay was performed to determine how much IFN-γ was produced 
by each group. Antigen-dependent restimulation of the splenocytes resulted in 
a significant increase in the production of IFN-γ from each group. The 
splenocytes from vaccinated mice produced more IFN-γ during the 24-hour 
culture than the groups that were not vaccinated and this was not reduced 
when the splenocytes were from mice with established AML (Figure 4.10). 
This result indicates that although the presence of established AML abrogates 
the protective benefit provided by the tumour/α-GalCer vaccine, it did not 
prevent the production of IFN-γ by AML-specific T cells. 
 
To determine if the presence of established AML altered the phenotype or 
IFN-γ production of either CD4+ or CD8+ T cells separately following 
vaccination, flow cytometry was performed on splenocytes harvested from 
therapeutically vaccinated mice seven days after vaccination. The gating 
strategy used to identify CD4+ and CD8+ T cells is depicted in figure 4.11A. 
Mice that were vaccinated in the absence of established AML had CD8+ T 
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cells that displayed a significant upregulation of the activation marker CD44 
and more of them produced IFN-γ when compared to CD8+ T cells from non-
vaccinated mice (Figure 4.11 B–C). The CD8+ T cells from mice with AML 
were similarly activated in response to vaccination. CD4+ T cells from mice 
vaccinated in the absence of AML challenge also upregulated CD44 and more 
of them produced IFN-γ when compared to the non-vaccinated control group 
(Figure 4.11 D–E). However, when vaccinated in the presence of established 
AML the CD4+ T cells did not display the same upregulation of CD44 as the 
vaccinated control group and less of them were found to be IFN-γ+. These 
data suggest that CD4+ T cell activation is inhibited in hosts with established 
AML but CD8+ T cell activation is unimpeded. It is possible that CD4+ T cell 
inhibition may be why the vaccine is ineffective in mice with established AML. 
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Figure 4.10: Antigen-specific T cells can be activated in the presence of 
established AML. C57BL/6 mice were administered 1x105 AML cells intravenously 
and were vaccinated with 7.5x105 irradiated AML cells loaded with α-GalCer seven 
days later. The vaccine-induced immune response was then allowed to develop for 
one week before the mice were culled, the spleens were removed and 1x106 
splenocytes were cultured for 24 hours. A multiplex bead-based cytokine assay was 
performed on the resulting supernatant and the level of IFN-γ produced was 
determined. One set of samples was not restimulated (closed circles) and another 
set was restimulated by culture with 1x105 DCs loaded with the lysate from the AML 
cell line C1498, at a ratio of one DC to the lysate of six AML cells (open circles). This 
graph represents three experiments, each of which had five mice per group. *P < 
0.05, **P < 0.01 (one-way ANOVA with a Bonferroni post test). 
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Figure 4.11: Vaccine-induced CD4+ T cells but not CD8+ T cells are suppressed 
by the presence of established AML. C57BL/6 mice were administered 1x105 AML 
cells intravenously and were vaccinated with 7.5x105 irradiated AML cells loaded with 
α-GalCer seven days later. The vaccine-induced immune response was then allowed 
to develop for one week before the mice were culled and the spleens removed. The 
activation status of the splenic T cells was then analysed by flow cytometry using an 
antibody for CD3 to identify T cells and antibodies for CD4 and CD8 to differentiate 
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the T cell populations. Anti-CD44 was used to determine the activation status of the 
T cells and an IFN-γ antibody to determine their functionality. The gating strategies 
are displayed in A. (B) The MFI of CD44 on CD8+ T cells and (D) CD4+ T cells. The 
percent of CD8+ or CD4+ T cells that were IFN-γ positive is displayed in (C) and (E), 
respectively. This figure represents two experiments with five mice per group. *P < 
0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA with a Bonferroni post test). 
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4.2.8 AML-induced Tregs suppress the vaccine-mediated 
protection 
The previous result suggested that AML-specific CD4+ T cells are inhibited by 
the presence of established AML, however the mode by which this occurs had 
not been analysed. It was therefore determined if the presence of established 
AML was associated with elevated levels of suppressor cells. The immune 
suppressor cell Tregs, are often found in higher numbers in AML-hosts and 
therefore the number of Tregs in mice with established AML was analysed 
(282, 397). Mice were administered 1x105 AML cells intravenously and the 
tumour was left to develop for 20 days to exacerbate the potential 
development of AML-associated suppressor cells. Mice were then culled and 
the number of Tregs in the livers and spleens was determined by flow 
cytometry. The liver was analysed as this tissue most consistently developed 
tumours in hosts and as Tregs have previously been found to increase in the 
liver in C1498 treated hosts (292). The identification of Tregs was based on 
expression of CD4 and Foxp3 (340); the gating used to detect these cells is 
displayed in figure 4.12A. Foxp3 expression was determined by intracellular 
antibody staining against Foxp3 or by conducting experiments in Foxp3-EGFP 
mice that express enhanced green fluorescent protein under the Foxp3 
promoter (Figure 4.12 B–C). Mice with established AML were found to have 
significantly increased numbers of CD4+ FoxP3+ cells in the liver compared to 
non-AML challenged control mice (from 4.1% of CD4+ cells in the naïve mice 
to 29.7% in AML-bearing mice; Figure 4.12 D–E), however no significant 
difference was found in the spleens (Appendix 8). 
 
To determine if the AML-associated increase in Tregs was responsible for the 
lack of protection provided by the vaccine in the therapeutic setting, Tregs were 
depleted from AML-bearing mice prior to vaccination using the monoclonal 
antibody PC61. This antibody specifically binds to the receptor CD25, which is 
expressed at high levels on Tregs, resulting in their depletion (398). After 
intraperitoneal administration, PC61 depleted 97% of Tregs in the spleen and 
blood for a minimum of one week following treatment (Appendix 9). In order to 
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avoid depleting vaccine-induced effector CD4+ and CD8+ T cells, which 
upregulate CD25 upon activation, PC61 was administered six days prior to 
vaccination. Treating mice with PC61 at this time enabled the depletion of 
Tregs, while the excess circulating PC61 antibody will largely be cleared before 
the development of effector CD4+ or CD8+ T cells. Mice were challenged with 
AML cells and the following day one group of mice received a single injection 
of PC61. One week after AML challenge the mice were vaccinated and their 
symptom-free survival was analysed. Mice depleted of Tregs prior to 
therapeutic vaccination had an increase in median symptom-free survival by 
10 days (Figure 4.13A). To ensure that PC61 was not providing mice with any 
protective benefit that is independent from the vaccine, the symptom-free 
survival of mice treated with PC61 alone or PC61 plus the tumour/α-GalCer 
vaccine was compared (Figure 4.13B). Administration of PC61 alone provided 
no protection against onset of AML-associated symptoms and therefore the 
protection seen in figure 4.13A was due to the efficacy of the tumour/α-GalCer 
vaccine in the absence of Tregs. Therefore, tumour-induced Tregs are able to 
suppress to vaccine-induced immune response. 
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Figure 4.12: Tregs are significantly elevated in AML-bearing mice. Mice were 
administered 1x105 AML cells intravenously and were culled 20 days later. The 
population of Tregs in the liver was analysed by flow cytometry using the gating 
strategy displayed in (A). Foxp3 expression was determined by using a CD4 antibody 
in combination with GFP expression from FoxP3-GFP mice (B) or a Foxp3 antibody 
(C). The levels of Tregs between the two groups are graphed in (D) and (E), using a 
Foxp3 antibody and Foxp3-GFP mice respectively. This represents three 
experiments, with five mice per group **P < 0.01 (t-test with Mann Whitney). 
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Figure 4.13: AML-associated Tregs inhibit the vaccine-induced protection 
against AML. (A) Depicts the symptom-free survival of mice that were administered 
1x105 AML cells and were vaccinated with 7.5x106 irradiated AML cells loaded with 
α-GalCer seven days later. One group of vaccinated mice were depleted of CD25+ 
cells (Tregs) prior to vaccination by intraperitoneal injection of 100 mg of PC61 the day 
after AML challenge. (B) The survival of AML challenged mice treated either with 
PC61 alone or PC61 in addition to tumour/α-GalCer vaccination is compared. A 
represents two experiments with five mice per group *P < 0.05 (log-rank Mantel-Cox 
test). (B) represents one experiment with five mice per group. **P < 0.01 (log-rank 
Mantel-Cox test). 
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4.2.9 AML establishment increases the number of myeloid 
derived suppressor cells  
Another immunosuppressive cell type associated with tumour development is 
the MDSC. A substantially higher number of MDSCs are found in the blood of 
high-risk leukaemia patients compared to low-risk leukemic patients or healthy 
controls, and these have been associated with T cell tolerance (399). The 
MDSC population in mice with established AML was therefore analysed to 
determine if they could be involved in inhibiting the vaccine-induced AML 
protection in the therapeutic setting. Mice were challenged with AML cells, 
which were allowed to grow and develop for 20 days in order to exacerbate 
the AML-associated suppression. At day 20, the mice were culled and the 
number of MDSCs in the spleen was determined by flow cytometry, using 
antibodies to identify the CD11b+ Ly6G+ and the CD11b+ Ly6C+ MDSCs; the 
gating strategy is displayed in figure 4.14A (298). Interestingly, a significant 
increase in the Ly6G+ MDSC population was observed in the spleens of AML-
bearing mice relative to naïve mice, however no difference was observed in 
the CD11b+ Ly6C+ MDSCs (Figure 4.14 B and C). These data therefore 
indicate the possibility that MDSCs, like Tregs, inhibit the vaccine-induced 
immune response. 
 
The suppressive quality of the MDSCs from these mice was also analysed by 
determining their ability to suppress T cell proliferation. Naive T cells stained 
with CFSE were cultured with MDSCs isolated from the spleens of AML-
bearing or naïve mice. The naïve T cells were then stimulated with anti-CD3 
and anti-CD28 antibodies and T cell proliferation was determined by CFSE 
dilution. The MDSCs from mice with established AML significantly suppressed 
the proliferation of CD4+ T cells but not CD8+ T cells, when compared to the 
culture of MDSCs from naïve mice (Figure 4.14E). Thus, the MDSCs from 
AML hosts were more immunosuppressive.  
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Figure 4.14: AML-bearing mice have a significantly elevated number of MDSCs 
in the spleen. C57BL/6 mice were administered 1x105 AML cells intravenously and 
were culled 20 days later. The MDSC population in the spleen was analysed by flow 
cytometry using antibodies to identify the CD11b+ and Ly6G+ granulocytic MDSCs, 
using the gating strategy displayed in (A). The percent of CD11b+ cells that were 
Ly6G+ (B) or Ly6C+ (C) between the two groups is graphed. CD11b+ cells were 
isolated from the spleens and cultured with CFSE labelled T cells (at a 1:1 ratio) that 
were stimulated with anti-CD3 and anti-CD28 for 72 hours. The ability of the MDSCs 
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to suppress T cell proliferation was then analysed by CFSE dilution using an anti-
CD3 antibody to isolate the T cells. (D) A representative histogram of CFSE dilution 
is displayed for CD4+ cells cultured with CD11b+ splenocytes from naïve mice (black 
line) or tumour challenged mice (dotted line). Unstimulated T cells are represented in 
the plots as the shaded section. (E) The percent of CD4+ cells that had diluted CFSE 
is graphed. This represents three experiments with five mice per group *P < 0.05 (t-
test with Mann Whitney).  
 
 
4.2.10 C1498 AML cells suppress T cell proliferation 
Having found that there are a variety of suppressive factors involved in hosts 
with established tumours it is possible that the tumour cells themselves are 
able to suppress the function of the vaccine induced immune response. To 
determine if C1498 cells have T cell suppressive capabilities, C1498 cells or 
CD11b+ splenocytes from naive mice were cultured with CFSE stained naïve 
T cells. The T cells were then stimulated with anti-CD3 and anti-CD28 
antibodies and T cell proliferation was determined by CFSE dilution. Both 
CD4+ and CD8+ T cells were significantly suppressed when cultured with 
C1498 cells. Interestingly, CD4+ T cell proliferation was significantly more 
suppressed when cultured with C1498 cells than CD8+ T cells. This may 
explain why the vaccine-induced CD4+ T cells were suppressed in the 
presence of established tumours. 
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Figure 4.15: C1498 cells suppress T cell proliferation. C1498 cells or CD11b+ 
cells isolated from the spleens of naive mice were cultured with CFSE labelled naïve 
T cells that were stimulated with anti-CD3 and anti-CD28 for 72 hours. The ability of 
the C1498 cells to suppress T cell proliferation was then analysed by CFSE dilution 
using an anti-CD4 and anti-CD8 antibodies to identify the T cells. A representative 
histogram of CFSE dilution is displayed for CD4+ (A) and CD8+ (C) cells cultured with 
naïve splenocytes (black line) or C1498 cells (dotted line). Unstimulated T cells are 
represented in the plots as the shaded section. The percent of CD4+ (B) or CD8+ (D) 
cells that had diluted CFSE is graphed. This figure represents three experiments, 
each with five mice per group. *P < 0.05, **P < 0.01  (t-test with Mann Whitney). 
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4.2.11 The effect of chemotherapy on AML-associated 
immune suppression 
As the first line of treatment for AML is chemotherapy, which often drives 
patients into remission, it was of interest to determine if chemotherapy would 
alter the immune environment in a manner that favours immunotherapy. 
Chemotherapies, which can significantly reduce tumour burdens, are often 
associated with the generation of an immunosuppressive environment (400). 
As this may impact the ability of a vaccine to be effective when administered 
during remission, the immune system had to be analysed following 
chemotherapy. For this purpose, we examined the effect of the chemotherapy 
cytarabine. Cytarabine was chosen because it is used clinically for the 
treatment of AML and therefore is of relevance to this model (401). In 
addition, after cytarabine treatment the neutrophil and lymphocyte 
compartment has been demonstrated to return to normal within 6 days and 
this treatment provided an environment for effective immunotherapy (402). 
Therefore, the effect of cytarabine treatment on T cells was analysed in mice 
with AML. While the T cell population was reduced in the spleens of mice with 
untreated AML, mice treated with cytarabine after AML administration had 
similar numbers of CD8+ and CD4+ T cells as naïve controls (Figure 4.16 A–
B). Moreover, while expression of CD44 on CD8+ and CD4+ T cells was 
reduced in animals with AML, whereas in cytarabine-treated animals the 
expression was similar to that seen in naïve healthy controls (Figure 4.16 C–
D).  
 
The population of suppressor cells in AML bearing mice was analysed in 
hosts receiving either no treatment or the chemotherapeutic agent cytarabine 
to determine if cytarabine reduced immune suppression. Cytarabine was 
administered 24 hours following AML challenge and nineteen days later the 
immune environment of the host was analysed. The period of nineteen days 
following cytarabine treatment was chosen, as this would allow repopulation 
of the host’s immune compartments that had been depleted by the 
chemotherapeutic treatment. The Treg population in the liver was analysed 
and as was seen previously was significantly larger in the AML only control 
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group relative to naïve mice (Figure 4.17). Mice treated with cytarabine 
following AML challenge displayed no reduction in the Tregs population in the 
liver relative to the tumour only control. 	  
 
 
Figure 4.16: Cytarabine reduces AML-associated T cell suppression. Mice were 
challenged with 1x105 AML cells and 24 hours later a course of chemotherapy was 
initiated. Three doses of cytarabine were administered ten hours apart, each 
consisting of 3 mg administered intraperitoneally. (A–D) The T cell populations in the 
spleen were analysed. T cells were identified as CD3+ cells expressing either CD8 or 
CD4. The proportion of live cells expressing CD3 and CD8 (A) or CD3 and CD4 (B) 
is graphed. The MFI of CD44 on the CD3+ CD8+ cells (C) and CD3+ CD4+ cells (D) is 
graphed. This figure represents three experiments, each with five mice per group. *P 
< 0.05, **P < 0.01, ***P < 0.001 (one-way ANOVA with a Bonferroni post test). 
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Figure 4.17: The effect of cytarabine on AML-associated Tregs. Mice were 
administered 1x105 AML cells intravenously and the following day one group of mice 
was intraperitoneally administered three 3 mg doses of cytarabine, administered ten 
hours apart. The mice were culled 20 days after AML challenge and the population of 
Tregs in the liver was analysed by flow cytometry using the gating strategy displayed 
in 4.12A. An antibody was used to identify the Foxp3 positive cells. The graph 
compares the percent of all live cells from the liver that are CD3+ CD4+ and FoxP3+ 
cells. This represents a single experiment with five mice per group. **P < 0.01 (one-
way ANOVA with a Bonferroni post test). 
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4.2.12 The tumour/α-GalCer vaccine is effective following 
chemotherapy 
As most AML patients achieve remission with chemotherapy, the most likely 
use for a vaccine-based therapy will be an attempt to prevent relapse post-
chemotherapy. To examine whether the tumour/α-GalCer vaccine would have 
any efficacy in this setting, AML-bearing mice were administered cytarabine 
and then were vaccinated while still symptom-free, or received no further 
treatment. Cytarabine treatment alone was sufficient to significantly delay the 
onset of symptoms of tumour-burden when compared to untreated animals, 
with no increase in protection associated with vaccination (Figure 4.18A). 
However, it was when the surviving animals were rechallenged with an 
elevated dose of AML intravenously that the benefit of the combined treatment 
became most apparent. All animals that received the vaccine post-
chemotherapy were completely protected from rechallenge, whereas all 
animals that received cytarabine chemotherapy alone developed symptoms 
associated with AML-burden within 20 days (Figure 4.18B). Thus, 
chemotherapy-induced remission provided an environment for effective 
vaccination with tumour/α-GalCer to protect against rechallenge. 
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Figure 4.18: The tumour/α-GalCer vaccine is effective following chemotherapy. 
Mice were challenged with 1x105 AML cells and 24 hours later a course of 
chemotherapy was initiated. Three doses of cytarabine were administered ten hours 
apart, each consisting of 3 mg administered intraperitoneally. (A) On day 23 one 
group of the chemotherapy treated mice were vaccinated with 7.5x105 irradiated AML 
cells loaded with α-GalCer and their symptom-free survival was analysed. (B) The 
remaining mice were then rechallenged on day 45 with 5x105 AML cells and the 
symptom-free survival was again followed. This graph represents two experiments, 
with five mice in the AML only groups and ten mice in the cytarabine treated groups. 
(A-B) P < 0.0001 (Log-rank Mantel-Cox Test). 
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4.3 Discussion 
The experiments presented in this chapter show that vaccinating mice with 
the tumour/α-GalCer vaccine prior to AML challenge prevented the 
accumulation of leukemic blasts in the blood and bone marrow and provided 
hosts with complete protection against AML development. The hypothesis 
tested here, that an intravenously administered vaccine is dependent on the 
function of resident langerin+ CD8α+ DCs in the spleen, was supported as 
depletion of the langerin+ CD8α+ DCs made the anti-AML vaccine ineffective. 
If the AML had time to establish prior to vaccination then the anti-AML 
protection was ablated, which was to some degree associated with 
suppression of langerin+ CD8α+ DCs and CD4+ T cells. Hosts with established 
AML had elevated numbers of the suppressor cells Tregs, which contributed 
significantly to the inhibition of the vaccine in the therapeutic setting, and had 
increased numbers of MDSCs with heightened suppressor function in vitro. In 
addition, the C1498 cells themselves were able to suppress T cell proliferation 
in vitro, which suggests they may have been able to suppress the vaccine-
induce immune response. Driving AML-bearing hosts into remission with 
chemotherapy enabled the vaccine to develop an immune response capable 
of protecting mice from AML rechallenge. The results from this chapter may 
significantly contribute to the future design of more potent vaccines. 
 
Following administration, the tumour/α-GalCer vaccine must stimulate iNKT 
cells by presenting α-GalCer on CD1d. Either the irradiated AML cells do this 
directly, as C1498 cells express CD1d, or the tumour/α-GalCer complex is 
acquired by a host DCs, which then present α-GalCer on CD1d to iNKT cells. 
Liu et al. showed support for the latter with an α-GalCer-adjuvanted 
plasmacytoma vaccine, by demonstrating that DCs that acquired the 
administered irradiated tumour cells had higher expression levels of CD1d 
than other DCs (329). Furthermore, using an α-GalCer-adjuvanted vaccine to 
treat a murine glioma provided mice with significant anti-tumour protection 
even though the glioma cell line used, GL261, did not express CD1d (331). 
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While it is likely that α-GalCer is presented by resident cells with the vaccine 
used in this study, more work is required to formally establish this. However, 
what is clear is that resident cells are required for the resultant anti-AML 
activity, with langerin+ CD8α+ DCs critically involved, which suggests that 
cellular material is transferred to host APCs. 
 
The administration of free α-GalCer in combination with tumour antigens has 
been demonstrated to be effective at activating anti-tumour CD8+ T cells in a 
manner that was dependent on DC licensing by iNKT cells (53, 78). In this 
thesis, α-GalCer was loaded into AML cells that were then irradiated, as this 
has proved to provide a more efficient anti-tumour response than 
administering irradiated tumour cells in combination with α-GalCer in other 
published models (330), and in work conducted by colleagues in my 
laboratory (Hunn, unpublished). Using whole tumour cells in the vaccine 
enables the generation of anti-tumour CD4+ and CD8+ T cells against multiple 
antigens, in addition to avoiding the complications of needing to identify 
specific tumour antigens. Importantly, loading the α-GalCer onto whole tumour 
cells reduces the effective dose, which has been shown to limit the 
“exhaustion” phenotype that is typically seen in iNKT cells when high doses of 
free α-GalCer are used (331). When iNKT cells become exhausted, they are 
no longer able to provide the helper function required for vaccine activity 
(Dickgreber et al, unpublished observation), which limits the ability to re-
vaccinate until the exhaustion period is over, which can take several weeks in 
animal models. 
 
This α-GalCer-adjuvanted vaccine strategy is an effective treatment for a 
variety of different murine tumours (330-332), inducing another model of AML 
(AML-ETO9a) where vaccine-induced activity was seen in both the 
prophylactic and therapeutic settings (333). The difference in activity in the 
therapeutic setting compared to the work published here may reflect the 
different tumour cells used, as the evidence provided here shows that this 
malignant clone promotes a highly suppressive environment. Intrinsic qualities 
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of the tumour may be relevant with AML-ETO9a, making it potentially more 
sensitive to T cell mediated killing, by expressing a more immunogenic range 
of tumour antigens. In support of this, the AML1/ETO oncogene mutation, 
which is expressed by these tumour cells is associated with a favourable 
outcome in the clinic (403). 
 
Although the α-GalCer-adjuvanted vaccine strategy has been studied in a 
variety of different tumour models, the type of effector cell generated by the 
vaccine that protects against tumour development varies in each setting. For 
the treatment of a murine lymphoma model (EL-4), the vaccine was 
dependent on iNKT cells and NK cells but independent of CD4+ and CD8+ T 
cells (404). In contrast, protection mediated by a vaccine for the treatment of 
the murine lymphoma (A20) was dependent on activation of CD4+ T cells but 
not CD8+ T cells (330), as was a vaccine for the treatment of an orthotopic 
model of glioma (GL261) (331). The effector functions of both the CD4+ and 
CD8+ T cells were required for the treatment of a model of melanoma (B16) 
(332), as was seen for the AML model described here (Figure 4.3). 
Interestingly, this result was different to the study of AML-ETO9a, where anti-
AML activity was dependent on the CD8+ T cells, iNKT cells and NK cells, but 
was independent of CD4+ T cells (333). The differences between the effector 
cells generated in these studies is likely due to the different tumour cell lines 
used, such as the different tumour antigens presented and perhaps 
differences in sites and modes of uptake of the vaccine-derived material. For 
example, Shimizu et al., found that their live B16 melanoma vaccine was killed 
in the spleen by iNKT cells (332) and the vaccine was dependent of CD4+ and 
CD8+ T cells. In contrast, tumour cells that were lethally irradiated for the 
vaccine may have died in different tissues, such as the mediastinal lymph 
nodes as was found by Hunn et al., and in this case the vaccine was 
dependent on CD4+ T cells but not CD8+ T cells (331). Different sites and 
modes of cell death would alter the location, subset and activation status of 
the DCs that acquired the tumour antigen. Different sites and modes of cell 
death may result in different danger signals and phagocytosis signals being 
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released that could alter the location, subset and activation status of the DCs 
that acquired the tumour antigen as well. 
 
The hypothesis of this study was that effective anti-AML activity induced by an 
intravenously administered vaccine is dependent on the function of resident 
langerin+ CD8α+ DCs in the spleen. The data presented here support this 
hypothesis, as the protection mediated by the tumour/α-GalCer vaccine was 
dependent on langerin+ CD8α+ DCs. However, langerin is expressed by other 
APCs in different locations, including the lung (405), where the vaccine is 
likely to circulate. Due to the intravenous administration of the vaccine and the 
likelihood of the irradiated AML cells circulating to the spleen, it is probable 
that the splenic langerin+ CD8α+ DCs are the langerin+ cells that have an 
essential role in generating the vaccine-induced effector CD8+ T cells. In 
addition, splenectomised mice fail to elicit potent CD8+ T cell responses to 
soluble antigens co-injected with α-GalCer (Osmond, unpublished 
observation), providing strong evidence that it is the splenic cells that are 
required. In addition, langerin+ CD8α+ DCs have been shown to be proficient 
at acquiring irradiated cells in the blood, such as those within the vaccine 
(371). In contrast, an α-GalCer-adjuvanted glioma cell based vaccine could 
still provoke anti-tumour responses in splenectomised mice, with responses 
generated in the lung-draining lymph nodes (331). However, this vaccine was 
shown to function independent of CD8+ T cells and langerin-expressing cells.  
 
After acquiring the irradiated AML cells, the langerin+ CD8α+ DCs could 
present the α-GalCer on CD1d for the stimulation of iNKT cells and cross-
present antigens from the AML cell for presentation on MHC class I. It should 
be noted however that α-GalCer can be presented by other DC subsets (107). 
Once iNKT cells have been activated by α-GalCer presented on CD1d they 
are able to license DCs (78, 81). The combination of the iNKT cell licensing 
with the irradiated AML cells provides DCs with the three signals required to 
activate T cells; antigens from the irradiated tumour cell presented via MHC, 
the co-stimulatory molecules required for T cell activation and cytokine 
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production resulting from licensing. Of note, the presence of established 
tumours suppressed the vaccine-induced activation of langerin+ CD8α+ DCs 
relative to the vaccine only control group, however they were still significantly 
activated as they upregulated CD40 and CD86 after vaccination and produced 
significant quantities of IL-12. While langerin+ CD8α+ DCs are efficient at 
cross-priming CD8+ T cells, it is possible that langerin+ CD8α+ DCs stimulate 
both CD4+ and CD8+ T cells, as they are likely to be able to more efficiently 
acquire the vaccine-derived irradiated AML cells from the blood than the other 
DC subsets (371). However, it cannot be ruled out that the other DC subsets 
are acquiring antigens and directly presenting them on MHC II for the 
stimulation of CD4+ T cells.  
 
It was demonstrated that iNKT cells are activated following vaccination, 
however it was not determined if the iNKT cells or NK cells perform any 
tumour cell killing as a result of vaccination. Figure 4.3 demonstrates that both 
CD4+ and CD8+ effector cells are essential for the vaccine-induced immune 
response to mediate AML cell killing, however CD4 is also expressed by a 
subset of iNKT cells and therefore by depleting all CD4+ cells with the anti-
CD4 antibody the CD4+ iNKT cells may have also been removed from the 
host. It is therefore possible that the depletion of the CD4+ iNKT cells may 
have contributed toward the decreased protection provided by the vaccine in 
this experiment. Further evidence for the role of CD4+ T cells was from studies 
in vaccinated MHC II-/- mice, which were not protected from AML development 
due to the inability to present antigens to CD4+ T cells (Appendix 10). 
Furthermore, in these depletion experiments, the ablation of CD8+ cells with 
an anti-CD8 antibody could have also have depleted the CD8α+ DCs, which 
includes the langerin+ CD8α+ DCs, however the depleting antibody was not 
administered until five days after vaccination, at which point the langerin+ 
CD8α+ DCs are likely to have performed their vaccine induced stimulation of T 
cells. However, this does not rule out the potential of iNKT cells or NK cells to 
provide some anti-tumour protection as a result of vaccination. By performing 
an experiment, similar to figure 4.3, where both CD4+ and CD8+ cells were 
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depleted, it may have been possible to determine if cells other than the CD4+ 
and CD8+ T cells function as effectors. Because the vaccine-induced 
protection was not completely ablated with the single depletion experiments, it 
is possible that the double depletion will do this. If this did occur then the 
effector cells likely consist solely of CD4+ and CD8+ T cells and the residual 
survival seen with the single depletions is due to the remaining T cell 
population. If the double depletion does not reduce the vaccine-induced 
symptom-free survival further than the single depletion then it is likely that the 
CD4+ T cells function by enhancing CD8+ T cell killing, which would explain 
the similar ablation of symptom-free survival with both single depletions. In 
addition, if this is the case, other effector cells, such as NK or NKT cells, are 
performing some effector function to maintain the protection seen in the single 
depletion experiments.  
 
The development of AML in mice generated an increase in the number of Tregs 
within the host, although it was not determined whether they were developed 
within the thymus as natural Tregs and proliferated in the presence of tumours 
or if they differentiated from naïve CD4+ T cells as induced Tregs. The activity 
of IDO has been demonstrated to differentiate CD4+ T cells into CD4+ Foxp3+ 
Tregs due to the metabolites of tryptophan catabolism, specifically 3-
hydroxyanthranillic acid, which induce DCs to produce TGF-β (282, 393, 406). 
The increase in Tregs observed in this study may be the result of stimulation by 
metabolites of tryptophan catabolism, as IDO can be expressed by AML cells 
(393, 407). In addition, C1498 cells have been demonstrated to express the T 
cell inhibitory molecule PDL-1 (408) and the expression of PDL-1 on tumour 
cells has been correlated with an increase in the number and function of Tregs 
(409). It would have been possible to determine if these pathways were 
methods by which Tregs were generated in this model by initially determining if 
the C1498 cells used in these experiments express IDO or PDL-1 and then 
analysing if the Treg population still increased in tumour-bearing hosts when 
these pathways were blocked. For example, treating hosts with the IDO 
inhibitor, 1-methyl tryptophan, may have prevented the increase in tumour-
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associated Tregs, which would implicate IDO as an inducer of Tregs (393). A 
similar experiment could be conducted using anti-PD-1 to block the binding of 
PDL-1 expressed by tumour cells to PD-1 expressed by T cells (410). 
 
The tumour/α-GalCer vaccine was ineffective in the presence of established 
tumour, but efficacy was partially restored by depletion of Tregs before 
vaccination. While the vaccine was able to activate iNKT cells, DCs and CD8+ 
T cells in the presence of established AML, CD4+ T cells were significantly 
inhibited in terms of activation status and IFN-γ production. However, figure 
4.10 shows that the overall levels of vaccine-induced antigen-specific IFN-γ 
production were not altered by tumour-associated suppression. When 
comparing figure 4.11 C and E, it is obvious that a much greater proportion of 
CD3+ cells producing IFN-γ are CD8+ T cells and as these are not 
suppressed, the amount of IFN-γ produced is largely unaffected by the 
presence of established AML. This would perhaps imply that CD4+ T cells 
play a critical role other than as a large provider of IFN-γ. This could possibly 
include functions such as DC licensing, as the helper function of CD4+ T cells 
and iNKT cells is synergistic (411), or the activation of other immune cells 
such as macrophages, that can then attack AML cells. 
 
It is possible that the vaccine-induced T cells become suppressed after 
leaving secondary lymphoid organs, as the AML-associated suppression may 
prevent the T cells from migrating to or entering the sites of AML cell 
accumulation, such as the bone marrow. In addition, it is possible that the 
Tregs that induce the immune suppression reside within these sites and 
therefore only suppresses T cells following migration (412). Tumours that 
recruit Tregs have been found to have increased levels of the suppressive 
cytokines IL-10 and TGF-β (413) and effector T cells within tumours display 
reduced proliferation and perforin and granzyme B production (414-416). A 
study demonstrating the therapeutic benefit of an α-GalCer-adjuvanted 
vaccine for the treatment of melanoma found that more CD8+ T cells infiltrated 
the tumour when the Tregs were depleted (417). Therefore, by looking at the T 
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cell population in the spleen it is possible that we are analysing the immune 
response in sites of relatively little immunosuppression. It would have been 
interesting to examine the suppressive environment in the bone marrow as 
AML cells accumulate at this sight and it may have been possible to detect 
significantly more Tregs in this compartment. By examining the vaccine in hosts 
depleted of Tregs prior to therapeutic vaccination it may have been possible to 
determine if Tregs were preventing the infiltration of T cells into the bone 
marrow. In addition, analysis of the activation status of T cells within the bone 
marrow may have provided interesting results. 
 
There are other factors that may cause the therapeutic vaccine to be 
ineffective besides the suppression generated by AML. As AML is typically a 
fast growing tumour cell, in the therapeutic setting the disease may have 
progressed to a point where the AML cells were able to grow faster than they 
could be removed by the immune system. In addition, the AML cells may be 
edited by the endogenous immune system prior to vaccination, thereby 
making it a more immunoresistant cell that cannot be attacked by the vaccine-
induced immune response (418). This is unlikely to be the case in the animal 
model; however, as the AML is only administered seven days prior to 
vaccination. It would have been possible to test this by challenging mice with 
C1498 for seven days and then removing tumour cells from the bone marrow 
or blood. The tumour cells, which may have been immunoedited in vivo, could 
then be expanded by culture. It would then be possible to determine if these 
cells had become resistant to the vaccine-induced immune response by 
challenging mice with these tumour cells 7 days following vaccination with the 
original tumour cells. If the mice were protected from tumour development by 
the vaccine, as seen in figure 4.1, then the tumour cells would not have been 
made resistant by immunoediting. 
 
As the majority of AML patients achieve complete morphologic remission 
following chemotherapy it seems likely that this setting may provide a suitable 
environment for using an α-GalCer-adjuvanted vaccine strategy to prevent 
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relapse (375, 419). However, this had to be examined as chemotherapies are 
also able to generate immunosuppressive environments, including by 
developing Tregs (400). Here, we used cytarabine, which is in routine clinical 
use for both intensive and palliative treatment of AML, to induce remission 
and invoke an environment suitable for subsequent vaccination. Hosts with 
established AML had a reduced percent of T cells in the spleen, however this 
was restored to levels comparable to naïve mice by treatment with cytarabine. 
These data imply that the suppressive environment generated by AML is 
partially ablated with cytarabine treatment, and by vaccinating at this point 
hosts were protected from AML rechallenge. The rechallenge at this point was 
a model of AML relapse, which occurs in the majority of AML patients treated 
with chemotherapy. However, due to time constraints, relapse of the C1498 
AML model following cytarabine treatment was not a feasible experimental 
model. Previous studies have demonstrated that mice relapse following 
treatment of AML with cytarabine (402, 420), and this has been demonstrated 
to occur in the model used in this chapter (Appendix 11). It would; however, 
have been more appropriate to examine the ability of the tumour/α-GalCer to 
prevent natural relapse following cytarabine treatment. 
 
It should be noted once again that a lack of statistical power might have 
caused some type two errors within the experiments of this chapter, such as 
for the IL-4 production in the presence of 14-day-old tumours in figure 4.6C. 
Therefore, some differences between the groups may not have been 
detectable. It is possible that with a larger sample size these differences 
would have been distinguishable. 
 
4.4 Conclusion 
The experiments presented in this chapter show that a vaccine consisting of 
irradiated AML cells loaded with α-GalCer can prevent the development of 
AML following challenge. The vaccine-induced immune response was 
dependent on the langerin+ CD8α+ DCs, and involved CD4+ and CD8+ T cells 
for anti-tumour effector function. In contrast to the efficacy of the vaccine in 
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the prophylactic setting, the vaccine was ineffective in mice with established 
AML, which was attributed in part to Tregs, and may involve suppressive 
activity of MDSCs and the tumour cells themselves. Although the langerin+ 
CD8α+ DCs were suppressed in the presence established tumours they were 
still significantly activated by the vaccine and therefore langerin+ CD8α+ DC 
suppression is not likely to be the method by which the vaccine efficacy was 
suppressed. By driving hosts into remission with chemotherapy prior to 
vaccination, it was possible to illicit responses that protected from AML 
rechallenge. A potential clinical application for a similar vaccine is therefore in 
a setting of chemotherapy-induced morphologic remission to prevent relapse. 
Knowledge of the importance of langerin+ CD8α+ DCs for vaccine efficacy 
may aid in the future design of more potent anti-tumour vaccines. 
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DCs are critical for eliciting T cell mediated immunity, however their functions 
in specific T cell-mediated immunotherapies is not well defined. There is 
considerable heterogeneity within the DC population that may be related to 
functional differences, including differing T cell stimulatory capabilities. This 
thesis addresses the possibility that specific DC subsets are involved in 
promoting effector CD8+ T cells for effective cancer immunotherapy. 
Experiments were conducted in a murine model system, which has the 
advantage of having advanced DC phenotyping techniques, including ablation 
models, such as the langerin-targeted conditional ablation model described 
here. While the human counterparts to murine DCs have not been well 
defined, the overall concepts addressed in this thesis, namely that specific DC 
subsets in the host are more effective than others in mediating CD8+ T cell 
immunity, will need to be considered when developing effective 
immunotherapies. 
 
Recent studies have indicated some key features and functions of murine 
splenic langerin+ CD8α+ DCs, most relevant of which is their potent ability, 
relative to other splenic DCs, to cross-prime CD8+ T cells and to produce IL-
12 (107). In addition, the position of these DCs in the marginal zone of the 
spleen suggests a function in scanning the blood for debris. These features 
suggest that they may be an effective DC subset at activating or maintaining 
immunotherapy associated CD8+ T cells. The aim of this study was therefore 
to determine if langerin+ CD8α+ DCs were required to stimulate effector CD8+ 
T cells in a model of adoptive therapy and generate effector CD8+ T cells 
following vaccination. 
 
In chapter three, the langerin+ CD8α+ DCs were found to play a role in the 
anti-tumour response in a murine model of adoptive T cell therapy. The 
tumour model used was an intravenously administered lymphoma, which 
circulated and seeded at multiple locations in the host, including the liver, 
kidneys, ovaries, inguinal lymph nodes, spleen and lumbar lymph nodes. 
Initial analysis indicated that the model tumour antigen, OVA, was presented 
to the immune system in a manner that permitted recognition by naive OVA-
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specific CD8+ T cells. This likely reflected release of the antigen from the 
tumour and uptake of antigen by resident DCs, as the T cell proliferation was 
significantly reduced in absence of langerin+ CD8α+ DCs. Furthermore, 
sufficient naive OVA-specific CD8+ T cells became activated to induce some 
anti-tumour activity. In the setting of adoptive T cell therapy, the absence of 
langerin+ CD8α+ DCs resulted in reduced anti-tumour efficacy of activated 
OVA-specific CD8+ T cells, which was associated with less transferred CD8+ 
T cells in the blood and spleen. The langerin+ CD8α+ DCs were therefore 
capable of stimulating and enhancing the anti-tumour activity of effector CD8+ 
T cells during immunotherapy. The hypothesis tested, that the effective anti-
tumour activity of an adoptive transfer-based immunotherapy is dependent on 
the function of resident langerin+ CD8α+ DCs in the spleen, has therefore 
been supported by this study. The functional status of specific resident DC 
populations is therefore an aspect to be considered when developing adoptive 
T cell therapies, to ensure appropriate endogenous stimulation. 
 
In chapter four it was demonstrated that langerin+ CD8α+ DCs were required 
for the efficacy of a whole tumour cell-based vaccine that was administered 
intravenously to harness the stimulatory potential of iNKT cells. This chapter 
involved the development and characterisation of a tumour/α-GalCer vaccine 
that provides mice with protection against AML. The results show that anti-
leukaemia activity generated by the vaccine was ablated in animals depleted 
of langerin+ CD8α+ DCs. It is therefore likely that following vaccination and 
iNKT cell licensing, langerin+ CD8α+ DCs use vaccine-derived tumour cells as 
a source of antigen for the stimulation of endogenous naïve T cells to 
generate anti-tumour effector CD8+ T cells. Activated CD4+ T cells were also 
required for anti-AML activity; however, without a defined tumour antigen it 
was not possible to establish whether langerin+ CD8α+ DCs stimulated both 
sets of T cell effectors. The hypothesis tested, that effective anti-tumour 
activity induced by an intravenously administered vaccine is dependent on the 
function of resident langerin+ CD8α+ DCs in the spleen, is supported by this 
research. The functional status of specific resident DC populations is 
therefore an aspect that should also be considered during the development of 
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effective vaccine-mediated therapy, particularly in settings such as 
haematological malignancies, where whole-tumour vaccines may be practical. 
 
5.1 The strengths and weaknesses of the lang-
EGFPDTR mouse model 
The lang-EGFPDTR mouse model is an effective way to deplete langerin+ 
DCs, as they can be selectively depleted by DT administration. Mouse models 
that deplete DCs by knocking out genes essential to specific DC subsets may 
result in the mice having developmental issues as a result of the absence of 
these cells during growth. However, the selective depletion with the lang-
EGFPDTR model bypasses the implications of langerin DC depletion during 
mouse development. However, this model does have one significant flaw for 
this study, which is that the splenic langerin+ CD8α+ DC subset is not the only 
DC subset that expresses langerin. Therefore, other langerin+ DC subsets are 
also depleted by DT administration, which includes langerhan cells in the 
epidermis and a CD103+ langerin+ DC subset found in the dermis and lung. 
This was taken into consideration during study design and intravenous 
tumours were used in these experiments to encourage the interaction 
between the tumour cells and the splenic DCs as the tumour circulates 
through the blood. Likewise, the intravenous administration of the two 
immunotherapies in these studies also promoted interaction with the langerin+ 
CD8α+ DCs. However, this does not rule out the possibility that the other 
langerin+ DC subsets have an essential role in stimulating CD8+ T cells 
against tumours administered intravenously.  
 
It would be possible to specifically determine if the splenic langerin+ CD8α+ 
DCs were the langerin+ DC subset required during adoptive CD8+ T cell 
therapy or for the tumour/α-GalCer vaccine by analysing the symptom-free 
survival of mice following treatment with either therapy in splenectomised 
mice. If splenectomised mice did not have a delay in their symptom-free 
survival, as DT treated lang-EGFPDTR mice did, then the vaccine functioned 
independently of splenic DCs and therefore the splenic langerin+ CD8α+ DCs, 
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and vice versa. A similar study performed by researchers within my lab group 
found that splenectomised mice fail to elicit potent CD8+ T cell responses to 
soluble antigens co-injected with α-GalCer (Osmond, unpublished 
observation), which suggests that splenic DCs are required. 
 
5.2 Experimental limitations 
There are a variety of different ways to analyse CFSE dilution plots, some of 
which are more appropriate than others. For example, analysis of CFSE 
dilution using replication index analyses the fold expansion of the proliferating 
cells rather than of the total cell population. However, these forms of analyses 
require differentiation between the division generations. Because of an 
inability to distinguish between he generations in some of the experimental 
CFSE plots, such as is seen in figure 4.14D and figure 4.15 A and C, it was 
not possible to use proliferation algorithms to analyse the individual 
generations. For this reason, the percent of cells that had divided was 
analysed in all experiments for consistency, excluding the experiment 
conducted in appendix 5, where all cells had downregulated CFSE and 
therefore percent divided was also not an appropriate analysis. In this 
experiment the MFI of CFSE was used for analysis. 
 
Throughout this thesis the function of the langerin+ CD8α+ DCs has been 
examined with particular attention given to their role in stimulating CD8+ T 
cells. While we did not determine specifically what the stimuli langerin+ CD8α+ 
DCs provide to CD8+ T cells we have suggested that it is likely the result, in 
part, of the cross-presentation of tumour antigens and the cross-priming of 
CD8+ T cells. For the experiments in chapter 3, It would have been relevant to 
specifically determine if this was occurring by isolating langerin+ CD8α+ DCs 
from the spleens of mice, pulsing them with or without OVA and/or an 
activating stimulus and culturing them with effector OT-I T cells. It is possible 
that this would have enabled us to determine whether the stimuli provided by 
langerin+ CD8α+ DCs was dependent on their activation status and/or antigen 
presentation by analysing the subsequent T cell response. However, due to a 
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difficulty in isolating langerin+ CD8α+ DCs from hosts and maintaining them in 
culture for extended periods of time, this was not possible. 
 
It is possible that some subtle differences in experimental results were missed 
due to small sample size. This may apply to experiments looking at effector 
phenotype of activated cells transferred into tumour challenged hosts, where 
no obvious difference were observed in the presence or absence of langerin+ 
CD8α+ DCs. Increasing the sample size may have provided more informative 
results; however, this would have increased the expense and practicality of 
performing of these experiments. 
  
5.3 Langerin+ CD8α+ dendritic cells and their human 
counterpart 
The information found in this thesis regarding the langerin+ CD8α+ DCs will be 
most beneficial to human studies if a human counterpart to the langerin+ 
CD8α+ DC is found with similar function. A population of CD11c+ CD123- 
CD141+ DCs is claimed to be similar to the CD8α+ DCs and this subset has 
been demonstrated to be efficient at cross-presenting tumour antigens and to 
produce high levels of IL-12, which are both traits characteristic of langerin+ 
CD8α+ DCs (447). This DC subset is found in a variety of non-lymphoid 
tissues, and is therefore perhaps more similar to the broader mouse 
population of CD103+ DCs, which does include the splenic CD8α+ DC 
population (448). It may therefore be possible to specifically identify multiple 
DC subsets with the human CD141+ DCs, one of which may include a 
heightened propensity for cross-priming, as is the case for murine langerin+ 
CD8α+ DCs. 
 
5.4 The role of langerin+ CD8α+ dendritic cells in 
adoptive T cell therapy of established tumours 
This study has made it evident that resident langerin+ CD8α+ DCs provide a 
stimulus in the context of adoptive T cell therapy with activated CD8+ T cells; 
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however, it was not determined what the specific stimulus consists of. Some 
key characteristics of the langerin+ CD8α+ DCs may be relevant. One such 
characteristic is the strong ability of the langerin+ CD8α+ DCs to produce IL-12 
in response to different activation stimuli, such as TLR stimulation and 
“feedback” from activated iNKT cells (107). IL-12 has a direct effect on a 
variety of cells but its most relevant functions include inducing IFN-γ 
production by NK cells, Th1 cells and CD8+ T cells and inducing CD8+ T cell 
proliferation (421-423). The IFN-γ produced by NK cells in response to IL-12 
also inhibits TGF-β signalling and thereby blocks its suppressive effects on 
CD8+ T cell proliferation (424).  
 
Other cytokines that may be the stimulus provided by the langerin+ CD8α+ 
DCs to the transferred effector CD8+ T cells include IL-2 and IL-15, which 
induce T cell proliferation and increase T cell survival in vivo. It is likely that 
the cytokines IL-2 or IL-15 would be presented in trans to T cells. Specifically, 
DCs would present IL-2 bound on CD25 (IL-2Rα) to T cells expressing IL-2Rβ 
and IL-2Rγ, thereby bringing together the three IL-2 receptor subunits on the 
T cell in combination with IL-2 (425). IL-15 would be presented on IL-15Rα on 
the DC, which would bind to IL-2 receptor beta and gamma subunits 
expressed by T cells, as with IL-2. The trans presentation of these cytokines 
would enable the antigen-specific T cells to provide a stronger response 
against the antigen due to increased survival and proliferation (426). Treating 
patients with IL-2 following adoptive cell therapy has been studied extensively 
and has been demonstrated to improve the persistence of transferred cells, 
thereby enhancing the anti-tumour protection provided by the therapy (427-
430). 
 
IL-15 is produced at varying levels by different DC subsets, with the splenic 
CD8α+ DC population being the superior producers (431, 432). In addition to 
inducing T cell proliferation, IL-15 has the potential to aid adoptive therapy by 
preventing activation-induced apoptosis, and thereby enhancing T cell 
survival (433). The trans presentation of IL-15 by DCs induces T cell 
homeostatic proliferation and the development of memory cells (432). In 
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addition, IL-15 can convert tolerant CD8+ T cells into immunogenic CD8+ T 
cells for use in adoptive therapy (433, 434). This cytokine has also been used 
in combination with adoptive therapy, similarly to IL-2, to enhance the 
persistence of transferred T cells (318). Interestingly, not only was it found to 
be as successful as IL-2 at improving the anti-tumour protection provided by 
adoptive therapy but the benefit received when combining adoptive therapy 
with IL-2 treatment was dependent on the production of IL-15 by endogenous 
immune cells (318). This indicates that IL-2 may drive the in vivo production of 
IL-15, which then induces T cell proliferation and increases the survival of 
transferred cells. It is therefore plausible that upon transfer of effector CD8+ T 
cells into tumour-bearing mice, the T cells bind to tumour antigens presented 
on MHC molecules by langerin+ CD8α+ DCs, which results in the production of 
IL-2 and/or IL-15, thereby inducing proliferation or increasing the survival of 
the transferred cells. In order to specifically determine if the stimulus is IL-2 or 
IL-15, an experiment involving the administration of these cytokines following 
adoptive therapy in mice depleted of langerin cells may determine if the effect 
of langerin depletion on T cell proliferation is ablated. In addition, a similar 
response to langerin depletion may be generated by the transferring T cells 
into mice that have restricted production of IL-2 or IL-15 by DCs, either by 
blocking the cytokine receptors or by substituting IL-2 KO or IL-15 KO DCs 
into mice. 
 
The signals required for the stimulation of naïve CD8+ T cells has been 
studied extensively; however, the stimuli required to stimulate effector CD8+ T 
cells is not well understood. The potent ability of the langerin+ CD8α+ DCs to 
cross-prime CD8+ T cells (107) makes it possible that the level of tumour 
antigen presentation by these DCs is an important feature of the stimulus 
presented to the transferred T cells. However, a preliminary experiment that 
involved increasing the presence of endogenous antigen by intravenously 
administering OVA protein prior to adoptive therapy in mice without tumours 
did not induce proliferation of the transferred cells (Appendix 12). This 
preliminary study suggests that the presentation of tumour antigen alone is 
insufficient to effectively stimulate transferred effector CD8+ T cells. However, 
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this experiment needs to be repeated before this can be confirmed. The 
inability of the langerin+ CD8α+ DCs to stimulate the transferred cells in this 
setting is presumably because the endogenous DCs were in an immature 
state and therefore the antigen was presented in the presence of signal one 
(antigen presentation) but the absence of signals two and three (co-
stimulation and cytokines respectively). Therefore, it is likely that the stimulus 
presented by langerin+ CD8α+ DCs includes signal two and/or three. To gain 
further insight into the stimuli presented to effector CD8+ T cells by langerin+ 
CD8α+ DCs it may be beneficial to analyse the stimuli required for 
restimulation of memory cells, although the specific signals required are still 
debated. Earlier studies demonstrated that only signal one was required for 
memory CD8+ T cell reactivation in mice (435, 436), however the experiments 
performed in these studies were all in vitro. More recent studies now indicate 
that CD28 co-stimulation is essential for effective memory recall (437-439). 
This was determined by intraperitoneally challenging C57BL/6 mice with PR8 
influenza A virus and then intranasially rechallenging them 60 days later. 
Blocking CD28 co-stimulation with an anti-CD28 antibody significantly 
reduced the number of antigen specific CD8+ T cells that accumulated in the 
lung following rechallenge, compared to isotype control mice (438). The 
number of IFN-γ+ CD8+ T cells and the cytotoxic function of the CD8+ T cells 
was also significantly reduced in the absence of co-stimulation and the ability 
of mice to clear the secondary infection was impaired (438). Another recent 
study found that recall of memory CD8+ T cells upon secondary challenge 
was dependent on both CD28 and CD27 stimulation (440). Here, memory 
CD8+ T cells were generated by intraperitoneally administering OVA with an 
anti-CD40 antibody and 23 days later mice were rechallenged intravenously 
with the MHC class I binding OVA antigen, SIINFEKL, and anti-CD40. 
Blocking CD80/86 or CD70, the CD28 and CD27 co-receptors, respectively, 
with antibodies prior to rechallenge significantly reduced the anti-CD40 
mediated expansion of OVA-specific memory CD8+ T cells (440). The 
requirements for CD28 and CD27 stimulation was also seen for memory recall 
in mice rechallenged with peptide and the TLR agonist LPS (440). These 
studies suggest that the stimuli provided by langerin+ CD8α+ DCs to effector 
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CD8+ T cells may include antigen/MHC, CD80/86 and CD70 binding to the 
TCR, CD28 and CD27 expressed by the T cell, respectively. Langerin+ CD8α+ 
DCs may be able to provide these signals, which are associated with 
activated DCs, as a result of being stimulated by DAMPS that have been 
released from tumour cells, either killed by the endogenous immune system 
or by the transferred effector CD8+ T cells. 
 
Signal three typically consists of IL-12 or IFN-α and these function to extend 
the proliferation of CD8+ T cells by promoting IL-2 signalling (441), which is 
essential for both the generation of memory CD8+ T cells and for their 
effective recall during secondary challenge. The IL-2 required to generate 
memory CD8+ T cells that could respond to secondary challenge, derived 
from the CD8+ T cells themselves (76). Furthermore, memory CD8+ T cells 
generated in CD28-/- mice following intranasal inoculation with the vaccinia 
virus produced significantly less IL-2 (437), which suggests that memory 
precursor CD8+ T cells produce IL-2 as a result of CD28 co-stimulation during 
priming. It was therefore hypothesised that memory CD8+ T cells also require 
CD28 co-stimulation during secondary challenge to induce their production of 
IL-2. This was confirmed by restoring the recall response of memory CD8+ T 
cells generated in CD28-/- mice by administering IL-2 intraperitoneally 
following rechallenge. These observations perhaps suggest that in the 
experiments conducted in this thesis, the transferred effector CD8+ T cells 
receive antigen and co-stimulation from langerin+ CD8α+ DCs, which 
ultimately stimulates IL-2 production by the CD8+ T cells, thus inducing their 
proliferation. 
 
The evidence that resident DCs can play a significant role in determining the 
function of transferred cells may be extremely beneficial to the area of 
adoptive cell therapy. It is possible that deliberately activating resident DCs in 
vivo following transfer, or providing the transferred cells an equivalent 
stimulus in vitro prior to transfer, could serve to enhance the anti-tumour 
activity of the T cells in the tumour-laden host. For example, it may be 
possible to enhance the protection provided by adoptive therapy by ensuring 
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that langerin+ CD8α+ DCs are activated prior to transfer by vaccinating mice 
with a tumour/α-GalCer vaccine, using the relevant tumour cell, prior to 
adoptive therapy. The results in chapter four demonstrate that the tumour/α-
GalCer vaccine activates langerin+ CD8α+ DCs. In addition, the administration 
of irradiated tumour cells may increase the amount of antigen acquired by the 
langerin+ CD8α+ DCs for presentation to the transferred cells and thereby 
promote their stimulation. The combination of these two therapies may also 
provide enhanced anti-tumour protection as the hosts will have been 
transferred a population of effector CD8+ T cells targeted against a specific 
antigen and the vaccine will activate naïve T cells against multiple antigens 
from the tumour. The importance of the langerin+ cells could be determined in 
this experiment by depleting them prior to vaccination.  
 
The main implication of this study is that the endogenous immune system has 
a significant effect on an immunotherapy and the ability of an immunotherapy 
to provide anti-tumour protection may largely depend on the status of the 
endogenous immune system prior to administration. 
 
5.5 The role of langerin+ CD8α+ dendritic cells in 
initiating an immune response generated by an 
iNKT cell-based vaccine 
A vaccine consisting of irradiated tumour cells pulsed with α-GalCer protected 
mice against AML challenge in a CD4+ and CD8+ T cell dependent manner, 
with initiation of the anti-tumour response dependent on langerin+ CD8α+ DCs 
in the spleen. Given the key role of CD8+ T cells, the involvement of langerin+ 
CD8α+ DCs is likely due to their ability to effectively cross-prime CD8+ T cells. 
It is not clear what role CD4+ T cells have in this therapy but it is possible that 
their main role was in performing a helper function by licensing DCs and 
enabling them to more effectively stimulate CD8+ T cells. However, it is also 
possible that the CD4+ T cells mediated tumour-killing either directly, similar to 
CD8+ T cells, or indirectly by inducing other immune cells such as 
macrophages to attack tumour cells. 
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When administered therapeutically, the vaccine was unable to delay the 
development of symptoms associated with AML burden. This may have been 
partially due to tumour-associated suppression of langerin+ CD8α+ DCs as 
their activation, following vaccination, was significantly reduced in tumour-
bearing hosts. However, the expression of the co-stimulatory molecules CD40 
and CD86 were still significantly upregulated in tumour-bearing hosts 
following vaccination, relative to naïve hosts. Langerin+ CD8α+ DCs produce 
large quantities of IL-12 following activation and serum IL-12 correlates with 
langerin+ CD8α+ DC activation. Serum IL-12 levels were similar following 
vaccination in mice with or without established AML, indicating effective DC 
activation. Furthermore, the vaccine was able to activate CD8+ T cells in mice 
with established AML. These results likely indicate that the langerin+ CD8α+ 
DCs were functionally activated by vaccination in the presence of established 
tumours.  
 
CD4+ T cells were significantly inhibited in mice with established AML as 
indicated by reduced expression of the activation marker CD44 and a reduced 
proportion of CD4+ T cells producing IFN-γ. If the vaccine activated CD4+ T 
cells functioned by licensing DCs then it is probable that their inhibition would 
result in DCs with reduced expression of the activation markers CD40 and 
CD86 and less serum IL-12, due to the lack of CD4+ T cell help. However, this 
is not what was observed as CD11c+ DCs were similarly activated following 
vaccination in mice with or without established AML. In addition, as some 
residual anti-AML activity was seen in the absence of CD8+ T cells, other 
CD4+ T cell functions are likely involved independently of CD8+ T cells. 
Therefore, it is possible that vaccine-activated CD4+ T cells are involved in the 
killing of AML cells, either directly by producing cytotoxic molecules or 
indirectly by activating macrophages to mediate killing. The direct killing of 
AML cells by CD4+ T cells is unlikely as the AML cell line used, C1498, does 
not express MHC class II and therefore the CD4+ T cells would be unable to 
recognise the AML cells for a direct attack (442). As the proportion of CD4+ T 
cells capable of producing IFN-γ was significantly reduced in tumour-bearing 
mice, it is possible that the decreased CD4+ T cell-derived IFN-γ is why the 
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vaccine was ineffective therapeutically. It should be noted here that 
significantly fewer CD4+ T cells were capable of producing IFN-γ relative to 
CD8+ T cells (Figure 4.11 C and E). However, the amount of IFN-γ required 
for a CD4+ T cell to activate an MHC class II expressing cell, such as a 
macrophage, may be relatively low due to the formation of a synapse between 
the two cells upon TCR engagement. Therefore, an essential function of CD4+ 
T cells in the vaccine-mediated anti-AML immune response may be the 
activation of innate cells, such as macrophages, which then attack the AML 
cells. In fact, CD4+ T cell-mediated activation of macrophages has been 
demonstrated to provide anti-tumour responses in a variety of tumour models 
including, intraocular tumours (443), melanoma (191), myeloma (444) and 
interestingly a B cell lymphoma (192).  
 
Mice with established AML had elevated numbers of MDSCs in their spleens, 
which were demonstrated in vitro to have a significant suppressive effect on T 
cell activation. It would therefore be of interest to determine how the vaccine 
would perform therapeutically in mice depleted of their MDSCs. A recent 
study determined that β-glucan, a cell wall component of various pathogens, 
including yeast, fungi and bacteria, aids in driving immature MDSCs into a 
more differentiated cell type. This reduced their suppressive function and as a 
result aided in the activation of anti-tumour CD4+ and CD8+ T cells (445). 
Treating mice with β-glucan, prior to therapeutic vaccination may therefore 
provide an enhanced anti-tumour immune response. It would also be 
interesting to determine how long the vaccine would delay the onset of 
symptoms associated with AML development in leukemic mice treated with β-
glucan and depleted of Tregs.  
 
The C1498 AML cells also had significant suppressive functions on T cells. 
The method by which AML cells suppress T cell proliferation is unknown, 
however as leukaemia cells typical express IDO it is likely that the depletion of 
tryptophan by IDO is responsible for the reduced T cell proliferation (407). It is 
possible that the leukaemic cells in AML-bearing mice were responsible for 
the inhibition of the vaccine in the therapeutic setting. It would therefore be 
Chapter 5: General discussion 186 
beneficial to reduce the amount of AML cells within a host prior to vaccination 
to reduce the amount of suppressor cells, as would be done with a 
chemotherapeutic agent such as cytarabine. This may explain why the 
vaccine was able to generate an immune response in tumour-bearing hosts 
following cytarabine treatment, as the suppressive C1498 cells may have 
largely been removed, leading to a more appropriate environment for 
vaccination. The suppressive functions of both the tumour-associated MDSCs 
and the C1498 cells had a larger impact on CD4+ T cells, relative to CD8+ T 
cells. This is interesting, as the vaccine appeared to be ineffective in tumour-
bearing hosts due to the suppression of CD4+ T cells. Therefore, it seems 
likely that the role these suppressive cells played a significant role in 
suppressing the vaccine-induced CD4+ T cells in tumour-bearing hosts, 
resulting in ineffective vaccination. However, it is possible that the 
suppressive effect of MDSCs observed in figure 4.14 was not actually a 
suppressive quality of MDSCs, but of AML cells that had upregulated CD11b 
in vivo, although we have no evidence of this occurring. 
 
The tumour/α-GalCer vaccine is potentially a feasible treatment to prevent 
AML relapse in the clinic, as a characteristic of AML is the accumulation of 
leukemic blasts in bone marrow, which can be aspirated from bone marrow 
fluid for vaccine manufacture; this procedure is routinely performed as a 
diagnostic test for AML. Vaccination has the obvious benefit over allo-SCT as 
the difficulties involved in finding a suitable donor are not required. In addition, 
the fact that the tumour derives from the host may indicate that the vaccine 
will also be much more tolerable than allo-SCT, although this is not validated. 
Clearly, evidence of the clinical efficacy of this vaccine would be required 
while comparing its function to allo-SCT. Current studies show that allo-SCT 
reduces the relapse rate from 52 % in the chemotherapy only arm to 36 % 
with the combined treatment (446). Clinical grade α-GalCer has already been 
developed and administered in humans. Patients with solid tumours received 
an intravenous dose of α-GalCer ranging from 50-4800 µg/m2 on days one, 
four and fifteen of a four week cycle. No adverse effects were seen in any of 
the patients treated, however no clinical responses were detected either 
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(326). This is likely due to the use of α-GalCer as a sole agent, which would 
largely be dependent on cells of the innate immune system such as NK and 
NKT cells. In mouse models there is compelling evidence that α-GalCer is 
more efficient as an adjuvant, however this remains to be formally tested in 
humans (53, 78). 
 
5.6 Future directions 
Having found a function of langerin+ CD8α+ DCs in promoting tumour 
immunotherapies it would be beneficial to the improvement of 
immunotherapies in the clinic if the stimulus provided by langerin+ CD8α+ DCs 
to transferred effector CD8+ T cells was determined. This information may 
provide unique ways to enhance the efficacy of adoptive cell therapy by 
stimulating endogenous APCs. This research would likely require isolating 
langerin+ CD8α+ DCs from tumour challenged mice and analysing their ability 
to stimulate CD8+ T cells in vitro. The stimulation of T cells under these 
conditions could be compared to stimulation by langerin+ CD8α+ DCs pulsed 
with antigen and/or an activating stimulus, or antigen pulsed langerin+ CD8α+ 
DCs with the addition of cytokines to the culture, such as IL-2 or IL-15. These 
experiments may help elucidate what the specific stimuli provided to the 
transferred CD8+ T cells is, which would then enable in vivo experiments to be 
conduced in an attempt to replicate these stimuli in langerin+ depleted mice. 
For example, if the langerin+ CD8α+ DCs are found to be stimulating the 
transferred T cells by producing IL-15, it may be possible to provide this 
stimuli by administering IL-15 into hosts, before or after adoptive transfer, 
thereby eliminating the therapies dependency on langerin+ CD8α+ DCs. Once 
the stimuli are determined, it would be possible to perform research with the 
aim of improving the function of adoptive therapies by either enhancing the 
function of the endogenous DCs or by producing these stimuli artificially. 
Therefore, research conducted into combining another therapy with adoptive 
CD8+ T cell therapy, with the aim of improving the stimuli provided by 
langerin+ CD8α+ DCs to the transferred T cells, may provide results 
translatable to the clinic. This was examined in figures 3.15 and 3.16; 
however, this was examined under limited conditions and significantly more 
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work could be done in this area, including the use of a variety of different 
treatments, with different treatment times and doses. It would then be relevant 
to apply these experiments to another tumour model, such as a melanoma, as 
this may be more applicable to the clinic. However, in this tumour model the 
role of the endogenous DCs would first need to be confirmed. The hypothesis 
of this research would be “that stimulating endogenous DCs enhances the 
efficacy of adoptively transferred CD8+ T cells for the treatment of tumours”. 
 
Further experiments into the tumour/α-GalCer vaccine would also be 
beneficial, as this could prove to be a promising replacement for the current 
post-remission therapy for AML. Future experiments into this vaccine should 
include the development of a model, which incorporates remission of AML 
following cytarabine treatment, in place of the secondary challenge used in 
this thesis. The tumour/α-GalCer vaccine could then be compared to allo-SCT 
in its ability to prevent AML relapse. It would also be interesting to compare 
allo-SCT and the tumour/α-GalCer vaccine for the treatment of different 
models of AML, particularly humanized models of leukaemia and 
spontaneous leukaemia’s. In the latter of which, the vaccine would need to be 
generated from the bone marrow of a mouse that developed a spontaneous 
tumour and then be administered into another host, which would more closely 
resemble what would occur in the clinic with this vaccine. The hypothesis of 
this research would be “that a tumour/α-GalCer vaccine for the treatment 
relapsing acute myeloid leukaemia is more effective that allo-SCT”. 
 
5.7 Novel findings 
The aim of this thesis was to gain an understanding of the function of 
langerin+ CD8α+ DCs in stimulating effector CD8+ T cells and generating 
effector CD8+ T cells from naive T cells following immunotherapy for 
intravenously administered tumours. We demonstrate for the first time that 
effector CD8+ T cells transferred for the treatment of an intravenous 
lymphoma are stimulated by langerin+ CD8α+ DCs in vivo. This stimulation 
resulted in the accumulation of transferred effector CD8+ T cells in both the 
blood and spleen and provided the hosts with greater protection mediated by 
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the immunotherapy. Furthermore, a vaccine-induced immune response, which 
generated CD4+ and CD8+ effector T cells, was dependent on the function of 
langerin+ CD8α+ DCs for the vaccine to protect against AML development. 
Therefore, this research provides a novel function for the endogenous splenic 
langerin+ CD8α+ DCs in stimulating and generating effector CD8+ T cells 
following T cell-based immunotherapies for the treatment of intravenous 
tumours. The implication of this information is that immunotherapies 
administered for the treatment of intravenously administered tumours is likely 
to be dependent on the function of endogenous splenic DCs. Therefore, the 
functional status of the splenic DCs may determine the protective benefit 
provided by some immunotherapies. The endogenous network of APCs 
should therefore be taken into consideration during the design of novel 
immunotherapies. 
 
A novel vaccine for the treatment of AML was also characterised within this 
thesis. It was found to generate an immune response capable of targeting and 
killing AML cells. However, the established tumour generated a suppressive 
environment capable of inhibiting the protective function of the vaccine, 
despite stimulating iNKT cells and leading to DC activation. We have 
demonstrated a successful combination of immunotherapy following 
chemotherapy. Given the suppressive environment of the C1498 AML cells, it 
is likely that the reduction of these cells via cytarabine treatment aided in 
reducing some tumour-associated immunosuppression and thereby 
developing an immune environment suitable for immunotherapy. This finding 
is relevant clinically as there is an unmet need for effective post-remission 
therapies for AML that have reduced toxicity, cost and dependency on 
suitable donors, compared to the current post-remission therapy, allo-SCT.
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VI. Appendices 
I. Appendix 1 
 
Appendix figure 1. Antibody titration. Splenocytes were removed from a 
CF7BL/6 mouse.  The spleenocytes were separated into different groups for staining. 
Samples were stained with the antibody CD8 A700, at a dilution of 1:100, 1:200, 
1:500 or 1:1000. Flow cytometry was performed on the samples to determine the 
lowest concentration of antibody that enabled differentiation between the positive and 
negative populations. The dilution 1:200 was chosen as an appropriate concentraion. 
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II. Appendix 2 
 
Appendix figure 2. The proportion of OT-I lymphoid cells that are OT-I CD8+ T 
cells. Lymph nodes were removed from a naïve OT-I mouse. Flow cytometry was 
performed on the single cell suspension using antibodies for CD8 and Vα2 to identify 
the cells that were CD8+ OT-I T cells. The gating strategy used to identify these cells 
is depicted on the top row, with the proportions of cells that express CD8 and Vα2. In 
addition, the proportion of these cells that express CD62L and CD122 is also 
displayed (bottom row). This experiment was performed twice. 
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III. Appendix 3 
 
Appendix figure 3. Treatment of E.G7-OVA-bearing hosts with DT does not 
alter the symptom-free survival. Lang-EGFPDTR mice were intravenously 
administered 1x106 E.G7-OVA cells. One group of tumour challenged mice were 
treated with 350 ng of DT intraperitoneally 2 days before tumour challenge and every 
2–3 days later and the symptom-free survival was analysed. This represents a signal 
experiment with five mice per group. *P < 0.05 (Log-rank Mantel-Cox Test). 
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IV. Appendix 4 
 
Appendix figure 4. Transferred effector CD8+ T cells proliferate in the 
presence of established tumours. Lang-EGFPDTR mice were intravenously 
administered 1x106 E.G7-OVA cells and 12 days later were administered 5x106 
activated OT-I T cells labelled with CFSE. One group of tumour challenged mice 
were treated with 350 ng of DT intraperitoneally 2 days prior to transfer and every 2–
3 days following. Blood samples were taken 3 days (A) and 7 days (B) after transfer 
and flow cytometry was performed to analyse the CFSE expression on the 
transferred T cells using CD8, Vα2 and CD45.1 to identify them. The MFI of CFSE 
on the transferred cells is displayed. This represents a single experiment with five 
mice per group. *P < 0.05 (one-way ANOVA with a Bonferroni post test). 
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V. Appendix 5 
 
Appendix figure 5. Transferred effector CD8+ T cells develop memory. 
C57BL/6 mice received 1.25x106, 5x106, 2x107 or no activated OT-I T cells 
intravenously. (A) On days 3, 7 and 12 following transfer a blood sample was taken 
from each host and flow cytometry was performed to identify the transferred T cell 
population using CD8, Vα2 and CD45.1 expression. The percent of CD8+ cells that 
are Vα2+ and CD45.1+ over time is displayed. (B) 28 days following transfer, 1x106 
E.G7-OVA cells were administered into each group and the symptom free survival 
was analysed. This represents a single experiment with five mice per group. (A) *P < 
0.05, ***P < 0.001 (one-way ANOVA with a Bonferroni post test). (B) ***P < 0.001 
(Log-rank Mantel-Cox Test). 
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VI. Appendix 6 
 
Appendix figure 6. CD4 and CD8 cell depletion. C57BL/6 mice were treated 
intraperitoneally with either anti-CD8 (2.43; 250 µg per mouse) or anti-CD4 (GK1.5; 
125 µg per mouse). Seven days later the spleens were removed and flow cytometry 
was performed to analyse the remaining T cell populations. T cells were identified by 
CD3 expression and CD4 and CD8 were used to identify the CD4+ and CD8+ T cells. 
This experiment was performed once with two mice per group. 
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VII. Appendix 7 
 
Appendix figure 7. Treatment of E.G7-OVA-bearing hosts with DT does not 
alter the symptom-free survival.  Lang-EGFPDTR mice were intravenously 
administered 1x105 C1498 cells. One group of tumour challenged mice were treated 
with 350 ng of DT intraperitoneally 2 days before tumour challenge and every 2–3 
days later and the symptom-free survival was analysed. This represents a signal 
experiment with five mice per group. *P < 0.05 (Log-rank Mantel-Cox Test). 
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VIII. Appendix 8 
 
Appendix figure 8. C1498 does not increase the Treg population in the 
spleen. Mice were administered 1x105 AML cells intravenously and were culled 20 
days later. The population of Tregs in the spleen was analysed by flow cytometry using 
the gating strategy displayed in figure 4.14A. Foxp3 expression was determined by 
using a CD4 antibody in combination with GFP expression from FoxP3-GFP mice. 
The proportion of CD4+ cells expressing FoxP3 is graphed. This represents two 
experiments, with five mice per group **P < 0.01 (t-test with Mann Whitney). 
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IX. Appendix 9 
 
Appendix figure 9. Regulatory T cell depletion with PC61. C57BL/6 mice were 
treated intraperitoneally with 100 µg of PC61 or left untreated. Seven days later the 
spleens were removed and the Treg population in was analysed by flow cytometry 
using CD4 and CD25 for Treg identification. Flow plots demonstrate the effect of PC61 
on the CD4+ CD35+ cells. This experiment was performed once with two mice per 
group. 
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X. Appendix 10 
 
Appendix figure 10. The tumour/α-GalCer vaccine is ineffective in MHCII-/- 
mice. One group of C57BL/6 and one group of MHC II-/- mice were treated with 
7.5x105 irradiated AML cells loaded with α-GalCer. Seven days later the mice were 
challenged with 1x105 C1498 cells along with another group of naïve mice from each 
mouse strain. The symptom-free survival was assessed. This represents a single 
experiment with five mice per group. **P < 0.01 (Log-rank Mantel-Cox Test). 
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XI. Appendix 11 
 
Appendix figure 11. Hosts administered cytarbine for the treatment of AML 
relapse. C57BL/6 mice were challenged with 1x105 AML cells and 24 hours later a 
course of chemotherapy was initiated. Three doses of cytarabine were administered 
ten hours apart, each consisting of 3 mg administered intraperitoneally. The 
symptom-free survival was followed. This represents the combination of two 
experiments with three mice per experiment. 
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XII. Appendix 12 
 
Appendix figure 12. Antigen presentation alone does not stimulate transferred 
T cells. C57BL/6 mice were intravenously administered 5x106 activated OT-I T cells. 
One group of mice was challenged with 1x106 E.G7-OVA cells 12 prior to adoptive 
transfer and another received 200 µg of OVA protein 24 hours prior. Seven days later 
a sample of blood was extracted from each host and flow cytometry was performed 
to identify the transferred T cell population using CD8, Vα2 and CD45.1. The 
proportion of CD8+ cells that express Vα2 and CD45.1 is displayed. This represents 
a single experiment with five mice per group. ***P < 0.001 (one-way ANOVA with a 
Bonferroni post test). 
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